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Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous 
system (CNS) with inflammation, demyelination and neurodegeneration as hallmarks of 
the pathology [1-3]. Diagnosis is based on the presence of CNS lesions that are dissemi-
nated in time and space. The clinical manifestations and course of the disease are very het-
erogeneous. In approximately 85% of the patients, the initial phase of the disease course is 
characterized by a first neurological attack, i.e. clinically isolated syndrome (CIS). More than 
half of CIS patients encounter subsequent episodes of attacks (relapses) that usually last for 
days or weeks, i.e. relapsing-remitting MS (RRMS). Over time, up to 90% of RRMS patients 
develop permanent neurological deficits where progression of clinical disability becomes 
more prominent, i.e. secondary progressive MS (SPMS). In 15% of MS patients, the disease 
is already progressive from the time of onset and is called primary progressive MS (PPMS). 
The activity and progression of the disease is clinically assessed using magnetic resonance 
imaging (MRI) and standardized measures for disability such as Expanded Disability Status 
Scale (EDSS) scores. The different clinical courses of MS are summarized in Figure 1.
MS is a widely studied neurological disease in terms of epidemiology and is the pri-
mary cause of non-traumatic disability in young adults. MS is mainly found in individuals 
of northern European ancestry, with a prevalence estimated between ~1 per 400-1,000 
individuals in Western countries. Approximately 2.3 million people worldwide suffer from 
MS and it is associated with a high economic burden (between 23.100-50.500 euros per 
person with MS per year in The Netherlands). MS disease onset is typically between 20 and 
35 years of age and has a female to male ratio of 2.5 [4-6].
1.1 Pathology
The hallmark of MS pathology is the formation of lesions (focal plaques) within the 
CNS, which are areas of demyelination that are located around postcapillary venules. 
Lesions are found in both the white- and grey matter of the brain, but also in the spinal 
cord and optic nerve [7-10]. Another known, but incompletely understood feature of MS 
is breakdown of the blood-brain barrier (BBB) [11]. It is thought to involve pro-inflam-
matory cytokines and chemokines produced by CNS-resident cells, endothelial cells and 
infiltrating leukocytes [12, 13]. The increased recruitment of activated leukocytes such as 
macrophages and lymphocytes due to a disrupted BBB causes inflammation and demye-
lination, followed by oligodendrocyte loss, reactive gliosis and neuro-axonal damage [13, 
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14]. Following demyelination, myelin sheaths are often regenerated (i.e. remyelination), 
leading to clinical recovery after a relapse [15]. However, remyelination is a limited process; 
it depends on age, disease duration, lesion location, axonal integrity and the presence of 
oligodendrocyte progenitor cells [16]. This remyelination process is more efficient early in 
the disease course and at a younger age [17]. Remyelination failure contributes to irrevers-
ible neurodegeneration [18], which occurs already in the earliest phases of the disease and 
is most likely the cause of permanent clinical disability later in the disease [19]. 
In the progressive phase, CNS inflammation is compartmentalized and originally 
thought to be purely mediated by CNS-resident cells [20]. However, recent evidence shows 
that also CNS-resident lymphocytes play a role by slowly accumulating in the connective 
tissue spaces of the brain, such as the perivascular Virchow Robin spaces and meninges 
[21-23]. Within the meninges, these cells form follicle-like structures that partly resemble 
tertiary lymphoid follicles and where local reactivation of lymphocytes might occur to 
drive progressive disease [24]. These structures are found in approximately 40% of SPMS 
patients and link to a more severe clinical course, shorter disease duration and earlier death 
[25, 26]. Although neurodegeneration is most likely the result of ongoing inflammation 
and demyelination in the CNS (outside-in hypothesis), there are some indications that neu-















Figure 1. The heterogeneous clinical course of MS.
Clinically isolated syndrome (CIS) is the first clinical presentation of MS. After a period of subsequent neuro-
logical attacks, the majority of relapsing-remitting MS (RRMS) patients will develop secondary progressive dis-
ease (SPMS). A small number of MS patients have progressive disease right from the start of the course, which is 




2. ETIOLOGY OF MS
2.1. Life style and environmental factors
One of the most well established risk factors is Epstein-Barr virus (EBV) infection in 
adolescence and early adulthood, causing infectious mononucleosis in 30-40% of EBV-
infected individuals [27]. Almost all MS patients are seropositive for EBV, while this is the 
case for 90-95% of healthy individuals. However, individuals with MS have higher levels of 
antibodies against EBV nuclear antigen 1 (EBNA1) [28]. Evidence for this association mostly 
comes from epidemiological studies and it remains incompletely understood how EBV is 
involved in the pathogenesis of MS [29-33]. Another important risk factor is the lack of 
sun exposure, correlated to low vitamin D levels. Low vitamin D levels are associated with 
an increased risk of MS and a higher disease activity. Although the mechanism of how 
vitamin D is involved in MS pathogenesis is unknown, it has an important immune regula-
tory role [34, 35]. Smoking and obesity are two other risk factors associated with MS. The 
risk of smoking is dose-dependent, and links to faster disability progression [36]. Not only 
active, but also passive smoking has been reported to be associated with disease onset 
[34]. Furthermore, obesity during adolescence is associated with a 2-fold increased risk of 
MS and a worse clinical outcome during disease [37]. Obesity is associated with low-grade 
inflammation, with increased pro-inflammatory mediators are produced in fat tissue [38], 
possibly contributing to MS pathology. Other less-established environmental risk factors 
are excessive alcohol or caffeine consumption and shift work [34]. 
Pregnancy is a natural modifier of MS disease activity. Pregnant women with MS 
are protected from relapses during the third trimester, while relapse risk is significantly 
increased after delivery [39-41]. During these time periods, there are enormous fluctua-
tions in hormones such as estradiol, estriol and progesterone, probably affecting immune 
mechanisms that contribute to relapse occurrence. Adaptations in maternal immune tol-
erance are required for tolerating the fetus during pregnancy. Placenta-derived hormones 
such as estriol and progesterone can directly affect immune cell function. It has been 
suggested that estriol exhibits dose-dependent effects on immune cells, where low levels 
promote and high levels inhibit cell-mediated immunity [42]. How pregnancy influences 
immune subsets to modulate neuro-inflammatory activity in patients with MS remains a 
question to be solved. 
2.2 Genetic risk factors 
The proof for genetic predisposition to MS comes from monozygotic and dizygotic 
twin studies. The risk in monozygotic twins is 35% compared with 6% in dizygotic twins 
and 3% in normal siblings. Additionally, according to several family studies, 15% to 20% 
of people with MS have a relative with the disease. The major genetic risk factor in MS 
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is the human leukocyte antigen (HLA) class II locus [34, 43]. More than 30 independent 
genetic associations within the extended HLA region have been identified [44]. Individuals 
who are homozygous carrier of the major HLA-DRB1*1501 allele have an OR exceeding 
6.0 for developing MS and that is associated with younger age at onset [45]. Next to HLA-
DRB1*15:01, HLA-DRB1 has multiple other associations with MS, with four amino acid 
changes capturing most of them [46]. HLA-DRB1*15:01 is often linked to a haplotype 
consisting of both DQA1*01:02 and DQB1*06:02 alleles. Furthermore, the presence of HLA 
class I allele HLA-A*02:01 is protective for MS [47]. HLA genes are highly polymorphic and 
encode for molecules regulating the adaptive immune system (discussed in more detail 
below). Their contribution to and regulation during the pathogenesis of MS is poorly 
understood [48].
Interestingly, there is considerable interaction between the HLA-DRB1*1501 allele and 
various environmental factors such as EBV and vitamin D. The association of both infec-
tious mononucleosis (caused by EBV infection) and anti-EBNA1 antibody levels with MS 
risk is increased in the presence of HLA-DRB1*1501 [49]. Furthermore, there is a vitamin 
D responsive element (VDRE) zone in the promotor region of the HLA-DRB1*1501 gene, 
which seems to regulate its expression [50]. SNPs in genes involved in vitamin D metabo-
lism have also been identified to be associated with MS, and VDRE sites are enriched close 
to or in other MS-associated genes [47, 51]. 
Genome wide association studies (GWAS) have identified 200 genetic risk variants 
outside the HLA locus for MS [52]. Identification of the causal genes and their interplay is 
warranted to understand the functional pathways and mechanisms involved in the patho-
genesis. Most of these variants encode for molecules involved in the immune system and 
are associated with several other autoimmune disorders, such as type 1 diabetes, SLE and 
rheumatoid arthritis. No genetic overlap is seen with typical neurodegenerative diseases 
and only a few variants have a function in the CNS, supporting the fact that MS has an 
immune-mediated onset [53, 54]. A large part of these risk variants influence promotor 
and enhancer regions of genes regulating the function of B and T lymphocytes [53], which 
are cells of the adaptive immune system. 
3. ADAPTIVE IMMUNE SYSTEM
Adaptive immunity is also known as acquired or specific immunity, which is required 
for generating so-called ‘memory’ after a first encounter with a pathogen, such as a virus 
or bacteria. This makes sure that the same pathogen is efficiently recognized and cleared 
after subsequent encounters. B lymphocytes specifically recognize extracellular antigens 




that are processed and presented by HLA molecules. Antibodies produced by B cells neu-
tralize microorganisms by blocking the surface of the pathogen, form immune complexes 
with microorganisms that are detected by other immune cells, or facilitate cell lysis by 
activating the complement system. In general, CD8+ cytotoxic T lymphocytes (CTLs) detect 
endogenously derived (i.e. viral or tumor) antigens presented on HLA class I to directly 
kill their target cell. CD4+ T helper (TH) lymphocytes are activated by exogenously derived 
antigens presented on HLA class II to enhance the effector function of other immune 
cells, including B lymphocytes and CTLs. To generate an adaptive immune response in 
secondary lymphoid organs such as the lymph node, lymphocytes first have to undergo 
several selection and developmental processes in the bone marrow (both B and T cells) 
and thymus (T cells). During these processes, unique B- and T-cell receptors are formed 
and tested to be able to specifically react to pathogens and not, for example, self-antigens.
Originally, MS was mainly considered a T cell-driven autoimmune disease, in which 
pro-inflammatory T cells enter the CNS and recognize self-antigens such as myelin. This 
was mainly concluded from studies in the animal model of MS, experimental autoimmune 
encephalomyelitis. However, this T-cell centric view did not adequately explain responses 
to therapy [55]. Results from new anti-CD20 therapy now also puts B cells forward as key 
players in the pathogenesis of MS. In particular, this indicates that B cells already have 
a disease-inducing role in the periphery, likely as the result of defects in their selection 
and development (see also 4.1). Furthermore, B cells are also involved in sustaining local 
inflammation in the more progressive phase of the disease (see section 4.3).
3.1. B-cell development
Within the bone marrow, CD34+ stem cells differentiate into pro- and pre-B cells that 
form immature B cells. During these first steps of differentiation, the B cell receptor (BCR) is 
generated and edited to increase specificity against non-self but prevent reactivity against 
self [56, 57]. First, at the pro-B cell stage, the BCR heavy chain is produced by recombina-
tion of so-called V(D)J gene segments. After developing into pre-B cells, the heavy chain 
will be presented on the cell surface in conjunction with a surrogate light chain, which 
enables selection of productive heavy chains. B cells without a productive heavy chain are 
removed from the repertoire. B cells with a self-reactive BCR are removed by central toler-
ance checkpoints. This mechanism keeps self-reactive B cells in check through apoptosis, 
BCR editing or anergy. Next, the light chain is rearranged and subsequently expressed on 
the surface of immature B cells. These immature B cells exit the bone marrow and enter the 
circulation as new emigrant/transitional B cells. Because BCR rearrangement is a random 
process and despite central tolerance checkpoints, approximately 25% of the circulating B 
cell populations are still able to recognize self-antigens [58]. 
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Transitional B cells constitute 5-10% of the total peripheral B-cell pool in healthy adults 
and are unresponsive to BCR stimulation. Transitional B cells enter the spleen where a cru-
cial cell-fate decision oriented toward either a T-cell independent (TI) or a T-cell dependent 
(TD) response occurs. They either enter the marginal zone (MZ) and develop into IgM+IgD+ 
natural effector memory B cells or short-lived IgM+ plasma cells [59-61] in a T cell-indepen-
dent manner via extensive BCR cross-linking or activation of Toll-like receptors (TLR) and 
other innate receptors [62-64], or exit the spleen as naive mature B cells for further T-cell 
dependent differentiation.
These naive mature B cells enter the follicle of secondary lymphoid organs and are able 
to respond to antigens via their BCR. To become fully activated, B cells need a second and 
third signal [65], which is provided by costimulatory molecules and cytokines expressed 
by the interacting TH cells at the follicular border. An important costimulatory interaction 
is between CD40 on the B cell and CD40 ligand (CD40L) on the TH cell. This interaction is 
not only important for the activation of B cells, but is next to HLA class II/T-cell receptor 
(TCR) interaction essential for inducing peripheral B-cell tolerance. This second tolerance 
checkpoint suppresses or eliminates most of the remaining self-reactive B cells via similar 
processes as in the bone marrow [66-68]. Moreover, inducible ICOSL expression on B cells 
promote the interaction between B- and T cells via the surface receptor ICOS on T cells [69, 
70]. ICOS-ICOSL interaction results in the production of IL-21 and IL-4 by TFH cells, necessary 
for B cell differentiation and survival [70]. Another important co-stimulatory interaction is 
between the B7 molecules (CD80/86) on the B cell and their T cell-activating binding part-
ner CD28, inducing T cells to proliferate and produce cytokines such as IL-2, IFN-γ, TNF-α 
and GM-CSF, but not IL-4 [71, 72]. 
After the initial interaction with TH cells, naive mature B cells either differentiate into 
IgM+ short-lived plasmablasts or enter active sites in the follicles called germinal centers 
(GCs). Within GCs, B cells undergo somatic hypermutations and interact with TFH cells and 
follicular dendritic cells to further mature into memory B cells or long-lived plasma cells 
[73]. Memory B cells have the capacity to self-renew, but may also form plasmablasts as a 
precursor for antibody-secreting plasma cells. Memory B cells exit the germinal centers to 
reside in the marginal zone or enter the circulation. Plasmablasts also exit germinal centers 
and migrate to the bone marrow or other tissues to become long-lived plasma cells [74, 
75] (Figure 2). 
The initial GC responses generate IgM-only memory B cells, which can undergo subse-
quent class-switching by rearranging the constant region of the heavy chain to form other 
isotypes [76-78]. Four different IgG (IgG1-4) and two different IgA (IgA1-2) subclasses are 
known [79]. Although class-switching does not alter the antigen specificity, it does influ-
ence the effector function of B cells [80]. All IgG subclasses are involved in pathogen neu-
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Figure 2. Peripheral B-cell development.
Immature B cells are formed in the bone marrow and enter the circulation as transitional B cells (IgM+IgD+). These 
transitional B cells traffic to the spleen, where they either proliferate in the marginal zone (MZ) and become 
IgM+IgD+ natural effector B cells, or exit the spleen as naive mature (NM) B cells. When these cells encounter an 
antigen in the lymph node, a primary immune response is generated resulting in the formation of IgM+ mem-
ory B cells. These cells enter the circulation either as IgM-only B cells or short-lived plasmablasts, or undergo 
class-switching within germinal centers (GC). A GC response is dependent on the interaction of B cells with folli-
cular T helper (TFH) cells via HLA-II antigen presentation, co-stimulation and cytokine production. GC B cells exit 
the lymph nodes as switched memory B cell (IgA+/IgG+/IgE+) or antibody-secreting cells. These antibody-secret-
ing cells re-enter the bone marrow (and possibly also inflamed tissues) to become long-lived plasma cells.
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and inducers of antibody-dependent cell-mediated cytotoxicity [81]. IgM is primarily 
involved in complement activation [82]. Furthermore, while IgA1 is the predominant sub-
class found in mucosal tissues and serum regulating the first and second line of defense 
against invading pathogens, IgA2 is commonly found in the lower intestinal tract regulat-
ing local microflora [83, 84]. Finally, IgE is the last possible isotype and is the mediator of 
allergic responses and parasitic infections [85].
3.2. B-cell antigen processing and presentation
A unique feature of B cells is their capacity to specifically recognize, take up and pro-
cess antigens via the BCR for HLA-II-mediated presentation to CD4+ TH cells. The efficiency 
of this pathway is important for determining which antigen-specific B and TH cells will 
develop into effector subsets and contribute to an adaptive immune response. After rec-
ognition by the BCR, antigens are taken up, processed and presented on HLA-II molecules 
to T cells [86]. Specific antigen recognition mediates BCR oligomerization and downstream 
signaling that promotes dynamic actin cytoskeletal rearrangements. This enables efficient 
BCR-antigen uptake and internalization into endosomal compartments. The interaction 
between the BCR and its cognate antigen additionally triggers the biogenesis of MHC class 
II-containing antigen loading compartments (MIICs), in which both the antigen and the 
accessory molecules such as HLA class II molecules and proteases assemble [87-89]. To 
reach these compartments, HLA class II molecules that are synthesized in the endoplasmic 
reticulum (ER) need to bind to a specific chaperone termed the invariant chain (CD74 or 
li). This binding is required for correct folding of the HLA class II molecules, preventing 
unwanted early antigen binding, and directing HLA class II molecules to the endo-lyso-
somal system [90]. The cytoplasmic tail of Ii contains two di-leucine sorting motifs, result-
ing in the transport of HLA-II molecules to the MIICs, either directly from the trans-Golgi 
network or indirectly via the plasma membrane [91]. This depends on the binding of 
adaptor protein AP1 (trans-Golgi network adaptor) and AP2 (plasma membrane adaptor) 
to these Ii sorting motifs [92, 93]. Ii also promotes the interaction with myosin II, which is 
required for the assembly of HLA class II and BCR-antigen complexes in MIICs. For efficient 
HLA class II peptide loading in these compartments, both the antigen and Ii need to be 
cleaved by specific proteases, such as cysteine protease cathepsin S [94], signal peptide 
peptidase-like 2a (SPPL2a) [95] and IFN-γ-inducible lysosomal thiol reductase (GILT) [96]. 
The cleavage of Ii leaves a small remnant peptide bound to the binding groove, termed 
class-II associated invariant chain peptide (CLIP). CLIP is then exchanged for an antigenic 
peptide via a process catalyzed by HLA-II chaperones HLA-DM and HLA-DO [97]. This 
cleavage also removes the endosomal retention motif of Ii, enabling HLA class II/peptide 
complexes to be exported to the plasma membrane and presented to CD4+ T cells (Figure 




II, functioning as a high-affinity receptor for the macrophage migration inhibitory factor 
(MIF) [98-100]. MIF is a pro-inflammatory cytokine that has been shown to control B-cell 
proliferation, migration and survival in mice [98, 101]. 
4. B CELLS AND MS
4.1. Defects in peripheral B-cell development
Even in healthy individuals, a minority of self-reactive B cells survive both central 
and peripheral tolerance checkpoints during development and remain present in the 
ER
















Figure 3. BCR-mediated antigen presentation pathway. 
After antigen recognition via the BCR, the BCR-antigen complex is internalized and transported into MIICs. At the 
same time, a HLA-II molecule is formed in the endoplasmic reticulum (ER) and needs to bind to the invariant chain 
(li or CD74) in order to stabilize and enter these same compartments. Once HLA-II/Ii complexes have arrived in the 
MIIC, proteases such as cathepsin S, SPPL2a and GILT are required for the cleavage of Ii into CLIP and antigens into 
peptides. CLIP remains bound to the HLA-II peptide-binding groove and is exchanged for an antigenic peptide, a 
process regulated by chaperones HLA-DM and HLA-DO as well as GILT. After peptide loading, the HLA-II/peptide 
complex is transported to the plasma membrane and presented to a CD4+ T cell. 
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circulation [58]. In most autoimmune diseases, both central and peripheral B-cell tolerance 
checkpoints are impaired [67, 102, 103]. Interestingly, in MS patients, only peripheral toler-
ance is defective, resulting in more naive self-reactive B cells with an activated phenotype 
in the circulation [67, 104]. In this regard, it may be that the defect in peripheral tolerance 
in MS is a consequence of regulatory T cell (TREG) dysfunction. TREGs are essential for the 
maintenance of peripheral tolerance. Dysfunction of the suppressing capacity of the TREGs is 
associated with several autoimmune diseases including MS [105]. Both the frequency and 
regulatory function of TREGs have been reported to be lower in MS patients than in healthy 
individuals [106, 107]. However, a B-cell intrinsic defect underlying the escape from periph-
eral tolerance cannot be excluded.
After these initial tolerance checkpoints, receptor editing of memory B cells, by induc-
ing somatic hyper mutations, can result in more self-reactive clones than the ancestor 
memory B cells [108]. Additionally, loss of anergy might result in reactivation of self-reac-
tive B cell clones. The important characteristic of anergic B cells is the abrogation of their 
BCR signaling capacities [109, 110], therefore they are not responding to self-antigen and 
do not undergo rapid apoptosis, but persist in secondary lymphoid tissues [111, 112]. 
Although most anergic B cells are a result of arrest at the developmental stage, displaying 
a transitional phenotype, B-cell anergy can also be induced in the periphery via chronic 
antigen stimulation. Self-antigens or persistent infections are able to chronically induce 
the BCR, resulting in an unresponsive (’exhausted’) B cell [113, 114]. Despite their inability 
to signal via the BCR, anergic B cells retain the ability to present antigen and respond to 
TH cell-derived stimuli [109, 115]. Self-tolerance within the T cell compartment ensures 
that these anergic B cells do not receive activating signals. However, if self-reactive BCR 
cross-react with a certain pathogen, there may be loss of anergy resulting in the activation 
of B-cell populations capable of driving autoimmunity [108, 109].
4.2. T-cell activation by antigen presenting B cells
The striking effect of anti-CD20 therapies to limit new MS relapses has shifted the frame-
work of MS immunopathogenesis. The contribution of B cells to CNS inflammatory disease 
activity have been linked to the antibody-independent functions of B cells, as part of cas-
cades of immunological interactions in the periphery that mediate disease activity. B-cell 
depletion therapy significantly reduce pro-inflammatory TH-cell responses in MS, both ex 
vivo and in vivo [116]. Furthermore, MHC class II expression on murine B cells was reported 
to be indispensable for the onset of experimental autoimmune encephalomyelitis (EAE), a 
mouse model of MS [117, 118]. Moreover, CD40L expression is required to induce costimu-
latory activity on antigen presenting cells for in vivo activation of CD4+ T cells in EAE [119]. 
The in silico evidence that autoimmunity-associated HLA class II molecules have an altered 




variants in the HLA class II pathway, insinuates that antigens are differently processed and 
presented by B cells [121, 122]. This is supported by the increased ability of memory B cells 
to trigger CNS-infiltrating TH cells in MS patients carrying HLA-DRB1*1501 [122]. Next to the 
genetic variants directly within the MHC region, GWAS studies have identified multiple 
SNPs that might be involved in the regulation of antigen presentation [44]. 
Furthermore, B cells from MS patients have an altered capacity to produce pro-inflam-
matory cytokines such as IL-6, GM-CSF, TNFα and LTα and are deficient in the production 
of regulatory cytokine IL-10 [123-126]. Interestingly, this abnormal cytokine response of 
B cells from MS patients is most prominent when these cells were activated in the con-
text of IFN-γ or in the presence of TLR9 stimulation [127]. This suggests that infections 
that generate a TH1 host response, including bacteria and viruses, could trigger abnormal 
pro-inflammatory B cell cytokine responses in MS patients. This aberrant cytokine profile 
of B cells from MS patients can induce abnormal effector T-cell responses through TNFα 
and IL-6 as well as pro-inflammatory myeloid cell responses. Strikingly, anti-CD20 thera-
pies reduces the pro-inflammatory responses of TH1 and TH17 cells as well as myeloid cells 
in the periphery of MS patients [123, 126, 127].
Although the antibody-independent function of the B cell is mostly linked to their role 
in the periphery, local interactions within the CNS between B- and T cells also probably 
contribute to the disease. Cerebrospinal fluid (CSF) and CNS B cells of MS patients express 
elevated levels of HLA class II and T-cell co-stimulatory B7 molecules [128-130]. It can 
therefore be expected that infiltrating B cells also re-activate local T cells to mediate MS 
pathology (Figure 4).
4.3. Enhanced recruitment of B cells to the CNS
The BBB is dysfunctional during the early phase of MS, resulting in local recruitment of 
pathogenic immune cells including B cells [131]. Differences in expression of chemokine 
receptors, integrins and pro-inflammatory cytokines by infiltrating memory B cells and 
plasma cells mediate their trafficking in and out of the CNS [132, 133], but also their local 
organization and impact (Figure 4). Chemokines expressed in the CNS might contribute to 
the migration of lymphocytes across the BBB by acting as chemoattractants and sustain-
ing ongoing inflammation; i.e. elevated levels of CXCL10, CXCL12, CXCL13 and MIF were 
found in the CSF of MS patients [134]. Hence, chemokine receptor profiles of B cells are 
a determining factor for which functional B cell subsets will be attracted to the inflamed 
CNS. For example, migration of memory B cells and plasma cells may be facilitated by the 
expression of chemokine receptors such as CCR6, CXCR3 and CXCR4 [135]. Furthermore, 
high levels of integrin α4β1 (VLA-4) allow B cells to bind to VCAM-1 on brain endothelial 
cells, contributing to the migration of B cells across the BBB [136]. This is supported by 
the reduced B-cell infiltration into the CNS and disease susceptibility in EAE mice when 
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VLA-4 is inhibited [137]. Additional studies in EAE demonstrate that MIF antibody inhibi-
tion reduces vascular cell adhesion protein 1 (VCAM-1) expression on the BBB and results 
in decreased recruitment of inflammatory cells, suggesting that MIF plays a role in the 
homing and transmigration of CNS-specific B and T cells [138]. Furthermore, activated 
leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule that is expressed 
by B cell and drives their migration across multiple CNS barriers [139]. Moreover, ALCAM 
expressing B cells are increased in both peripheral blood and brain lesions of MS patients 
[140]. 
Within the CNS of MS patients, B cells have been found to accumulate in active white 
matter lesions and the meninges, the membrane covering the brain and spinal cord [20]. 
They can be detected in both early and late stages of MS, but are most abundant in patients 
with RRMS [20, 141]. B cells are enriched in perivascular lesions and only rarely in the sub-
arachnoid space [13, 24, 141]. Within the meninges, B cell-rich follicle-like structures local-
ize next to cortical lesions, presumably mediating progressive loss of neurological function 
in MS [21, 142]. This meningeal inflammation is associated with a more aggressive MS 
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Figure 4. Recruitment and impact of B cells in the CNS of MS patients. 
Both memory B and T cells are able to migrate through the blood-brain barrier (BBB) or via the blood-CSF barrier 
(BCSFB) through the expression of chemokine receptors, adhesion molecules and pro-inflammatory cytokines. 
After entering the CNS, B and T cells probably interact in perivascular spaces and meningeal follicle-like struc-




loss [21, 22]. Although ectopic follicle-like structures have only been described in SPMS 
patients, meningeal aggregates of B cells can also be found in patients with RRMS and PPMS 
[143, 144]. These B cell-rich structures share some features with tertiary lymphoid follicles 
seen in other organ-specific chronic and acute inflammatory conditions [145]. They not 
only recapitulate the cellular and structural organization of secondary lymphoid organs, 
but also support the function of germinal centers. They retain the necessary molecular 
machinery to support B cell differentiation and proliferation including class-switching and 
antibody diversification [145]. However, many of the regulatory mechanisms that govern 
tolerance in secondary lymphoid organs are not seen in these autoimmunity-associated 
tertiary lymphoid follicles [146]. This allows the entry of autoreactive B cells and their 
differentiation into plasma cells that potentially release disease-specific auto-antibodies, 
which has already been shown in rheumatoid arthritis [147] and Sjögren’s syndrome [148]. 
Another possible role for B cells in these tertiary lymphoid follicles is to reactivate pro-in-
flammatory T cells that contribute to MS pathology [122]. 
4.4. Increased antibody production in the CNS 
In contrast to healthy individuals, high antibody levels are found in the CSF of MS 
patients. These CSF antibodies include characteristic oligoclonal bands (OCBs), as seen in 
CSF electrophoresis of isoelectric focusing. CSF OCBs are used as a diagnostic tool in MS. 
IgG OCBs can be found in 90% of MS patients, while IgM OCBs are present in approximately 
30-40% of MS patients and have been associated with more active disease [149, 150]. The 
pathogenic role of antibodies in the CNS and the relevant antigen specificities of the B cells 
involved in MS remain unclear. Owing to the demyelinating nature of the disease, myelin 
proteins such as MOG, MBP and proteolipid protein have been extensively investigated 
as target antigens of B cells in MS patients. Despite extensive investigation, studies have 
yielded mixed results regarding the specificity of B cells and antibodies and might actu-
ally identify patients who do not have MS [151-153]. Additionally, studies demonstrated 
CSF antibody reactivity against various viral and self-antigens, indicating that the B-cell 
response might not be directed against a single epitope, antigen or cell type and is highly 
diverse between MS patients [154-156].
The presence of elevated immunoglobulin synthesis rates in the CSF of MS suggests 
that immunoglobulin is being produced locally within the CNS (intrathecal production). 
This intrathecal production of immunoglobulin is supported by somatic hypermutation 
analysis of B cells and plasma cells, which had demonstrated a restricted number of 
expanded clones within the CNS of people with MS [157-160]. These clones are shared 
between different CNS compartments, i.e. CSF, meninges and parenchyma, and similar to 




5. SCOPE OF THIS THESIS
The strong and rapid beneficial clinical effects of anti-CD20 treatment in MS patients 
have revealed that B cells serve as antigen-presenting rather than antibody-producing 
cells in the periphery. B-cell depletion therapy does not remove antibody-producing 
plasma cells but significantly reduces pro-inflammatory TH-cell responses in MS. However, 
the exact underlying antibody-independent functions of B cells in MS are poorly under-
stood. It is likely that during MS pathogenesis, B cells not only trigger, but also receive 
signals back from TH cells to develop into CNS-infiltrating pathogenic B cell subsets (Figure 
5). In this thesis, we aimed to uncover genes and pathways that are functionally altered in 
human B cells and potentially contribute to MS.
In chapter 2, we assessed the triggers, development and CNS infiltration capacity of 
pathogenic T-bet+CXCR3+ B cells in MS patients. We made use of blood, CSF, meningeal and 
brain tissues from MS patients to study the phenotype of CNS-infiltrating B cells. Similar 
analysis was performed for memory B cells trapped in the blood of anti-α4-integrin anti-
body (natalizumab)-treated MS patients. Both IFNγR-/TLR9-mediated GC-like differentia-
tion and BBB transmigration of T-bet+CXCR3+ B cells were assessed in vitro.
Since little is known about how B-cell intrinsic HLA class II expression is regulated 
during MS disease onset, we studied the impact of autoimmunity-associated risk locus 
CLEC16A on the B cell antigen processing and presentation pathway in MS in chapter 3. 
In chapter 4, we studied the MIF pathway as an underlying molecular mechanism of 
B-cell survival, migration and chronic inflammation in early MS. MIF associates with chronic 
inflammation and B-cell survival in mice and is upregulated in the CNS of MS patients. MIF 
utilizes as a receptor CD74, a molecule also involved in antigen presentation. How MIF 
regulates immune subsets to promote disease activity in MS was not studied before.
Pregnancy is a natural modifier of disease activity in MS patients, but the underlying 
mechanisms remain elusive. In chapter 5, we studied the effect of pregnancy on B-cell 
differentiation in MS patients both ex vivo and in vitro.
In chapter 6, we discussed how the interaction of B cells with T cells is possibly affected 
by intrinsic and extrinsic factors and drives the infiltration of pathogenic subsets into the 
CNS of MS patients. 
Finally, our findings on the role of B cells in MS are summarized, put in context and 





1 Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sorensen, P. S., Thompson, A. J., Wolinsky, J. 
S., et al., Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014. 83: 278-
286.
2 Krieger, S. C., Cook, K., De Nino, S. and Fletcher, M., The topographical model of multiple sclerosis: A 
dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm 2016. 3: e279.
3 Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S. and Rocca, M. A., Multiple sclerosis. 
Nat Rev Dis Primers 2018. 4: 43.
4 Collaborators, G. B. D. M. S., Global, regional, and national burden of multiple sclerosis 1990-2016: a 
systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019. 18: 269-285.
5 Kobelt, G., Eriksson, J., Phillips, G. and Berg, J., The burden of multiple sclerosis 2015: Methods of data 
collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler 2017. 23: 4-16.
6 Uitdehaag, B., Kobelt, G., Berg, J., Capsa, D., Dalen, J. and European Multiple Sclerosis, P., New 
insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands. Mult Scler 
2017. 23: 117-129.














Figure 5. Peripheral B- and T-cell interaction as underlying mechanism in MS .
Pathogenic B cells interact with CD4+ T effector cells in secondary lymph nodes to drive their development and 
recruitment to the CNS. This interaction depends on the potential of B cells to internalize, process and present 
antigen to and respond to costimulatory and cytokine signals derived from CD4+ TH cells. In MS, the antigen-pre-
senting and CNS-infiltrating capacity of B cells is probably influenced by genetic and environmental risk factors.
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ABSTRACT 
Objective: Results from anti-CD20 therapies demonstrate that B- and T-cell interac-
tion is a major driver of multiple sclerosis (MS). The local presence of B-cell follicle-like 
structures and oligoclonal bands in MS patients indicate that certain B cells infiltrate 
the CNS to mediate pathology. Which peripheral triggers underlie the development of 
CNS-infiltrating B cells is not fully understood. 
Methods: Ex vivo flow cytometry was used to assess chemokine receptor profiles of 
B cells in blood, CSF, meningeal and brain tissues of MS patients (n=10). Similar analy-
ses were performed for distinct memory subsets in the blood of untreated and natal-
izumab-treated MS patients (n=38). To assess T-bet(CXCR3)+ B-cell differentiation, we 
cultured B cells from MS patients (n=21) and healthy individuals (n=34) under T helper 
1 and TLR9-inducing conditions. Their CNS transmigration capacity was confirmed 
using brain endothelial monolayers. 
Results: CXC chemokine receptor 3 (CXCR3)-expressing B cells were enriched in 
different CNS compartments of MS patients. Treatment with clinically effective drug 
natalizumab prevented the recruitment of CXCR3high IgG1+ subsets, corresponding 
to their increased ability to cross CNS barriers in vitro. Blocking of IFN-γ reduced the 
transmigration potential and antigen-presenting cell function of these cells. IFN-γ-
induced B cells from MS patients showed increased T-bet expression and plasmablast 
development. Additional TLR9 triggering further upregulated T-bet and CXCR3, and 
was essential for IgG1 switching.
Interpretation: This study demonstrates that T-bethigh IgG1+ B cells are triggered by 
IFN-γ and TLR9 signals, likely contributing to enhanced CXCR3-mediated recruitment 
and local reactivity in the CNS of MS patients.
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INTRODUCTION 
B cells are one of the main contributors to chronic autoimmune pathology in multi-
ple sclerosis (MS), as supported by results from large genome-wide association studies 
[1]. B-cell repertoires in the central nervous system (CNS) and the periphery are closely 
connected, suggesting that disease-relevant B-cell networks interact at both sides of the 
blood-brain barrier [2-5]. There is evidence that the beneficial effects of anti-CD20 mono-
clonal antibody therapy are related to the ablation of functional B cells interacting with 
T cells [6, 7]. The meninges of MS patients contain tertiary lymphoid structures that are 
filled with B and T cells, close to cortical lesions [8]. This strongly suggests that B- and T-cell 
interaction is a major event in triggering and sustaining inflammation in the CNS. 
In MS, autoreactive (naive) B cells escape peripheral selection and probably receive 
specific signals from CD4+ T cells within secondary lymphoid organs to differentiate into 
memory populations before entering the CNS [5, 9, 10]. The presence of oligoclonal bands 
(OCB) in the cerebrospinal fluid (CSF) of MS patients implies that these memory B cells 
undergo local reactivation (with the help of CD4+ T cells) to further develop into immu-
noglobulin (Ig)-producing plasmablasts and plasma cells [8, 11]. Although memory B cells 
have been recently shown to promote the differentiation of CNS-infiltrating CD4+ T cells 
in MS, little is known about how and which functional B-cell subsets are triggered in the 
periphery to infiltrate the CNS and contribute to MS pathology.
In mice, the T helper 1 (Th1) cytokine interferon-gamma (IFN-γ) induces the interac-
tion between autoreactive B cells and CD4+ T cells to form tertiary lymphoid structures 
and promote systemic autoimmune diseases such as systemic lupus erythematosus (SLE) 
[12]. In these cases, IFN-γ induces the expression of the T-box transcription factor T-bet, 
resulting in enhanced Ig class switching and CXC chemokine receptor 3 (CXCR3) expres-
sion in murine B cells [13, 14]. Interestingly, B cell-intrinsic T-bet expression associates with 
increased pathogenic responses [14, 15] and is induced by systemic infections [16], a major 
environmental trigger in MS [17]. Toll-like receptor 9 (TLR9), which binds to pathogen-re-
lated CpG-DNA, integrates with the B-cell receptor (BCR), CD40 and cytokine signals to 
stimulate T-bet+ B-cell development [18, 19]. Additionally, B cells from MS patients were 
previously reported to exhibit an enhanced pro-inflammatory phenotype when activated 
with IFN-γ and TLR9 ligand CpG-DNA [7]. 
Here, we aimed to explore the CNS transmigration capacity of T-bet(CXCR3)-expressing 
B cells and which peripheral triggers are involved in the development of such popula-
tions in MS patients. We explored the recruitment of human CXCR3+ B cells to the CNS 
both ex vivo and in vitro. Furthermore, the susceptibility of blood-derived B cells from MS 
patients and healthy individuals to T-bet-inducing stimuli and how this influences their 
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differentiation into CXCR3+ memory subsets was determined using different T cell-based 
culture systems.  
MATERIALS AND METHODS 
Patients
Post-mortem CSF, meninges, brain tissues and blood samples were freshly obtained 
from MS brain donors (Netherlands Brain Bank, Amsterdam, The Netherlands). The main 
cause of death was legally granted euthanasia (8 of 10 donors). The two other donors died 
from pneumonia or MS. These tissues had a very short post-mortem delay of 8.92 hours 
[interquartile range (IQR): 8.50 – 9.50 hours] and pH of the CSF was 6.59 [IQR: 6.44 – 6.87]. 
All other MS patients and healthy controls were included at Erasmus MC (Rotterdam, The 
Netherlands), which is a national tertiary referral center for MS patients (MS Center ErasMS). 
Patients and controls were age- and gender-matched per study group. Patient charac-





female n (%) 
Age in years 
median (IQR)A 
Disease duration in 
months, median (IQR)B 
Ex vivo B cells, CNS vs blood  
MS 10 9 (90%) 52 (50 - 65) NA 
Ex vivo B cells, blood subsets  
HC 10 7 (70%) 47 (32 - 54 NA 
MS, no Tx 10 7 (70%) 45 (43 - 53) 48 (24 - 120) 
MS, NAT Tx 
      First cohort    
      Second cohort 
      Third cohortD 
 
10 7 (70%) 40 (29 - 46)C 90 (31 - 124) 
9 6 (66%) 36 (26 - 43)C 46 (41 - 130) 
9 5 (56%) 28 (21 - 43)C 28 (19 – 41) 
In vitro-stimulated B cells  
HC 
       Total 
       Naive 
 
10 8 (80%) 44 (32 - 56) NA 
8 5 (63%) 39 (27 - 50) NA 
MS, no Tx 
       Total 
       Naive 
 
9 7 (80%) 41 (34 - 56) 36 (36 – 73) 
12 8 (67%) 38 (28 - 42) 4 (3 – 15) 
 
A At time of sampling 
B Time from MS diagnosis to sampling 
C At time of pre-treatment sampling 
D IgG subclass instead of total IgG analysis 
 
MS = multiple sclerosis; HC = healthy control; NAT = natalizumab, Tx = treatment; IQR = interquartile 
range; NA = not applicable 
Table 1. Characteristics of patients and controls used in this study.
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2018. All patients gave written informed consent and study protocols were approved by 
the medical ethics committee of the Erasmus MC (Rotterdam) and VUmc (Amsterdam, The 
Netherlands). 
Mononuclear cell isolation from blood and CNS compartments
Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufactur-
er’s instructions from blood of MS patients and matched controls with the use of vacutainer 
CPT® tubes containing sodium heparin (BD Biosciences, Erembodegem, Belgium). 
PBMCs were frozen and stored in liquid nitrogen until use as previously described [20]. 
Mononuclear cells were isolated from buffy coats using Ficoll-Paque Plus (GE Healthcare, 
Freiburg, Germany) and density gradient centrifugation. Blood and CSF samples from MS 
brain donors were acquired post-mortem through heart puncture and ventricle drainage, 
respectively [20]. Heart blood mononuclear cells were isolated as described for buffy coat 
material. Collection tubes with CSF were centrifuged for 10 min at 500g. CSF and blood 
mononuclear cell fractions were resuspended in RPMI 1640 (Lonza, Verviers, Belgium) con-
taining 10% heat inactivated human AB serum (Sanquin, Rotterdam, The Netherlands) and 
1% penicillin/streptomycin (Lonza) and left to rest at 37oC until further use. Meninges were 
washed in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) 
3 times, cut into pieces and incubated with liberase (Roche Applied Science, Penzberg, 
Germany) for 1 hour at 37oC. After which the meninges were filtered through a cell strainer 
(45 µm) and cells were washed using Ficoll-Paque Plus (GE Healthcare). Single cell sus-
pensions from the meninges were resuspended in PBS containing 0.1% BSA until further 
use. Brain tissue samples were processed and single-cell suspensions were obtained as 
previously reported [21]. 
Antibodies and flow cytometry
Multicolor flow cytometric analysis was performed using fluorochrome-labeled mono-
clonal anti-human antibodies (mAbs; Table 2). PBMCs were stained extracellularly for 30 
minutes at 4oC. Cultured B cells were stained with a fixable viability stain (FVS 700) for 
15 min at 4oC and subsequently stained for either extracellular only or both extracellular 
and intracellular markers. For intracellular staining, cells were fixed with 2% paraformalde-
hyde (Merck, Schipol-Rijk, The Netherlands) and permeabilized with PBS pH7.4 containing 
0.3% BSA and 0.5% saponin (Sigma-Aldrich, Saint-Louis, MO) and stained with T-bet for 60 
min at 4oC. All measurements were conducted with an LSRII-Fortessa flow cytometer and 
analyzed using FACS Diva software, version 8.0.1 (both BD Biosciences). Ex vivo Th17.1 (IFN-
γhighIL-17low) and Th17 (IFN-γneg) cells in blood were defined as CCR6+CXCR3+CCR4- (Th17.1) 
and CCR6+CXCR3-CCR4+ (Th17), described recently [20]. 
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Human B-cell migration assays
FACS-sorted CD27- and CD27+ memory CD19+ B cells from buffy coat-derived PBMCs 
were placed on 96 wells permeable transwell plates with a 0.3 µm pore size (2×105 cells/
well; Corning, Amsterdam, The Netherlands). B-cell migration towards medium or CXC 
chemokine ligand (CXCL)10 (900 ng/ml; R&D Systems, Abingdon, UK) was analyzed after 
3h in 37°C. In addition, 2,5-5×105 memory B cells were placed on confluent monolayers of 
human brain endothelial cells (hCMEC/D3) on 5 μm pore size transwell plates (Corning) 
coated with collagen and migration was analyzed after 5 hours [22]. Percentages of memory 
B-cell subsets were compared before and after transmigration using flow cytometry.
Antigen-primed, autologous B- and Th-cell co-cultures 
BCR-mediated uptake and presentation of Salmonella typhimurium (S. typhimurium) 
SL1344 was used as a model for antigen presentation, as previously demonstrated [23]. 
mAb anti-human IgG (MH16-1, Sanquin, Amsterdam, The Netherlands) was mixed with 
mAb against S. typhimurium lipopolysaccharide (LPS) (1E6, Invitrogen, Paisley, UK) and rat 
  
  
Antibody marker Fluorochrome Clone Company 
CD3 AF700 SK7 BiolegendA 
CD3 BV785 SK7 BD Biosciences 
CD4 BV510 OKT4 BiolegendA 
CD19 BV785 HIB19 BD Biosciences 
CD20 AF700 2H7 BD Biosciences 
CD21  BV711 B-Ly4 BD Biosciences 
CD27 BV421 M-T271 BD Biosciences 
CD38 PE-Cy7 and PerCP-Cy5.5 HIT2 BiolegendA 
CD49d (VLA-4) APC 9F10 BD Biosciences 
CCR4 PE-Cy7 L291H4 BiolegendA 
CCR6 PE G024E3 BiolegendA 
CXCR3 BV605 and APC G025H7 BiolegendA 
CXCR5 APC-R700 RF8B2 BD Biosciences 
IgA  FITC IS11-8E10 Miltenyi BiotechB 
IgD PE and PE-CF594 IA6-2 BD Biosciences 
IgG ACP-H7 G18-145 BD Biosciences 
IgG1 PE HP6001 Southern BiotechC 
IgG2 AF488 HP6002 Southern BiotechC 
IgM  BV510 MHM-88 BiolegendA 
T-bet PE-Cy7 4B10 BiolegendA 
Fixable viability dye (FVS 700) AF700   BD Biosciences 
 
A Biolegend, London, UK 
B Miltenyi Biotech, Leiden, The Netherlands  
C Southern Biotech via ITK diagnostics, Uithoorn, The Netherlands 
 
Table 2. Monoclonal anti-human antibodies used for FACS.
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anti-mouse IgG1 antibody (RM161.1, Sanquin) to generate BCR-LPS tetrameric antibody 
complexes. Exponentially grown bacteria were washed twice with PBS, incubated with 
BCR-LPS tetrameric antibody complexes for 30 min at room temperature, and washed 
twice to remove unbound antibodies. B cells were incubated with viable anti-IgG coated 
S. typhimurium [23] at 20 bacteria per cell for 45 min at 37°C without antibiotics. Next, cells 
were washed 3 times and cultured for 60 min in media containing 100 µg/ml gentamicin 
(Invitrogen) to eliminate non-phagocytosed bacteria. B cells were co-cultured in RPMI 
supplemented with 5% fetal calf serum, 1% (100 U/ml) penicillin, 1% (100 µg/ml) strepta-
mycin (Lonza), 1% (2mM) ultraglutamine (Lonza), 0.1% (50 µM) beta-mercaptoethanol 
(Sigma Aldrich), 0.1% (20 µg/ml) apotransferrin (depleted for human IgG with protein-G 
sepharose; Sigma Aldrich) (further referred to as B-cell medium) and 10 µg/ml gentamicin 
together with autologous CD4+ T cells (MACS sorted). B cells (1 x 105) and T cells (0.5 x 
105) were cultured in 200 µl at 37°C in the presence of 5% CO2 in 96-well round-bottom 
plates (Greiner Bio-One; Alphen Aan Den Rijn, The Netherlands) for 6 days. Cultures were 
performed in the presence of recombinant interleukin (IL)-21 (50 ng/ml; Thermo Fisher 
Scientific, Landsmeer, The Netherlands), recombinant IL-2 (50 IU/ml, Miltenyi Biotec), and 
with or without an anti-IFN-γ blocking antibody (MD-1, 10 µg/ml, U-CyTech Biosciences, 
Utrecht, The Netherlands). 
IL-21/3T3-CD40L assay for human B-cell differentiation 
To mimic B-cell differentiation in vitro, murine NIH3T3 fibroblasts expressing human 
CD40L (3T3-CD40L) [23] were irradiated at 30 Gy using a RS320 X-ray (Beckhoff, Eindhoven, 
The Netherlands), taken up in B-cell medium and seeded on flat bottom 96-wells plates 
(10x103 cells per well; Greiner Bio-One) to allow adherence overnight. CD19+ (total) B cells 
were isolated from buffy coat-derived PBMCs using CD19 microbeads and the autoMACS 
Pro Separator (both Miltenyi Biotec). Total, naive (CD38-/dimCD27-IgG-IgA-) and memory 
(CD38-/dimCD27+IgG+) B cells were isolated from healthy and MS blood using a BD FACSAriaTM 
III cell sorter. These fractions were resuspended in B-cell medium and 20-25 x 103 cells were 
co-cultured with irradiated 3T3-CD40L cells and stimulated with a combination of IL-21 (50 
ng/ml; Thermo Fisher), IFN-γ (50 ng/ml; Peprotech/bio-connect, Huissen, The Netherlands) 
and CpG-ODN (2006-G5; 10 µg/ml; InvivoGen/bio-connect) at 37oC and 5% CO2. After 
6 and 11 days of culture, supernatants were collected and stored at -80oC until use for 
enzyme-linked immunosorbent assay (ELISA). The cells were stained and assessed using 
flow cytometry as described above. 
IgG1 ELISA
Nunc MaxiSorp plates (Sanbio BV) were coated overnight with anti-human IgG1 mono-
clonal capture antibody (1 µg/ml; clone MH161-1, Sanquin, Amsterdam, The Netherlands) 
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in PBS. After washing with PBS-0.02% Tween-20, the supernatants from in vitro B-cell cul-
tures (described above) were diluted in high performance ELISA buffer (HPE; Sanquin) and 
incubated for 60 min. Subsequently, plates were washed and incubated for 60 min with 
anti-human IgG conjugated with horseradish peroxidase, a monoclonal detection anti-
body (1 µg/ml; clone MH16-1, Sanquin). After washing, the ELISA was developed with MQ 
containing 0.11M sodium-acetate (pH 5.5), 100 µg/ml tetramethylbenzidine and 0.003% 
(v/v) H2O2 (all from Merck). The reaction was stopped by addition of 2M H2SO4 (Merck). 
Optical densities at 450nm were measured with a Biotek Synergy2. Background readings 
at 540nm were subtracted. Results were related to a titration curve of a serum sample of a 
healthy donor in each plate.
Statistical analyses
All data sets were analyzed with Graphpad Prism Software, version 7 (GraphPad 
Software Inc., San Diego, CA) and compared using two sided Mann-Whitney U tests, 
Wilcoxon matched-pairs signed rank test, 1 or 2-way ANOVA with Tukey’s post hoc test, 
Friedman paired with Dunn’s post hoc test and Spearman correlation coefficients (as indi-
cated in each figure legend). Experimental data are depicted as the mean ± SEM. Prior to 
statistical analyses, data sets were tested for normal distribution. p values less than 0.05 
were considered significant. 
RESULTS
CXCR3-expressing B cells are selectively enriched in distinct CNS 
compartments of MS patients 
Enhanced chemotaxis is one of the key mechanisms by which B cells can enter distinct 
CNS compartments of MS patients [11]. Production of the chemo-attractants CXCL10, 
CXCL13 and CCL20 in the CNS has been associated with B-cell recruitment, distribu-
tion and reactivity in MS [24-26]. We compared the presence of B cells that express the 
chemokine receptors that correspond to these ligands, CXCR3+ (CXCL10), CXCR5+ (CXCL13) 
and CCR6+ (CCL20) between paired blood, CSF, meningeal and brain tissues from 10 MS 
patients (Table 1). To realize this, single-cell suspensions were obtained from autopsied 
brain compartments using a standardized protocol [21]. From these fractions, viable 
CD45+CD3-CD19+ B cells were gated and analyzed for chemokine receptor expression 
using flow cytometry (Fig 1A). We were able to measure sufficient numbers of viable B 
cells from each compartment for all donors (mean [range], blood: 21,509 [610-98,562], 
CSF: 12,629 [50-59,499], meninges: 13,819 [91-36,644] and brain tissue: 2,889 [26-18,050]. 
The frequencies of CXCR3+, and not CXCR5+ or CCR6+ B cells were strongly increased in ex 
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vivo cell suspensions from MS brain tissues (p < 0.0001), meninges (p = 0.0003) and CSF 
(p < 0.0001) compared to blood (Fig 1B). Also CXCR3-expressing T cells, including Th17.1, 





























































































Figure 1. CXCR3+ B cells are abundant in the CNS compared to blood of MS patients. 
(A) Representative FACS plots and gating of CXCR3-expressing CD19+ B cells within viable CD45+CD3- lymphocyte 
fractions derived from the blood, CSF, meninges and brain tissue of an MS patient. (B) Frequencies of CXCR3+, 
CXCR5+ and CCR6+ B cells in distinct paired compartments from MS patients. For blood, CSF and meningeal sam-
ples each dot represents a different patient. A total of 10 brain tissues from 7 different MS patients were used for 
the analysis of CXCR3+ B cells. Any samples with less than 25 viable B cells were excluded from these analyses. 
Data are presented as the mean ± SEM. ****p < 0.0001, ***p < 0.001, and *p < 0.05. The p values for B were calcu-
lated by a 1-way ANOVA test.
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Reduced frequencies of CXCR3+IgG(1)+ B cells in the blood of MS patients 
are abrogated after natalizumab treatment 
To determine how CXCR3 is involved in the local attraction of different B-cell popula-
tions in MS, we assessed the proportions of CXCR3-expressing naive (CD27-IgM+; IgMnaive) 
and both IgM+ memory (CD27+IgM+; IgMmem) and IgG
+ memory (CD27+IgG+) B cells in the 
peripheral blood of untreated MS patients (n = 10) and age- and gender-matched healthy 
controls (HC, n = 10; Table 1 and Fig 2A). CXCR3- expressing IgG+ cells were reduced (p = 
0.007), while no differences were seen for IgMnaive and IgMmem cells in MS versus HC blood 
(Fig 2B). 
To address this potential migration of CXCR3+IgG+ memory B cells into the CNS, we ana-
lyzed the distribution of these B-cell subsets in the blood of MS patients treated with the 
anti-α4β1 integrin (VLA-4) antibody natalizumab (Table 1), a drug that effectively reduces 
MS disease activity by blocking lymphocyte recruitment to the CNS [27]. VLA-4 was most 
abundantly expressed on blood IgG+ B cells from MS patients prior to natalizumab treat-
ment (Fig 2C). Elevated frequencies of both IgMmem (pre-treatment versus 6m post-treat-
ment p = 0.042 and 12m post-treatment p = 0.011) and IgG+ (pre-treatment versus 6m 
post-treatment p = 0.022 and 12m post-treatment p < 0.001) B cells were found in blood 
of MS patients both 6- and 12-months post- versus pre-treatment (Fig 2D). However, only 
IgG+ and not IgMnaive or IgMmem B cells from MS patients treated with natalizumab for 12 
months, showed increased expression levels of CXCR3 (p < 0.01; Fig 2E), and not CXCR5 
or CCR6 (Fig 2F). These findings were validated in a second cohort of nine MS patients 
treated with natalizumab (Table1; data not shown). Notably, CD20 expression levels were 
Figure 2 (see right page). Reduced frequencies and natalizumab-mediated accumulation of CXCR3+IgG(1)+ 
B cells in MS blood.
(A) FACS gating strategy used to define IgMnaive (CD27
-IgM+), IgMmem (CD27
+IgM+) and IgG+ (CD27+IgG+) B-cell sub-
sets. (B) Gating and quantification of CXCR3-expressing IgMnaive, IgMmem and IgG
+ B-cell frequencies in the blood of 
untreated MS patients (n = 10; dark blue dots) and both age-/gender-matched healthy controls (n = 10; grey dots, 
see Table 1). (C) VLA-4 surface expression on IgMnaive, IgMmem and IgG
+ B cells from blood of MS patients before 
natalizumab treatment (n = 9). (D) The percentage of IgMnaive, IgMmem and IgG
+ B cells in MS blood before (black 
dots) and both 6 months (marine blue dots) and 12 months (light blue dots) after natalizumab treatment (paired 
samples; n = 10; see Table 1). Surface expression levels of (E) CXCR3, (F) CXCR5 and CCR6 on IgMnaive, IgMmem and 
IgG+ B cells in pre- and post-natalizumab-treated MS patient blood (n = 7-10). (G) CD20 expression on IgMnaive, 
IgMmem and IgG
+ B cells as well as paired CXCR3- and CXCR3+ IgG+ populations in blood of MS patients treated with 
natalizumab for 12 months (n = 8). (H-J) Gating example and quantifications of IgG1+ and IgG2+ B cells expressing 
CXCR3 in MS patients treated with natalizumab for 12 months (n = 9). Data are presented as the mean ± SEM. 
****p < 0.0001, ***p < 0.001, **p < 0.01 and *p < 0.05. The p values were calculated by Mann-Whitney U (B), 2-way 
ANOVA (C and G), Friedman paired (D-F) and Wilcoxon matched-pairs signed rank (G, I and J) tests.
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increased on IgG+ B cells and higher on CXCR3+ compared to CXCR3- counterparts in the 
blood of natalizumab-treated MS patients (Fig 2G).
Since intrathecally synthesized OCBs are restricted to the IgG1 subclass in the CSF of 
MS patients [28], we also analyzed IgG1+ B cells for their frequencies and CXCR3 expression 
in the blood of a third cohort of natalizumab-treated MS patients (Fig 2H). IgG1+ B cells 
not only expressed higher levels of CXCR3 (p = 0.007; Fig 2I), but also showed increased 
frequencies in post-treatment samples (p = 0.027; Fig 2J) compared to IgG2+ B cells. The 
selective accumulation of CXCR3high IgG(1)+ B cells in the blood of natalizumab-treated 
patients underlines the potency of this subset to transmigrate into the CNS to mediate MS 
disease activity. 
CXCR3+IgG1+ B cells have an enhanced capacity to transmigrate across 
the blood-brain barrier in vitro
To functionally test the transmigration potential of CXCR3+IgG1+ B cells into the CNS, 
we sorted memory B cells from the blood and assessed in vitro migration of subsets 
towards CXCL10. Fractions of CXCR3-expressing IgMmem, IgG1
+ and IgG2+ B cells were 
assessed within the total memory pool before and after migration through transwell filters. 
In contrast to IgMmem and IgG2
+ populations, IgG1+ B cells showed prominent recruitment 
to CXCL10 (p < 0.0001 before versus after migration; Fig 3A and B). This was not seen using 
medium only (Fig 3B). To mimic B-cell transmigration across the blood-CNS barrier, these 
experiments were repeated using cultured confluent monolayers of human brain endo-
thelial cells (BEC) [22]. We found a similar CXCL10-mediated migratory advantage of IgG1+ 
B cells (p < 0.0001; Fig 3A and C), which is consistent with the abundance of CXCR3 on 
IgG1+ compared to IgMmem and IgG2
+ B cells in MS patients (Fig 2G-I). These data demon-
strate that CXCR3high IgG1+ B cells in the blood have a heightened ability to infiltrate the 
CNS, probably accounting for the local IgG1 subclass restriction of OCB in MS patients [28]. 
IFN-γ promotes CXCR3 expression and CD4+ T-cell activation by human 
T-bet+ B cells under TFH1-like culture conditions 
In MS blood, the proportion of CXCR3+IgG+ B cells correlated to Th17.1 (IFN-γhighIL-17low; 
r = 0.566, p = 0.0003) and not to Th17 (IFN-γneg) cells (Fig 4A) [20]. Th cell-derived IFN-γ 
is known as a central driver of autoreactive B cells in mice [10] and also induces CXCR3 
expression on human memory B cells [29]. Therefore, we aimed to better understand how 
the differentiation and function of human CXCR3+ memory B cells is influenced by IFN-γ 
before entering the CNS. To address this, we mimicked the effects of IFN-γ-producing T 
follicular helper (TFH) cells on B-cell subsets in vitro. First, an IL-21-based human B- and T-cell 
co-culture system was used to assess whether Th1-derived IFN-γ influenced CXCR3 expres-
sion on IgG+ B cells in an antigen-specific manner. Since antigen uptake by B cells is limited 
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Figure 3. Enhanced migration of CXCR3+IgG1+ B cells across transwell filters and human brain endothelial 
monolayers in vitro. 
Sorted memory B cells from healthy donor blood were assessed for selective in vitro transmigration towards 
CXCL10. (A) Representative FACS plots and (B, C) quantifications of viable CXCR3-expressing IgMmem, IgG1
+ and 
IgG2+ B-cells migrating across transwell filters with and without confluent monolayers of human brain endothe-
lial cells (BEC). Percentages of subsets within the total memory pool were compared before and after migration, 
both to medium and CXCL10 (-BEC, n = 8; +BEC, n = 6). These experiments were performed in duplicate for each 
donor for which the average is shown. Data are presented as the mean ± SEM. ****p < 0.0001, **p < 0.01 and *p < 
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Figure 4. T helper 1 cytokine IFN-γ is a major trigger of CXCR3+(T-bet+) B-cell differentiation in MS. 
(A) Correlation of ex vivo CXCR3+IgG+ B cells with Th17.1 (IFN-γhighIL-17low) and Th17 (IFN-γneg) cells in MS blood 
pre- and post-natalizumab treatment (pre-Tx and post-Tx; n = 12). (B) Experimental model of Salmonella-primed 
autologous B- and T-cell co-cultures. (D-E) B cells from healthy donor blood were primed with S. typhimurium 
through BCR crosslinking using a tetrameric antibody complex, as described in the methods. This allows BCR-me-
diated Salmonella uptake, processing and presentation on MHC II molecules to Th cells. IL-21 was added with 
and without an IFN-γ blocking antibody to analyze the effects on CXCR3 expression by B cells (C), and on the 
proliferation, activation and effector memory phenotype of Th cells (D, E). These experiments were performed in 
two independent experiments and in duplicate for (C) four and (D, E) two different blood donors. (F) Correlation 
of surface CXCR3 and intracellular T-bet expression in ex vivo B cells of MS patients pre- and post-natalizumab 
treatment (pre-Tx and post-Tx; n = 9). (G, H) Total B cells from the blood of MS patients (n = 9) and both age-/gen-
der-matched healthy controls (HC; n = 10) were cultured in vitro under TFH-like conditions with IL-21, 3T3-CD40L 
cells and with or without IFN-γ for 11 days. Representative FACS plots and quantification of in vitro-induced T-bet+ 
B cells (G) and correlation of CXCR3 and T-bet expression in these cultured B cells (H) are shown. Data are present-
ed as the mean ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01 and *p < 0.05. The p values were calculated by 2-way 
ANOVA (c), 1-way ANOVA (D, E) and Wilcoxon matched-pairs signed rank (G) tests. The correlation coefficients 
and p values for A, F, H were calculated by Spearman rank.
2
53
Induction of CNS-infiltrating T-bet+ B cells in MS 
by the selectivity of the BCR, surface IgG was crosslinked with Th1-associated pathogen 
S. typhimurium for efficient internalization, processing and presentation to autologous Th 
cells (Fig 4B) [23, 30]. After 6 days of co-culture, we found that the induced expression of 
CXCR3 on Salmonella-containing IgG+ and not IgMnaive or IgMmem B cells was abrogated by 
the addition of an IFN-γ blocking antibody (p < 0.0001; Fig 4C). Furthermore, blocking of 
IFN-γ impaired B cell-induced T-cell proliferation, activation and effector memory forma-
tion (Fig 4D and E). This implies that IFN-γ additionally stimulates the antigen-presenting 
function of CXCR3+IgG+ B cells, in parallel with previous findings in mice [31]. 
CXCR3 expression is under the direct control of IFN-γ-inducible transcription factor 
T-bet, a critical regulator of memory B-cell differentiation in mice [13, 14]. Consistent with 
this, intracellular T-bet positively correlated to surface CXCR3 expression in ex vivo B cells (r 
= 0.644, p = 0.0003) and showed a similar association with Th17.1 (IFN-γhighIL-17low) cells in 
MS patients (Fig 4F and data not shown) [20]. To further explore the susceptibility of B cells 
to IFN-γ in MS [7], we compared B cells from MS and matched healthy control blood for IFN-
γ-mediated T-bet induction under TFH-like culture conditions. After 11 days of stimulation 
with 3T3-CD40L cells, IL-21 and IFN-γ, T-bet was predominantly upregulated in B cells of 
MS patients (p = 0.021; Fig 4G), while conditions without IFN-γ did not show this. This in 
vitro-induced T-bet was co-expressed with surface CXCR3 (r = 0.766, p = 0.0001; Fig 4H), 
in line with our ex vivo results (Fig 4F). These findings reveal that Th cell-derived IFN-γ is a 
major trigger of peripheral CXCR3(T-bet)+ B cells in MS.
IFN-γ stimulates plasmablast formation and synergizes with CpG-DNA to 
establish IgG1 switching during human TFH-like B-cell cultures
Besides IFN-γ, also TLR9 ligand CpG-DNA has been reported to induce T-bet in murine B 
cells [14, 18] and promote pro-inflammatory cytokine responses of B cells from MS patients 
[7]. To assess how TLR9 signals integrate with IFN-γ to regulate human T-bet+ B-cell develop-
ment, we first determined whether naive or memory B cells are more prone to this type of 
co-activation. Naive (CD27-IgG-) and memory (CD27+IgG+) B cells were sorted from healthy 
donor blood and stimulated with 3T3-CD40L cells, IL-21, IFN-γ and/or CpG-DNA. After 11 
days of naive B-cell cultures, both T-bet and CXCR3 expression was induced by IFN-γ, and 
further enhanced after addition of both IFN-γ and CpG-DNA (p = 0.001 and p = 0.021; Fig 
5A). This additional effect of CpG-DNA was not found when using sorted memory B cells 
(Fig 5B). Both IFN-γ- and CpG-DNA-induced T-bet(CXCR3)+ B cells also showed strongly 
reduced CD21 expression (data not shown), a typical feature seen for T-bet-expressing B 
cells [31].
During a germinal center response, naive B cells can either differentiate into plasmab-
last or memory populations, depending on the local inflammatory environment [10, 32]. 


























































































































































































































































































Figure 5. IFN-γ induces plasmablast differentiation, while both IFN-γ and CpG-DNA further upregulate 
T-bet and trigger IgG1 switching in B cells of MS patients.  
(A-D) Naive (IgG-CD27-; dots) and memory (IgG+CD27+; squares) B cells were sorted from peripheral blood of 
healthy donors and were cultured under TFH-like conditions with IL-21, 3T3-CD40L cells, with or without IFN-γ 
and/or CpG-DNA. Frequencies of T-bet+ and CXCR3+ B cells after 11 days of culture using (A) naive B cells (n = 12) 
and 6 days of culture using (B) memory B cells (n = 10-12). The frequencies of (C) plasmablasts (CD38highCD27+; n 
= 12) and (D) membrane-bound (m) mIgG1+ and mIgG2+ B cells were analyzed after culturing naive populations 
for 11 days (n = 12). (E) Correlation between cellular expression and secretion of IgG1, as determined by FACS and 
ELISA (pooled stimulation conditions for 5 donors). Naive B cells from the blood of MS patients (n = 6; dark blue 
dots) and healthy controls (n = 6; grey dots) were cultured under the same TFH-like conditions and analyzed for 
(F) plasmablast (CD38highCD27+) and (G, H) CXCR3+mIgG1+ and CXCR3+mIgG2+ B-cell differentiation after 11 days 
of culture. Data are presented as the mean ± SEM. ***p < 0.001, **p < 0.01 and *p < 0.05. The p values for A-D and 
F-H were calculated by the Wilcoxon matched-pairs signed rank test. The correlation coefficient and p value for E 
was calculated by Spearman rank correlation.
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subclass switching during IL-21-/CD40L-induced naive B-cell differentiation. After 11 days 
of culture, sorted naive B cells from healthy donors developed into plasmablasts under 
IFN-γ stimulatory conditions only (p = 0.034; Fig 5C). IFN-γ and CpG-DNA together did not 
induce plasmablast formation, but instead triggered IgG1 and not IgG2 expression on dif-
ferentiating B cells (IFN-γ only versus IFN-γ + CpG-DNA: p = 0.002; Fig 5D). Interestingly, 
this in vitro-induced IgG1 switching was subjected to differentiation of sorted naive (Fig 
5D) and not memory (data not shown) B cells. CpG-DNA alone did not upregulate CXCR3, 
T-bet and IgG1 in differentiating naive B cells (data not shown), indicating that both IFN-γ 
and TLR9 signaling are required for enhanced expression of these markers. To verify that 
B-cell intrinsic expression also corresponds with secretion of IgG1, we performed ELISAs 
on culture supernatants of these B cells. Indeed, the percentage of IgG1+ B cells positively 
correlated to IgG1 secretion (r = 0.640, p = 0.016; Fig 5E). 
Finally, to address how this is regulated in MS, we isolated naive B cells from MS patients 
and performed similar culture experiments. IFN-γ-mediated plasmablast formation was 
more induced after 11 days of culture compared to matched controls (p = 0.031; Fig 5F). 
This was not seen after stimulation with both IFN-γ and CpG-DNA. Instead, this type of 
triggering resulted in a robust induction of CXCR3+IgG1+, and not CXCR3+IgG2+ subsets 
in MS (Fig 5G and H). Collectively, these data demonstrate that TLR9 signaling potentiates 
IFN-γ-induced T-bet and CXCR3 expression during naive B-cell differentiation in vitro, and 
that this is important for IFN-γ-mediated formation of IgG1+ memory B cells rather than 
plasmablasts under TFH-like circumstances in MS.
DISCUSSION 
Evidence has accumulated that at least in the periphery, antibody-independent roles 
of B cells are driving the pathology of MS [7]. However, local production of autoantibod-
ies should not be ruled out as an underlying B-cell mechanism in this disease [33]. Even 
though autoreactive naive B cells are highly active in MS blood [9], the vast majority of 
B cells identified in the MS brain have undergone further maturation into antibody-pro-
ducing cells [34, 35]. It has also been demonstrated that memory B cells of MS patients 
are the most potent antigen-presenting cells and likely have specific pro-inflammatory 
propensities, including the capacity to express enhanced levels of immune activating 
molecules [35]. This is of special interest considering the presence of meningeal B cell-
rich follicle-like structures in MS and the adjacent subpial cortical demyelinating injury [8], 
which probably contributes to progressive loss of neurological function in patients with 
MS. Thus, identification of the particular B-cell subsets that can preferentially migrate into 
the CNS and clarifying how they may contribute to propagating local injury responses is of 
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considerable interest in such an organ-specific disease. In this study, we demonstrate that 
integrating IFN-γ and pathogen-associated TLR9 signals are critical for the development of 
human T-bet+ memory B cells, probably underlying their selective recruitment to the CNS 
of MS patients. 
Recent studies have shown that in MS identical B-cell clones are present in both the 
periphery and CNS [2-4]. The fact that these B-cell populations further undergo somatic 
hypermutation in the brain implies the presence of functional germinal centers within the 
CNS. Indeed, such structures have been identified in the meninges of MS patients and are 
obvious localizations to play a role here [8]. The enrichment that we observe of CXCR3+ B 
cells in paired CSF, meninges and brain tissue compartments compared to blood of MS 
patients is in line with studies that show higher levels of CXCR3 ligand CXCL10 in the CSF of 
MS patients [24]. These results are also consistent with our previous findings that CXCR3+ T 
cells, including Th17.1, are abundant within the CNS [20, 24], suggesting a common CXCR3-
driven lymphocyte recruitment pathway in MS [24, 36, 37]. Other studies have also put for-
ward CXCR5 and its ligand CXCL13 as important contributors to B-cell recruitment to the 
CNS [3, 38]. We did not find differences in CXCR5-expressing B cells between CNS tissues 
and paired blood. Hence, the CXCR5/CXCL13 axis is probably related to local organization 
rather than recruitment of pathogenic B (and T) cells [39, 40], in a process similar to that 
in secondary lymphoid organs [41]. While these studies indicate a role for germinal center 
B cells within the CNS, little is known about which peripheral mechanisms underlie their 
development and local recruitment. In mice, it has been shown that in an autoimmune 
setting, IFN-γ, likely produced by activated TFH cells, induce germinal centers [10], which 
can be found in meningeal follicle-like structures [8]. In these situations, IFN-γ induced 
B cell-intrinsic expression of T-bet, possibly resulting in enhanced Ig class switching and 
CXCR3 expression [13, 14]. This points to a central role of IFN-γ-associated CXCR3+ B-cell 
subsets in the meningeal process [10, 12].
 While the inducing effects of peripheral B cells on autoreactive Th1 cells are currently 
being elucidated [37], far less is known about the impact of Th1 cells on peripheral B-cell 
differentiation and function in MS patients. Therefore, we were interested in the signals 
needed for B cells to differentiate into T-bet+ cells and postulated that IFN-γ- and IL-21-
producing TFH1 cells in germinal centers can trigger development of such B cells. Indeed, in 
MS patients, B cells were found to express higher T-bet levels under TFH1-like culture con-
ditions. Furthermore, IL-21-based B- and T-cell co-cultures revealed that CXCR3-expressing 
IgG+ memory B cells were less induced after blocking of IFN-γ, which corresponds to stud-
ies that show IFN-γ regulates CXCR3 expression in human B cells [29]. Th cell proliferation, 
activation and effector memory formation were also affected in these cultures. In line with 
our findings, a recent study demonstrated that memory B cells induce proliferation of CNS-
infiltrating Th1 cells in MS, which was inhibited after IFN-γ abrogation [37]. Therefore, in MS 
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patients, peripheral interaction of CXCR3(T-bet)+ B and IFN-γ-producing Th cells probably 
generates a feedforward loop, in which IFN-γ enhances the potency of B cells as anti-
gen-presenting cells, resulting in the activation of (IFN-γ-producing) pathogenic Th cells.
Furthermore, we found that naive B cells from MS patients developed into plasmablasts 
rather than IgG1-switched memory B cells under IFN-γ-only conditions. Since T-bet medi-
ates class-switching in murine B cells [13], we expected that an additional signal would be 
required for triggering such a mechanism in human B cells. Besides TFH1 cells, also innate 
TLR signaling is critical for naive B-cell differentiation [42]. Especially pathogen-associated 
TLR9 and its ligand CpG-DNA have been shown to promote the development of T-bet+ 
B cells in mice [19, 31, 42]. Correspondingly, we found that the induction of MS-blood 
derived naive B cells with both IFN-γ and CpG-DNA resulted in the development of IgG1-
switched, T-bethigh B cells during TFH-like cultures. Likewise, CXCR3 surface expression was 
more enhanced under these conditions, reflecting the high CXCR3 levels on ex vivo IgG1+ 
B cells. This additional effect of TLR9 signaling on human T-bet+ B cells in MS links to the 
role of TLR9 in driving neuroinflammatory responses, including increased production of 
chemokines in the CNS [43]. Moreover, CXCR3+IgG1+ B cells showed an enhanced transmi-
gration potential over brain endothelial layers, and selectively accumulated in MS blood 
after natalizumab therapy. The importance of pathogenic immune cells in contributing 
to MS disease progression, such as CXCR3+ memory B cells, has been put forward by the 
recurrence of often-fatal clinical relapses in MS patients when discontinuing the use of 
natalizumab [27, 44, 45]. During these rebounds, EBV-infected memory B cells that have 
accumulated in the blood show massive influx into brain tissues of MS patients [45]. 
Furthermore, persistent viral infections are suggested to sustain the development of T-bet-
expressing B cells [15], which further supports the enhanced differentiation and local 
recruitment of CXCR3(T-bet)high memory B cells in an organ-specific autoimmune disease 
such as MS (Fig 6). 
Although the exact role of (local) autoantibody production in MS is not clear, the ques-
tion whether and how T-bet+ B cells are involved this process deserves further attention. In 
SLE, T-bet+ B cells have autoreactive BCRs and are prone to differentiate into IgG autoanti-
body producing plasmablasts [46]. Inappropriate T-bet expression in B cells also impaired 
CXCR3-mediated plasmablast differentiation within germinal centers [14] and autoanti-
body production [13]. In our study, IFN-γ- and CpG-DNA-induced human CXCR3(T-bet)high 
B cells showed increased IgG1 expression and secretion. This strongly suggests that after 
preferential recruitment and re-activation in the CNS, CXCR3(T-bet)highIgG1+ B cells are 
responsible for local production of IgG1 in MS (Fig 6) [28]. Although B cells within the CNS 
of MS patients show characteristics of an antigen-driven response, the specific antigens 
driving this response remain unknown. MS disease heterogeneity is reflected by the 
identification of several candidate target antigens, including non-myelin proteins such as 
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neurofilament light and RAS guanyl releasing protein 2 (RASGRP2) [33, 37]. In addition to 
this, increased Epstein-Barr nuclear antigen 1 (EBNA1)-specific IgG1 titers have been found 
in active MS, which may be explained by the interaction of B cells with pathogen-associ-
ated TLR ligands and EBNA1-specific, IFN-γ-producing T cells that cross-recognize myelin 
antigens [47]. Therefore, we propose that the relevant antigen specificity of B cells in MS 
can be found within this subset, which should be further explored in the near future. 
Taken together, not only a disrupted blood-brain barrier, but also peripheral T-bet-
mediated differentiation and transmigration of IgG1+ memory populations could explain 
how B cells are eventually able to mediate CNS pathology in MS patients (Fig 6). The rele-
vance of T- and B-cell interaction in tolerance breakthrough is stressed by the fact that anti-
gen-specific B cells are potentially 1000 to 10,000 times better presenters of autologous 
peptides to T cells than non-specific B cells [48]. We here reveal that human CXCR3(T-bet)+ 
B cells are a product of T- and B-cell interaction. Similar to SLE, such populations probably 
serve as potent antigen-presenting cells in CNS-specific autoimmune diseases such as MS 
[31]. Anti-CD20 therapy exerts immediate effects and is assumed to predominantly affect 
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Figure 6. IFN-γ and TLR9 signalling upregulate T-bet in peripheral B cells, likely driving CXCR3-mediated 
recruitment and IgG1 production in the CNS of MS patients. 
Our findings suggest that in the secondary lymphoid organs of MS patients, IFN-γ triggers naive B cells to differ-
entiate into T-bet-expressing populations in a TFH-dependent manner. Human T-bet
+ B cells either can develop 
into plasmablasts or undergo further differentiation into IgG1+ memory B cells mediated by TLR9 ligation. The 
enhanced CXCR3 expression on both IFN-γ- and TLR9-induced IgG1+ B cells makes these subsets highly capable 
of transmigrating across the blood-brain barrier and mediate local pathology in MS. 
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this function of B cells in MS patients [35]. The potential role of CXCR3(T-bet)+ B cells as 
prime targets of this therapy is further supported by their abundant CD20 expression, as 
shown in the current study. The development of new targeted strategies to inhibit T-bet 
function have the potential to become a double-edged sword in MS by suppressing 
pathogenic, IFN-γ-producing T (Th17.1) cells together with their counterpart CXCR3(T-
bet)+ B cells. Small molecule inhibitors of IFN-γ signaling (jakinhibs) [49]c and the TLR/
myD88 pathway [50] are already used in the clinics for other inflammatory diseases, and 
are promising candidates for combined suppression of IFN-γ and TLR signals to control 
pathogenic T-bet+ B cells in autoimmune diseases such as MS.
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ABSTRACT 
C-type lectin CLEC16A is located next to CIITA, the master transcription factor of 
HLA class II (HLA-II), at a susceptibility locus for several autoimmune diseases including 
multiple sclerosis (MS). We previously found that CLEC16A promotes the biogenesis 
of HLA-II peptide-loading compartments (MIICs) in myeloid cells. Given the emerging 
role of B cells as antigen-presenting cells in these diseases, we here addressed whether 
and how CLEC16A is involved in the B cell receptor (BCR)-dependent HLA-II pathway. 
CLEC16A was co-expressed with surface class II-associated invariant chain peptide 
(CLIP) in human EBV-positive and not EBV-negative B-cell lines. Stable knockdown 
of CLEC16A in EBV-positive Raji B cells resulted in an upregulation of surface HLA-DR 
and CD74 (invariant chain), while CLIP was slightly, but significantly, reduced. In addi-
tion, IgM-mediated Salmonella uptake was decreased and MIICs were less clustered 
in CLEC16A-silenced Raji cells, implying that CLEC16A controls both HLA-DR/CD74 
and BCR/antigen processing in MIICs. In primary B cells, CLEC16A was only induced 
under CLIP-stimulating conditions in vitro and was predominantly expressed in CLIPhigh 
naive populations. Finally, CLIP-loaded HLA-DR molecules were abnormally enriched 
and co-regulation with CLEC16A was abolished in blood B cells of patients who rap-
idly develop MS. These findings demonstrate that CLEC16A participates in the BCR-
dependent HLA-II pathway in human B cells and that this regulation is impaired during 
MS disease onset. The abundance of CLIP already on naive B cells of MS patients may 
point to a chronically induced stage and a new mechanism underlying B cell-mediated 
autoimmune diseases such as MS.
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INTRODUCTION
HLA class II (HLA-II) is a major risk factor for various autoimmune diseases, including 
multiple sclerosis (MS) [1]. During autoimmune pathogenesis, certain antigens are alterna-
tively processed and/or presented by HLA-II molecules to trigger autoreactive, or maybe 
even suppress regulatory CD4+ T cells [2, 3]. The strong clinical effects of anti-CD20 therapy 
put forward B cells as key players in such diseases by acting as potent antigen-presenting 
cells [4-6]. Currently, not much is known about which and how genes related to autoim-
munity contribute to changes in the HLA-II antigen presentation pathway of B cells [2, 7, 8].
Multiple genome-wide association studies (GWAS) have demonstrated that C-type 
lectin gene CLEC16A is associated with susceptibility to type I diabetes [9], rheumatoid 
arthritis [10], multiple sclerosis (MS) [11] and other autoimmune diseases [12]. CLEC16A is 
located at the 16p13 region next to CIITA, which is the master transcription factor of HLA-II 
[13]. C-type lectins are known to recognize and guide antigens into the endosomal system 
for processing and loading onto HLA-II molecules [14]. Although it lacks a functional anti-
gen recognition domain, CLEC16A has been demonstrated to induce autoimmunity in 
mice, probably by stimulating thymic epithelial cell antigen presentation [15]. Previously, 
we found that CLEC16A participates in retrograde transport of HLA-II-containing com-
partments (MIICs) in myeloid cells [16]. How this gene influences the B cell-intrinsic HLA-II 
pathway has not been studied so far.
The HLA-II pathway in B cells is a unique and tightly controlled process, in which the 
B-cell receptor (BCR) mediates antigen capture, uptake and processing in MIICs [17]. To 
reach these compartments, newly synthesized HLA-II α- and β-chains in the endoplasmic 
reticulum need to bind to the invariant chain (CD74), which guides their transport into the 
MIICs either directly or indirectly via the plasma membrane [18]. In the MIICs, the invariant 
chain is cleaved by specific proteases, leaving class II-associated invariant chain peptides 
(CLIP) bound to the HLA-II peptide-binding groove. After exchange of CLIP for antigenic 
peptides, HLA-II/peptide complexes are transported to the plasma membrane for presen-
tation [19]. 
In this study, we addressed how CLEC16A is regulated and influences the HLA-II path-
way in human B cells. CLEC16A is found to mediate BCR-mediated antigen uptake, HLA-DR/
CD74 processing and MIIC biogenesis in Raji B cells. Furthermore, surface CLIP is co-regu-
lated with CLEC16A in both B-cell lines and primary B cells, which is enhanced after CD40 
triggering. This process seems to be disturbed during the development of MS, since CLIP 






Both clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients, 
as well as healthy controls (HC) were included in the MS Center ErasMS at Erasmus MC 
(Rotterdam, The Netherlands). All patients and controls gave written informed consent 
and study protocols were approved by the medical ethics committee (MEC) of the Erasmus 
MC. CIS was defined as a first clinical attack of demyelination in the central nervous system 
[20] and diagnosed according to the 2017 revised McDonald criteria [21]. The diagnosis of 
clinically definite MS (CDMS) was made when a patient experienced two attacks with clin-
ical evidence of two separate lesions according to the Poser criteria [22]. CIS patients were 
sampled within 4 months after their first attack. From our prospective CIS cohort (PROUD, 
MEC-2006-188), we selected patients who were diagnosed with CDMS within 1 year after 
CIS diagnosis (high-risk CIS) and patients who did not develop CDMS for at least 5 years of 
follow-up (low-risk CIS). These patients were matched for age and gender. RRMS patients 
were diagnosed according to the McDonalds criteria [23] and matched with healthy con-
trols for both age and gender (MEC-2014-033). Patient characteristics are summarized 
in Table I. Buffy coats were obtained from healthy volunteers (Sanquin, Amsterdam, The 
Netherlands). 
Blood sampling
PBMCs and plasma were isolated from whole blood with the use of CPTTM heparin 
tubes, while serum was isolated using coagulation tubes (both BD Biosciences, San Jose, 
CA). Samples were processed according to the manufacturer’s instructions. PBMCs were 











time in years, 
median (IQR)* 
Disease duration 





HC  12 9 (75%) 43 (21-65) NA NA NA 
CIS 
Low-risk 11 7 (64%) 38 (23-48) 8.4 (6.2 - 11.8) 2.0 (0.9 - 3.8) 2 (MP) 
High-risk 9 7 (78%) 30 (25-37) 4.2 (3.1 - 5.1) 2.1 (0.1 - 3.9) 2 (MP) 
RRMS  12 9 (75%) 43 (21-63) NA NA 1 (Copaxone) 
 
*, at time of sampling; †, time CIS to sampling; RRMS according to the McDonald 2010 criteria. 
Abbreviations: HC, healthy control; CIS, clinically isolated syndrome; IQR, interquartile range; MP, 
methylprednisolone; NA, not applicable or available; RRMS, relapsing-remitting MS. 
Table I . Clinical information of patients and healthy controls.
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SNP genotyping
Whole blood samples were collected from CIS patients and DNA was isolated by a stan-
dardized method [24]. Samples were genotyped on the Immuno-Chip and were subjected 
to the standard quality controls [25]. Genotyping was done within the framework of the 
International Multiple Sclerosis Genetics Consortium (IMSGC) [26].
Human B-cell lines
Ten Epstein-Barr virus (EBV)-positive (Raji, Daudi, EB1, JVM2, JVM3, JVM13, Namalwa, 
DoHH2, EHEB, AKATA) and eight EBV-negative (Ramos, DG75, CA24, U698-M, MC116, ROS-
50, WSU-NHL, Karpas422) human B lymphoma and leukemia cell lines (B-LCLs) were used 
in this study. All B-LCLs were purchased from DSMZ or ATCC.
CLEC16A antibody production 
CLEC16A monoclonal antibodies (clone 7A4 [16] and clone 4F11; both IgG2b) were 
generated by immunizing F344 (SAS FISCH) rats with a 27-mer C-terminal human peptide 
(CLEC16A954-980: VIVNETEADSKPSKNVARSAAVETASL) linked to KLH and standard mono-
clonal antibody production services performed by ImmunoPrecise Ltd (Victoria, Canada). 
The fidelity of hybridoma clones was initially screened by ELISA using peptide-BSA coated 
wells and then by probing HEK293T cells transfected with either vector alone (pEGFP; 
Clontech, Palo Alto, CA) or bearing full-length human CLEC16A cDNA. Monoclonal CLEC16A 
antibodies were found to be applicable for flow cytometry by binding to paraformalde-
hyde-fixed protein and Western blotting using CLEC16A-transfected HEK293T cells. 
Flow cytometry and cell sorting
In-depth flow cytometric analysis and cell sorting of B cells were performed using 
anti-human monoclonal antibodies against CD3 (SK7), CD19 (HIB16), CD38 (HIT2), CD74 
(LN2), HLA-DM (MaP.DM1), HLA-DR (L243), IgM (MHM-88, all Biolegend, London, UK), 
CD27 (M-T271), IgD (IA6-2), IgG (G18-145, all BD Biosciences) CLIP (CerCLIP.1, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and IgA (IS11-8E10, Miltenyi-Biotec GmbH, Bergisch 
Gladbach, Germany). FVS700 (BD Biosciences) was used for the detection of viable cells. 
The used CerCLIP.1 antibody specifically recognizes CLIP-loaded HLA-II, while L243 anti-
body detects peptide-loaded HLA-II (called HLA-DR; [7]). For intracellular staining of CLIP 
and HLA-DR, cells were fixed with 2% paraformaldehyde and permeabilized with PBS 
pH7.4 containing 0.2% BSA and 0.5% saponin (Sigma-Aldrich). For intracellular staining of 
CLEC16A, the BD Cytofix/Cytoperm™ kit (BD Biosciences) was used and staining was per-
formed according to the manufacturer’s protocol. Cells were first stained with rat-anti-hu-
man CLEC16A antibody (7A4) followed by a FITC-labeled F(ab’)₂ fragment donkey-anti-rat 
IgG (H+L) (Jackson Immuno Research, UK). A rat-anti-human IgG2b antibody (Biolegend) 
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was used as a negative control. Total (CD19+) and naive mature (CD38dimCD27-) B cells were 
isolated using a high-speed cell sorter (FACSAriaIII; BD Biosciences), resulting in purities of 
more than 95%. All measurements were performed on an LSRFortessa flow cytometer and 
data were analyzed using FACSDiva 8.1 software (both BD Biosciences). 
RNA isolation and quantitative PCR
Total RNA was isolated using GenEluteTM Mammalian RNA Kit (Sigma-Aldrich, St Louis, 
MO) and mRNA was reversely transcribed into cDNA following a standard laboratory pro-
tocol with the use of SuperScript II® Reverse Transcriptase (Invitrogen, Paisley, UK). Primers 
and probes were selected by using the Universal Probe Library Assay Design Centre (Roche 
Applied Science, Penzberg, Germany). To quantify target gene expression levels, qPCR was 
performed using an Applied Biosystems QuantStudio 5, which was programmed for the 
initial step of 2 min at 50°C and 10 min 95°C, followed by 40 thermal cycles of 15s at 95°C 
and 1 min at 60°C. For the calculation of relative mRNA expression, CT values were related 
to standard curves, which were generated for each gene of interest. All data were nor-
malized to 18S rRNA levels. HLA-DOB expression was determined using Power SYBR green 
(Invitrogen) and measured on an Applied Biosystems StepOnePlus. Primer sequences are 
listed in Table II.
In vitro activation of human B cells
B cells of healthy donors were negatively sorted using the B-cell isolation kit II and 
MACS (Miltenyi Biotec). B cells were cultured in RPMI supplemented with 5% fetal calf 
serum, 1% penicillin/streptavidin, 0.1% beta-mercaptoethanol, 1% Ultraglutamine, 0.1% 
apotransferrin (depleted for human IgG with prot-G sapharose). B cells were activated for 
24 and 48 hours using various stimulation cocktails including anti-IgM (10 µg/ml, Jackson 
Immuno Research), sCD40L (100 ng/ml, Enzo Life Sciences, New York, USA), CpG (10 µg/ml, 
 
Gene Forward primer Reverse primer 
BTK TGTTGAAACAGTGGTTCCTGA TGCTCCATTTCACTGGACTCT 
CBLB GTGCACCTCTTGCCTTACG CCTTTTATTTCACAACGACAGAAA 
CD74 ATGAGCAACTGCCCATGC CAGGATGGAAAAGCCTGTGT 
CIITA AACAGGATTCACGGATCAGC CAGCGTGGTTAGTGTCCTCA 
CLEC16A TGCCCCTCTACGTGTACTCA GAGACACCGGCAGGCTAAT 
HLA-DMB GAACTCCCGGCATCTTTACA CAACAGACAGGTGCTTTCCA 
HLA-DOB GGAGAAAGATGCTGAGTGGC GCTCTTGAGACCTCATTACC 
HLA-DRA AGCCTCTTCTCAAGCACTGG GGCACACACCACGTTCTCT 
IFI30 CTACGGAAACGCACAGGAA TCTTCTCCATGCTGGCACTT 
MARCH1 TCAGGACATCTGCAGAATCTGTCAC TCACAGCAGCGTGTATCTGAG 
 
Table II. Primers used for qPCR.
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Invitrogen), IFN-γ (100 ng/ml, Peprotech, London, UK) or IL-21 (50 ng/ml, Thermo Fisher 
Scientific, Massachusetts, USA).
Western blotting 
For western blotting, cells were lysed in radio-immunoprecipitation assay (RIPA) lysis 
buffer supplemented with 10% complete protease inhibitor cocktail (Roche, Mannheim, 
Germany) on ice for 30 minutes, centrifuged at 4°C for 10 minutes at 10,000 x g. Cell 
lysates were reduced with 10% 2-mercaptoethanol, denatured for 5min at 95○C, loaded 
onto a 10% precast polyacrylamide gel (Bio-Rad, Hercules, CA) followed by immunoblot-
ting on a Immobilon-P membrane (Merck Millipore, Darmstadt, Germany) for 1 hours 
at 4°C. Membranes were blocked in 5% nonfat dry milk and incubated with rat-anti-hu-
man CLEC16A (clone 7A4 and 4F11; both IgG2b), rat-anti-human IgG2b isotype control 
(Biolegend) or mouse anti-human β-actin (AC-15; Abcam, Cambridge, UK). Horseradish 
peroxidase (HRP)-conjugated rabbit-anti-rat or goat-anti-mouse (Dako, Glostrup, Denmark) 
were used as secondary antibodies. Protein bands were visualized using Western Lightning 
Plus-ECL (Perkin Elmer Inc., Waltham, MA).
Generation of stable CLEC16A shRNA B-cell transfectants 
For CLEC16A knockdown, human B-LCLs Raji and Ramos were transfected with CLEC16A 
shRNA-containing pLKO.1 constructs (MISSION® shRNA Library, Sigma-Aldrich) using 
Nucleofector Kit V and AMAXA nucleofector II, both from Lonza (Basel, Switzerland). Two 
CLEC16A shRNAs were used to exclude off-target effects: #1, CAGCTCTGTATTTGACTTCTT 
and #2, GCTAAGACTGAACAGGATATT. After three days, puromycin (InvivoGen, Toulouse, 
France) was added at 0.25 µg/ml, which was increased to 0.5 µg/ml after one week of cul-
turing. CLEC16A levels were compared between CLEC16A and scrambled shRNA transfec-
tants at the same day of culture.
BCR-mediated uptake and processing of Salmonella
Salmonella Typhimurium SL1344 was used as a model system to assess IgM-mediated 
uptake and localization in MIICs, as described previously [27-29]. In short, anti-human 
IgM (MH15, Sanquin, Amsterdam, The Netherlands) was mixed with anti-Salmonella LPS 
(1E6, Invitrogen) and rat anti-mouse IgG1 (RM161-1, Sanquin) to generate stable tetram-
eric antibody complexes. Exponentially grown bacteria were washed twice with PBS, 
incubated with tetrameric antibody complexes for 30 min at RT and washed again to 
remove unbound antibodies. Scrambled and CLEC16A shRNA-transfected Raji cells were 
incubated with viable anti-IgM coated GFP-Salmonella T. [30] at 20 bacteria/cell for 45 min 
at 37°C without antibiotics. Cells were washed 3 times and cultured for 1 h in RPMI supple-
mented with 5% fetal calf serum, 1% penicillin/streptavidin, 0.1% beta-mercaptoethanol, 
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1% Ultraglutamine, 0.1% apotransferrin (depleted for human IgG using prot-G sepharose) 
and 100 mg/ml gentamicin (Invitrogen) to eliminate non-phagocytosed bacteria. Finally, 
cells were added to poly-L-lysine coated diagnostic black slides for 45 min and fixed with 
4% PFA for 15 min at RT. 
Immunofluorescence microscopy and analysis 
For immunofluorescence staining, fixed cells were permeabilized with 0.1% Triton 
X-100/PBS for 10 min at RT. Slides were then subsequently incubated with primary anti-
bodies mouse-anti-human CD63 (MEM-259, Abcam) and rabbit-anti-HLA-DR (kind gift 
from J. Neefjes) (1 h, RT) followed by staining with goat anti-rabbit AF594 and anti-mouse 
AF647 (Molecular Probes) (30 min, RT) as well as DAPI (Thermo Fisher Scientific; 10 min, 
RT). Finally, slides were mounted in Vectashield (Vector Laboratories, Peterborough, UK) 
and analyzed using the confocal laser-scanning microscope Zeiss LSM 700 and ZEN soft-
ware (Carl Zeiss, Oberkochen, Germany). We counted the number and calculated the per-
centage of B cells with clustered MIICs based on CD63 and HLA-DR expression in at least 
ten different images, with a minimum of 10 cells per image. The images were scored by 
two independent observers. We also determined the percentage of cells with Salmonella T. 
present inside MIICs. We analyzed 21-133 cells and 57-291 Salmonella T. bacteria in at least 
13 images per condition, with an average of two bacteria per cell in each condition.     
Statistical analyses
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., 
San Diego, CA). Data are expressed as median ± interquartile range (IQR), unless stated oth-
erwise. Mann-Whitney-U tests and unpaired t-tests were used to compare data between 
two groups. Wilcoxon matched-pairs signed-rank and paired t-tests were used to analyze 
paired datasets. Kruskal-Wallis or Friedman including Dunn’s multiple comparison tests, as 
well as one- or two-way ANOVA with Bonferroni’s corrections were used to compare more 
than two groups. All correlations were tested based on Spearman rho. P values less than 
0.05 were considered as statistically different.
RESULTS
EBV-positive and not -negative human B-cell lines show a correlation 
between surface CLIP and CLEC16A expression
Previously, we have shown that autoimmunity-related gene CLEC16A regulates MIIC 
biogenesis in human myeloid cells [16]. Since HLA-II peptide loading efficiency is deter-
mined in MIICs [18] and the presence of CLIP/HLA-II complexes on the plasma membrane 
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is considered a measure of inefficient antigenic peptide presentation [7], we assessed how 
both surface CLIP and HLA-DR levels are influenced by CLEC16A expression in human B 
cells. Since it is at least a challenge to modify genes in primary B cells, we first screened 
10 EBV+ and 8 EBV- human B-LCLs for CLIP, HLA-DR and CLEC16A expression. CLIP and not 
HLA-DR was expressed at a higher level on EBV+ versus EBV- B-LCLs (Figure 1A). Only in EBV+ 
B-LCLs, CLIP and CLIP-loaded HLA-DR molecules positively correlated to CLEC16A expres-
sion, which was not seen for HLA-DR expression alone (Figure 1B and Supplementary 
Figure 1A) or in EBV- B-LCLs (data not shown). These correlations were not driven by expres-
sion differences in HLA-DM and HLA-DO, two known chaperones of HLA-II peptide loading 
BA B-LCL B-LCL EBV+ B-LCL EBV+ B-LCL
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Figure 1. Association of surface CLIP and CLEC16A expression in unstimulated and stimulated human 
B-cell lines.
(A) Eight EBV- and ten EBV+ B-LCLs were screened for surface CLIP and HLA-DR expression using FACS. (B) Correla-
tion of CLEC16A with surface CLIP and HLA-DR levels in EBV+ B-LCLs. (C-E) CLIP (48h) and CLEC16A (24h) induction 
in CLIPlow (EBV-) B-LCL Ramos after CD40L-mediated stimulation. Expression levels are depicted as median ± IQR 
and were calculated as relative to unstimulated cells (dotted line). Mann-Whitney U test (A) or Friedman includ-
ing Dunn’s multiple comparison tests (C, D) were performed on unprocessed data (Supplementary Figure 1E). 
Conditions were compared to unstimulated B cells from the same donor (dotted line). For B and E, Spearman’s 
correlation coefficients were calculated. * p<0.05, ** p<0.01, **** p<0.0001.
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[31] (Supplementary Figure 1B), or other MS- and B cell-associated genes, including CBLB, 
IFI30 and MARCH1 (Supplementary Figure 1C). In vitro activation of CLIPlow (EBV-) Ramos B 
cells (Supplementary Figure 1D) using CD40L-containing cocktails triggered both surface 
CLIP and CLEC16A expression (Figure 1C-E and Supplementary Figure 1E). These findings 
suggest that CLEC16A is associated with processing and presentation of CLIP-loaded HLA-II 
molecules by B cells.
CLEC16A knockdown in EBV-positive Raji B cells causes cytoplasmic 
scattering of MIIC and interferes with CLIP/HLA-DR and CD74 surface 
expression
In line with previous work on HLA-II biology in human B cell lines [32], we used CLIPhigh 
Raji (EBV+) B cells (Supplementary Figure 1D) to generate stable CLEC16A knockdowns 
using two different shRNA constructs. In both CLEC16A shRNA transfectants, we found 
an approximately 50% reduction in CLEC16A expression, while levels of HLA-DRA and its 
master regulator CIITA remained unaffected (Figure 2A) compared to scrambled controls 
(dotted line). This resulted in significantly elevated HLA-DR (mean increase: 37%) and CD74 
(the precursor of CLIP; mean increase: 70%) and reduced CLIP (mean decrease: 15%) surface 
expression levels (Figure 2B and Supplementary Figure 2A). Stable CLEC16A knockdown in 
CLIPlow Ramos B cells did not affect surface HLA-DR, CD74 and CLIP (Supplementary Figure 
2B). Based on our earlier study [16], these discrepancies in HLA-II-associated CD74 and 
CLIP surface expression in Raji B cells after CLEC16A knockdown are probably related to 
disrupted processing in MIICs. To test whether the localization of MIICs was affected in 
CLEC16A-silenced Raji B cells, we analyzed how and where late endosomal markers HLA-DR 
and CD63 were co-expressed using confocal microscopy. MIICs in CLEC16A shRNA transfec-
tants were more scattered than clustered (Supplementary Figure 2C) compared to scram-
bled shRNA transfectants from the same experiments (Figure 2C and D; n=5). Consistent 
with our FACS results, HLA-DR seemed to be more expressed at the plasma membrane 
of CLEC16A shRNA transfectants (Figure 2C). These results imply that the recruitment of 
HLA-DR/CD74 to MIICs is controlled by CLEC16A in Raji B cells. 
BCR-mediated antigen uptake and transport into MIICs is impaired in 
CLEC16A-silenced Raji B cells 
In contrast to other types of antigen-presenting cells, antigen uptake and processing by 
human B cells critically depends on interaction with highly specific BCRs. This interaction 
not only results in internalization into the late endosomal system, but also triggers the bio-
genesis of MIICs [17, 33]. To determine whether CLEC16A participates in this tightly regu-
lated process and overcome the highly diverse antigen specificity of BCRs, we used a model 
in which GFP+ Salmonella Typhimurium was coated with tetrameric antibody complexes for 
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Figure 2. Effects of CLEC16A knockdown on surface expression of CLIP, HLA-DR and CD74 and cytosolic 
distribution of MIICs in CLIPhigh Raji. 
Relative CLEC16A, CIITA and HLA-DRA (A) and surface CLIP, HLA-DR and CD74 (B) levels in two different CLEC16A 
shRNA Raji transfectants after 25 days of puromycin selection. Data were compared to paired scrambled (scr) 
transfectants at the same day (dotted line, n=7-9). Expression levels are depicted as mean ± standard error of 
the mean, and are normalized to scrambled transfectants (dotted line). Paired t-tests were performed on unpro-
cessed data (Supplementary Figure 2A). (C) Representative confocal images for HLA-DR and CD63 expression in 
CLEC16A and scrambled shRNA Raji transfectants (more examples in Supplementary Figure 2C). (D) Percentages 
of CLEC16A and scrambled shRNA transfectants with clustered MIICs (n=5). Representative images (E) and quan-
tification of IgM-mediated Salmonella uptake after various incubation times (F) for two different CLEC16A and 
scrambled shRNA Raji transfectants. Data are representative for two independent experiments, with 21-133 cells 
and 57-291 bacteria in at least 13 images per condition analyzed. Paired t-test (D) or two-way ANOVA (F) was 
performed. In F, CLEC16A shRNA #1 and #2 were compared to the scrambled shRNA transfectants from the same 
experiment. * p<0.05, ** p<0.01, **** p<0.0001.
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BCR-mediated transport into MIICs [27]. Both scrambled and CLEC16A shRNA Raji transfec-
tants were incubated with viable anti-IgM-coated GFP-Salmonella and analyzed for inter-
nalization after different time points. In scrambled shRNA transfectants, Salmonella uptake 
and delivery to MIICs increased in time, resulting in 75-80% of Salmonella-containing cells 
after 165 min (Figure 2E and F). This was significantly lower in the two different CLEC16A 
shRNA transfectants, reaching a maximum uptake of approximately 40% (Figure 2F). These 
data indicate that CLEC16A regulates BCR-mediated uptake of antigens into MIICs in Raji B 
cells. Together with our earlier results, this implies that after antigen encounter, CLEC16A 
promotes the B cell-intrinsic HLA-II pathway by driving the retrograde trafficking of both 
HLA-DR/CD74 and BCR/antigen complexes for processing in the MIICs. 
Surface CLIP positively correlates to CLEC16A expression in ex vivo and in 
vitro-activated human B cells
To translate our findings to primary B cells, we studied the correlation between CLIP-
loaded HLA-DR molecules and CLEC16A expression in ex vivo and in vitro-stimulated blood 
B cells. Similar to EBV+ B-cell lines, a strong correlation was found between CLEC16A levels 
and CLIP, but not HLA-DR surface expression in B cells of healthy blood donors (Figure 
3A). In contrast, CLIP did not correlate to other genes that regulate the HLA-II pathway 
such as CIITA, CD74, HLA-DMB and HLA-DOB expression levels (Supplementary Figure 2D). 
To analyze this association on subset level, we separated transitional, naive mature, non-
switched (IgM-only and natural effector) as well as switched (IgG+ and IgA+) memory B cells 
from buffy coats (Supplementary Figure 3A). Both surface CLIP (Figure 3B) and CLEC16A 
(Figure 3C) were more expressed in transitional, naive mature and natural effector than in 
germinal center-associated IgM-only, IgG+ and IgA+ B cells. This suggests that CLEC16A is 
particularly involved in the HLA-II pathway of naive cells, and is downregulated together 
with surface CLIP after maturation into potent antigen-presenting memory cells in germi-
nal centers [34].
To further explore this co-regulation of CLIP and CLEC16A, B cells from healthy donors 
were stimulated with various combinations of T cell-dependent and -independent B-cell 
stimuli (anti-IgM, sCD40L, IL-21, CpG-ODN and IFN-γ) and analyzed using qPCR (24h) 
and FACS (48h). Under both germinal center-related and unrelated conditions (with and 
without IL-21), sCD40L was the strongest trigger for CLIP-loaded HLA-DR molecules and 
CLEC16A in B cells (Figure 4A-C and Supplementary Figure 3B). The positive correlation 
between surface CLIP and CLEC16A expression during in vitro activation (Figure 4D) is con-
sistent with our ex vivo findings (see Figure 3A). We were able to validate the association 
of CLEC16A with surface CLIP on protein level; CLEC16A was induced and co-expressed 
with CLIP in B cells after stimulation with anti-IgM and CD40L, as determined by Western 
blotting and FACS (Figure 4E-H; Supplementary Figure 3C). 
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These data demonstrate that T cell-dependent B-cell activation by CD40L triggers both 
surface CLIP and CLEC16A expression in healthy individuals. This probably makes naive B 
cells ready for optimal processing of IgM-internalized antigens in MIICs before developing 
into professional antigen-presenting memory cells [33]. 
CLIP-loaded HLA-II molecules are upregulated on ex vivo blood B cells of 
early onset MS patients
To explore the antigen-presenting efficiency of B cells in the context of human 
autoimmunity, we analyzed both CLIP and HLA-DR surface expression on blood B cells 
from 12 clinically definite, relapsing-remitting MS (RRMS) patients and 12 age- and 
gender-matched healthy controls (HC; Figure 5A, Table I). In contrast to HLA-DR, CLIP 
expression was significantly higher on B cells in RRMS (p=0.020; Figure 5B-C), resulting 
in increased CLIP/HLA-DR surface ratios (p=0.011; Figure 5D). To determine whether this 
was already true before clinically definite diagnosis, similar analyses were carried out for B 
cells of patients with clinically isolated syndrome (CIS), the first clinical presentation of sus-
pected MS [20]. In patients with very rapid onset of MS (<1 y, high-risk CIS; n=9), we found 
that both CLIP surface levels (p=0.002) and CLIP/HLA-DR expression ratios (p=0.007) were 
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Figure 3. Association of surface CLIP and 
CLEC16A expression levels in GC-independ-
ent and -dependent B-cell subsets. 
Total B cells of healthy controls (n=9, A) as 
well as individually sorted naive and mem-
ory B-cell subsets (B-C) from healthy blood 
donors (n=7-11) were analyzed for CLIP, 
HLA-DR (A) and CLEC16A expression using 
flow cytometry and qPCR, respectively. The 
following subsets were sorted by FACS: tran-
sitional (IgM+CD27-CD38high), naive mature 
(IgM+CD27-CD38-/dim), natural effector (Ig-
M+IgD+CD27+), IgM-only (IgM+IgD-CD27+), 
IgG+CD27+ and IgA+CD27+ B cells. The used 
gating strategy is depicted in Supplementary 
Figure 3A. Data are shown as median ± IQR. 
Spearman’s rank-order correlation (A) or Wil-
coxon matched-pairs signed rank tests (B, C) 













































































































































































































































































































































































Figure 4. Surface CLIP and CLEC16A induction in blood B cells after in vitro activation with GC-dependent 
and -independent stimuli.
Total B cells from healthy blood donors were sorted and stimulated for 24h and 48h with combinations of an-
ti-IgM, sCD40L, IL-21, IFN-γ and CpG-ODN. CLIP, CLIP/HLA-DR (FACS, 48h) and CLEC16A (qPCR, 24h) expression 
levels were compared between the groups (n=8-10; A-D). Data are depicted as the expression relative to un-
stimulated cells (dotted line; A-C). (E-F) Western blot analysis of CLEC16A expression in blood B cells using the 
7A4 monoclonal antibody. Cells were stimulated with a-IgM, a-IgM+sCD40L and a-IgM+sCD40L+IL-21+CpG-OD-
N+IFN-γ for 48h. CLEC16A levels were quantified and corrected for differences in β-actin expression using B cells 
from two independent experiments (F). (G) CLIP and CLEC16A expression on anti-IgM and CD40L-stimulated B 
cells from healthy blood donors, as determined by intracellular FACS. Rat IgG2b isotype was used as a negative 
control for CLEC16A intracellular staining. Percentages of cell in the gates are indicated in the plots. (H) Correla-
tion of CLEC16A and CLIP expression as determined by FACS before and after stimulation with a-IgM, with and 
without CD40L (n=4). Data are shown as median ± IQR. For A-C, Friedman including Dunn’s multiple compar-
ison tests were performed on unprocessed data (Supplementary Figure 3B). All conditions were compared to 
unstimulated cells of each donor (dotted line). Spearman’s correlation coefficients were calculated for D and H. 
** p<0.01, *** p<0.001, **** p<0.0001.
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elevated on B cells as compared to patients with slow or no onset of MS (>5 y, low-risk CIS; 
n=11; Figure 5E-G). After correction for MP treatment (n=2 in each group), CLIP expression 
remained significantly different (Table I and data not shown). In both RRMS and high-risk 
CIS, CLIP was upregulated on all naive and memory subsets analyzed, including transi-
tional (IgM+CD27-CD38high), naive mature (IgM+CD27-CD38-/dim), non-switched (IgM+CD27+) 
as well as switched (IgG+CD27+ and IgA+CD27+) B-cell subsets (Supplementary Figure 3A 
and Figure 6A). None of these subsets showed differences in surface HLA-DR levels (Figure 
6B). CLIP and HLA-DR expression on B cells from CIS patients were not influenced by the 























Figure 5. CLIP and HLA-DR expression on ex vivo B cells of different early MS patients. 
(A) Representative CLIP and HLA-DR expression on viable B cells. Surface expression levels and ratios (MFI) were 
compared between 12 relapsing-remitting MS (RRMS) patients and 12 matched healthy controls (HC) (B-D), as 
well as 11 low-risk and 9 high-risk CIS patients (E-G) using flow cytometry. Data are shown as median ± IQR. 





(rs1985372 and rs12708716) [26] (Supplementary Figure 4A), and other genes related to 
the HLA-II pathway (IFI30, rs11554159; MARCH1, rs72989863; CBLB, rs2289746) [35-39] 
(Supplementary Figure 4B). 
Notably, in contrast to healthy donors (Figure 3A), CLIP (and HLA-DR) did not correlate 
with CLEC16A levels in ex vivo B cells from RRMS patients (Figure 7A). Furthermore, B cells 
of patients already showed an upregulation of CLIP and CLEC16A after stimulation with 
Figure 6. CLIP and HLA-DR expression on distinct naive and memory B-cell subsets of early MS patients.
CLIP (A) and HLA-DR (B) expression on different B-cell subsets from early MS blood, including transitional (Ig-
M+CD27-CD38high), naive mature (IgM+CD27-CD38-/dim), non-switched memory (IgM+CD27+), IgG+CD27+ and Ig-
A+CD27+ B cells. The used gating strategy was similar to that in Supplementary Figure 3A. CLIP and HLA-DR MFI 
were compared between subsets of RRMS and matched healthy controls (n=12) and low-risk and high-risk CIS 
(n=9-11) groups. Data are shown as median ± IQR. Kruskal-Wallis test including Dunn’s multiple comparison were 
used to compare groups.* p<0.05, ** p<0.01. 
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IgM. In contrast to HC, this was not further upregulated after CD40L stimulation (Figure 
7B). Moreover, there was no correlation between surface CLIP and CLEC16A expression 
after in vitro activation in these RRMS patients (Supplementary Figure 3D), in contrast to 
healthy donors (Figure 4D). We did not find differences in ex vivo naive and memory subset 
distribution (Supplementary Figure 3E) and similar results were obtained in vitro using 
sorted naive mature B cells of these patients (Figure 7C). These data demonstrate that CLIP 
is abnormally increased in B cells of MS patients, and within co-regulation between CLIP 
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Figure 7. Surface CLIP and CLEC16A 
expression levels in ex vivo and in 
vitro-activated B cells from early MS 
patients.
(A) Total B cells of 10 RRMS patients 
were analyzed for CLIP, HLA-DR and 
CLEC16A expression using flow cytom-
etry and qPCR. Spearman’s correlation 
coefficients were calculated. (B) Surface 
CLIP/HLA-DR and CLEC16A levels for B 
cells from RRMS patients and age- and 
gender matched healthy controls be-
fore and after stimulation with anti-IgM 
and sCD40L for 24h (CLEC16A) and 48h 
(CLIP/HLA-DR; n=5-6). (C) Surface CLIP/
HLA-DR and CLEC16A levels in sorted 
naive mature B cells from RRMS pa-
tients before and after stimulation with 
anti-IgM and sCD40L for 24h (CLEC16A) 
and 48h (CLIP/HLA-DR; n=7). Data are 
shown as median ± IQR. Friedman in-
cluding Dunn’s multiple comparison 




This study reveals that CLEC16A contributes to the tightly coordinated antigen pre-
sentation pathway in B cells by influencing both BCR-mediated antigen uptake and MIIC 
biogenesis (Figure 8). CLEC16A expression associated with the presentation of CLIP-loaded 
HLA-II molecules by human B-cell lines and primary B cells. This association was not found 
in B cells from the blood of early MS patients, showing abnormal expression of surface CLIP 
and impaired co-regulation with CLEC16A.
Our ex vivo and in vitro results reveal that CLEC16A at least plays a role in the HLA-II 
pathway of IgM+ B cells. This is supported by an earlier study in mice [40]. Normally, CLIP 
remains bound to the peptide-binding groove of HLA-II molecules until the BCR is engaged 
with antigen. In the absence of antigen, surface CLIP and CLEC16A were upregulated after 
CD40L triggering, in line with previous studies [41, 42]. The co-regulation with CLEC16A 
may be explained by the fact that this gene is located next to CIITA, which is induced in 
CD40L-stimulated B cells [7]. This co-regulation was not present or further enhanced by 
CD40 triggering for naive B cells of MS patients. It has been shown that antigen-indepen-
dent, polyclonal activation of B cells triggers surface CLIP expression [43]. The increased 
expression of CLIP found on B cells of these patients may thus be promoted by chronic 
inflammation [44]. In our recent work, CD74 was downregulated particularly on naive B 
cells [45]. This possibly represents increased uptake and processing into CLIP, which has 
been shown to impede Treg activation in mice [46]. 
Both surface HLA-DR and CD74 were upregulated in CLEC16A-silenced Raji B cells. 
Since CLEC16A promotes dynein-mediated retrograde transport of late endosomes [16], 
CLEC16A is likely involved in the transport of HLA-DR/CD74 via the plasma membrane to 
MIICs [18]. After CLEC16A silencing, MIICs were found to be more dispersed throughout 
Raji B cells, which agrees with our previous observations in human myeloid cells [16]. The 
relatively small difference in CLIP expression in silenced Raji B cells can be explained by the 
fact that CLIP-loaded HLA-II is already highly abundant at the plasma membrane of wild-
type cells. In addition to HLA-DR/CD74 complexes, we found evidence that BCR/antigen 
complexes are trapped at the plasma membrane of CLEC16A-silenced Raji cells, suggesting 
that also antigens do not properly reach the MIICs for exchange with CLIP bound to HLA-II. 
Like CLEC16A, non-classical HLA-II chaperone HLA-DO is highly expressed in naive B cell 
populations [47], which inhibits such exchange via HLA-DM [31]. The antigen-presenting 
capacity of human B cells can also be influenced by other mechanisms such as EBV infec-
tion, BCR-driven actin reorganization and MIIC biogenesis, and even by BCR/antigen com-
plexes that interact with intracellular HLA-II proteins [17, 48, 49].
The discrepancy in effect of CLEC16A knockdown on HLA-DR surface expression 
between DCs [16] and B cells (this study) is likely the result of the different mechanisms 
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contributing to HLA-II expression in these antigen presenting cell types [50, 51]. In our 
previous study, CLEC16A was silenced in primary monocytes differentiating into immature 
DCs. In immature DCs, the majority of HLA-II molecules is present in MIICs [52]. This is in 
contrast to resting B cells, in which a large amount of HLA-II proteins is expressed at the 
plasma membrane [52]. DCs also differentially regulate antigen processing and presenta-
tion upon maturation, and internalize surface HLA-II more efficiently than B cells [52]. 
Previously, it was reported that CLEC16A silencing in human B leukemia cell line K562 
did not affect allogeneic T-cell activation [53]. However, in this study, transiently silenced 
cells were analyzed in a BCR/antigen-independent manner. For our work, we aimed to 
address the more long-term effects of CLEC16A on the BCR-mediated HLA-II pathway in 
human B cells and preferred the use of vector-based shRNAs because this also prevents 
the dilution of silencing RNAs through cell replication. Although the use of human B-LCLs 
is a limitation in this study, it does provide an indication that EBV infection (a strong but 












Figure 8. Model for CLEC16A as a regulator of BCR/antigen and HLA-II/CD74 processing in MIICs of human 
B cells. 
Before naive B cells encounter an antigen, CLEC16A likely mediates the retrograde trafficking of HLA-II/CD74 
complexes to MIICs for cleavage into CLIP. After BCR-mediated antigen uptake and processing in these compart-
ments, CLIP is exchanged for antigenic peptides within the HLA-II peptide-binding groove, which is followed by 
the transport of HLA-II/peptide complexes to the plasma membrane for presentation to CD4+ T cells. 
Chapter 3
84
After uptake of antigen within follicles, B cells process and present (self-)antigens to 
receive signals from cognate T follicular helper cells [54] and differentiate into potent 
antigen-presenting memory cells. Memory B cells are key triggers of pathogenic T cells 
infiltrating the brain in MS patients carrying the major HLA-DRB1*1501 risk allele [55]. 
Previous in silico analyses revealed that genetic variation in HLA-II risk loci influences 
the peptide-binding groove [56-58], and thus possibly the binding of CLIP. Although we 
focused on the role of CLEC16A here, there are several other minor risk loci that link to the 
(BCR-mediated) HLA-II pathway, including CIITA, IFI30, MARCH1 and CBLB [8, 57, 59, 60]. We 
did not find an association between B cell-intrinsic CLIP expression and the presence of 
these risk loci in CIS, including CLEC16A. However, this study lacks sufficient power to draw 
definite conclusions on this matter. In addition, many SNPs in CLEC16A have been reported 
to associate with MS risk [11, 26], which makes it a challenge to pinpoint the actual causal 
risk SNP, let alone whether CLEC16A is affected at transcriptional or post-transcriptional 
level. 
This work offers new insights into the regulation of the HLA-II pathway in human B cells. 
The co-regulation of CLIP and CLEC16A in B cells indicates that this gene contributes to the 
regulation of HLA-II peptide loading efficiency. We find indications that this goes via the 
internalization of both BCR/antigen and HLA-DR/CD74 complexes into MIICs. The abun-
dance of CLIP on (naive) B cells and the loss of its co-regulation with CLEC16A in MS implies 
that antigen processing and presentation to T cells is dysregulated. Further research into 
this phenomenon will be required to better understand the role of B cells as potent anti-
gen presenting cells in patients with autoimmune diseases such as MS.
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(A) Correlation of CLEC16A with surface CLIP/HLA-DR expression ratio in EBV+ B-LCLs. (B) The association of CLEC16A with HLA-
DM expression as well as HLA-DOB levels in EBV+ B-LCLs (n=9). (C) The association of surface CLIP levels with CBLB, IFI30 and 
MARCH1 expression in human EBV+ B-LCLs (n=9-10). Spearman’s correlation coefficients were calculated. (D) CLIP surface expres-
sion on Raji and Ramos wild type cells. (E) CLIP (48h) and CLEC16A (24h) induction in CLIPlow (EBV-) B-LCL Ramos after CD40L-me-
diated stimulations. Expression levels are depicted as median ± range and Friedman including Dunn’s multiple comparison tests 
















































































































































































































































(A) CLEC16A and surface CLIP, HLA-DR and CD74 levels in two different CLEC16A shRNA Raji transfectants. Paired t-tests were 
performed. (B) Relative expression levels of CLEC16A (qPCR) as well as surface CLIP, HLA-DR and CD74 (FACS) were compared 
between CLEC16A and scrambled shRNA transfectants of Ramos cells after 25 days of puromycin selection (n=5). Data were 
normalized and compared to the scrambled control per experiment (dotted line). Data are depicted as median ± IQR and paired 
t-tests were performed on unprocessed data. ** p<0.01 (C) Representative confocal images of clustered and scattered MIICs in Raji 
cells used for the quantification in Figure 2D. (D) The association of surface CLIP levels with CIITA, CD74, HLA-DMB and HLA-DOB 
expression in B cells from healthy blood (n=7-9). Spearman’s correlation coefficients were calculated.
3
91


























































































































































































































































































































(A) Used gating strategy to define transitional (IgM+CD27-CD38high), naive mature (IgM+CD27-CD38-/dim), natural effector (IgM+Ig-
D+CD27+), IgM-only (IgM+IgD-CD27+), IgG+CD27+ and IgA+CD27+ B cells. (B) Total B cells from healthy blood donors were sorted 
and stimulated with combinations of anti-IgM, sCD40L, IL-21, IFN-γ and CpG-ODN. CLIP, CLIP/HLA-DR (FACS, 48h) and CLEC16A 
(qPCR, 24h) expression levels were compared between the groups (n=8-10). Data are depicted as median ± range and Fried-
man including Dunn’s multiple comparison tests were used. ** p<0.01, **** p<0.0001 (C) Western blot analysis of CLEC16A in B 
cells from healthy blood using the 4F11 monoclonal antibody. Cells were stimulated with a-IgM, a-IgM+sCD40L and a-IgM+sC-
D40L+IL-21+CpG-ODN+IFN-γ for 48h. (D) Correlation of CLEC16A and CLIP/HLA-DR expression ratios on total B cells from RRMS 
patients (n=5) after stimulation with a-IgM and both a-IgM and sCD40L. Spearman’s correlation coefficients were calculated. (E) 
Distribution of B-cell subsets within the blood of RRMS patients (n=6) and HC (n=3) used for stimulation experiments, of which 












































































































































































































































CLIP and HLA-DR expression on B cells of CIS patients (n=24) were stratified based on the presence of risk alleles (A) HLA-
DRB1*1501 (rs3135388, A=risk allele), CLEC16A (rs1985372, G=risk allele; rs12708716, A=risk allele) and (B) IFI30 (rs11554159; 
A=risk allele) MARCH1 (rs72989863; A=risk allele) and CBLB (rs2289746; G=risk allele). Data are shown as median ± IQR.
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ABSTRACT 
In multiple sclerosis (MS), B cells survive peripheral tolerance checkpoints to 
mediate local inflammation, but the underlying molecular mechanisms are relatively 
underexplored. In mice, the macrophage migration inhibitory factor (MIF) pathway 
controls B-cell development and the induction of experimental autoimmune enceph-
alomyelitis. Here, we found that MIF and MIF receptor CD74 are downregulated, while 
MIF receptor CXCR4 is upregulated in B cells from early onset MS patients. B cells were 
identified as the main immune subset in blood expressing MIF. Blocking of MIF and 
CD74 signaling in B cells triggered CXCR4 expression, and vice versa, with separate 
effects on their pro-inflammatory activity, proliferation and sensitivity to Fas-mediated 
apoptosis. This study reveals a new reciprocal negative regulation loop between CD74 
and CXCR4 in human B cells. The disturbance of this loop during MS onset provides 
further insights into how pathogenic B cells survive peripheral tolerance checkpoints 
to mediate disease activity in MS.
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Dysregulation of MIF in B cells from MS patients
INTRODUCTION 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, 
in which infiltrating pro-inflammatory immune cells mediate local pathology [1]. The 
strong effects of anti-CD20 monoclonal antibody therapy in MS patients demonstrate a 
key role for peripheral B cells during the pathogenesis [2]. Immature B cells survive periph-
eral tolerance checkpoints in MS [3], but underlying mechanisms are poorly understood.
An important factor associated with chronic inflammation and cell survival is the mac-
rophage migration inhibitory factor (MIF) [4]. In the animal model of MS, i.e. experimen-
tal autoimmune encephalomyelitis (EAE), MIF levels are increased in the central nervous 
system [5]. Furthermore, anti-MIF treatment prevents disease onset and improves the 
course of the disease by decreasing the expression of VCAM-1, which impairs the homing 
of neuroantigen-specific T cells to the central nervous system [6]. Which and how immune 
subsets are regulated by MIF to promote disease activity in MS patients remains to be 
determined.
In murine B cells, triggering of the cognate receptor of MIF, CD74 (invariant chain), 
results in enhanced proliferation and pro-inflammatory cytokine production via NF-κB [7, 
8]. Besides functioning as an MHC class II chaperone protein, CD74 also has an MHC class 
II-independent role in B-cell maturation [9]. Interestingly, MIF is also a non-cognate ligand 
for chemokine receptor CXCR4 [10], which probably cooperate with CD74 to regulate 
B-cell development and function through MIF [11-13].
This study explores whether MIF, CD74 and CXCR4 expression in B cells is associated 
with early MS disease activity, and how the regulation and downstream effects of MIF 
receptors CXCR4 and CD74 affect human B-cell function. We show that MIF and CD74 
are downregulated and CXCR4 is upregulated in blood B cells from early MS patients. 
This is dependent on a B cell-intrinsic negative regulation loop between MIF, CXCR4 and 




Patient characteristics are summarized in Supplementary Table 1. All clinically isolated 
syndrome (CIS) and relapsing-remitting MS (RRMS) patients as well as healthy controls 
(HC) were included in MS Center ErasMS at Erasmus MC (Rotterdam, The Netherlands). CIS 
was defined as a first clinical attack of demyelination in the central nervous system [14]. 
Clinically definite MS (CDMS) was diagnosed when a patient experienced two attacks with 
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clinical evidence of two separate lesions according to the Poser criteria [15]. CIS patients 
were sampled within 4 months after their first attack. From our prospective cohort, we 
selected CIS patients who did not develop CDMS for at least 5 years of follow-up (low-risk 
CIS) and CIS patients who were diagnosed with CDMS within 1 year after CIS diagnosis 
(high-risk CIS). Fatigue severity was assessed using Krupp’s Fatigue Severity Scale (FSS) 
[16]. RRMS patients were diagnosed according to the McDonalds criteria [17] and were 
age- and gender-matched with healthy control subjects. For functional studies, buffy 
coats (Sanquin, Amsterdam, The Netherlands) were obtained from healthy volunteers. All 
patients and controls gave written informed consent and study protocols were approved 
by the medical ethics committee of the Erasmus MC.
Peripheral blood sampling
PBMCs and plasma were isolated from whole blood with the use of CPTTM heparin 
tubes, while serum was isolated using coagulation tubes (both BD Biosciences, San Jose, 
CA). Samples were processed according to the manufacturer’s instructions. PBMCs were 
stored in liquid nitrogen; plasma and serum were stored in -800C until analysis.
Human MIF ELISA
Enzyme-linked immunosorbent assay (ELISA) was used to measure human MIF levels 
in serum and plasma using the four-span approach, as previously described [18]. In brief, 
anti-human MIF polyclonal antibodies raised in chicken and rabbit were used as capture 
and trapping antibodies. Microtiter plates were coated with a duck anti-chicken antibody. 
A horseradish peroxidase-labeled goat anti-rabbit antibody was used for the detection. 
Distinct concentrations of rhMIF (R&D Systems, Minneapolis, MN) were used to generate 
a standard curve. The analytic sensitivity of the human MIF ELISA was 39 pg/mL and the 
coefficients of variation were 6% for intrarun and 12% for interrun.
Flow cytometry and cell sorting
In-depth flow cytometric analysis of B cells were performed using anti-human mono-
clonal antibodies against CD3, CD19, CD24, CD27, CD38, CD69, CD74, CD95, CXCR4, HLA-
DR, IgA, IgD, IgG and IgM. Details of these antibodies are indicated in Supplementary Table 
2. All measurements were performed on an LSRFortessaTM flow cytometer and data were 
analyzed using FACSDiva 8.1 software (both BD Biosciences). Guidelines for the use of flow 
cytometry in immunological studies have been followed [19].
Intracellular cytokine staining
Cells were stimulated for 5h using phorbol 12-myristate 13-acetate (PMA; 20ng/ml) and 
ionomycin (500ng/ml, both Sigma-Aldrich), in the presence of BD GolgiStopTM. Stimulated 
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cells were stained with BD Horizon™ Fixable Viability Stain 700, fixed and permeabilized 
using BD Cytofix/CytopermTM according to the provided protocol and stained for IL-6 and 
TNF-α (Supplementary Table 2, BD Biosciences).
RNA isolation and quantitative PCR
CD19+ B cells, CD3+ T cells, CD14+ monocytes and CD56-HLA-DR+ dendritic cells were 
sorted using a high-speed cell sorter (FACSAria IIITM; BD Biosciences), resulting in a purity 
of more than 95%. Subsequently, mRNA was isolated using GenEluteTM Mammalian RNA 
Kit (Sigma-Aldrich, St Louis, MO) and reversely transcribed into cDNA following a stan-
dard laboratory protocol with the use of SuperScript II® Reverse Transcriptase (Invitrogen, 
Paisley, UK). Primers and probes were selected by using the Universal Probe Library Assay 
Design Centre (Roche Applied Science, Penzberg, Germany). To determine target gene 
mRNA expression levels, qPCR was performed using an Applied Biosystems 7900 Sequence 
Detector, which was programmed for the initial step of 2 min at 500C and 10 min 950C, fol-
lowed by 40 thermal cycles of 15s at 950C and 1min at 600C. For the calculation of relative 
mRNA levels, CT values per gene were related to standard curves, which were generated 
for each gene of interest. 18S levels were measured as a control to normalize for RNA input. 
Primer sequences are listed in Supplementary Table 3.
In vitro activation and modulation of B cells
CD19+ B cells of healthy donors were isolated untouched by depleting all other cell 
types from peripheral mononuclear blood cells (PBMCs) using the B-cell isolation kit II 
and MACS (Miltenyi Biotec, Bergisch Gladbach, Germany). CD19+ B cells of patients and 
healthy controls were sorted using FACS and were cultured in RPMI supplemented with 
10% fetal calf serum and 1% penicillin/streptavidin for 24 hours or 3 days with various 
stimuli; anti-IgM (F(ab’)2, 10µg/ml, Jackson ImmunoResearch Inc., West Grove, PA) with or 
without MIF inhibitor ISO-1 (100 µM, R&D Systems), a neutralizing anti-human CD74 anti-
body (LN2; 10 µg/ml, BD Biosciences) or AMD3100 (10 µg/ml, Sigma-Aldrich). Proliferation 
rates were addressed by labelling B cells with CFSE (eBioscience, San Diego, CA) before 
in vitro activation. For MIF knockdown, the human B-cell line Raji was transfected with 
MIF shRNA-containing pLKO.1 constructs (MISSION® shRNA Library, Sigma-Aldrich) using 
Nucleofector Kit V from Lonza (Basel, Switzerland). Three different MIF shRNA constructs 
were used: #1 GACAGGGTCTACATCAACTAT, #2 CTACATCAACTATTACGACAT, and #3 
CCTGCACAGCATCGGCAAGAT. MIF mRNA and CD74 surface expression was analyzed and 




Cells were lysed in radio-immunoprecipitation assay (RIPA) lysis buffer supplemented 
with 10% complete protease inhibitor cocktail (Roche, Mannheim, Germany) on ice for 
30 minutes, centrifuged at 4°C for 10 minutes at 10,000 x g. Cell lysates were reduced with 
10% 2-mercaptoethanol, denatured for 5min at 95○C, loaded onto a 10% precast poly-
acrylamide gel (Bio-Rad, Hercules, CA) followed by immunoblotting on a Immobilon-P 
membrane (Merck Millipore, Darmstadt, Germany) for 1 hours at 4°C. Membranes were 
blocked in 5% nonfat dry milk and incubated with rabbit anti-human NF-κB1 p105/p50 
(D7H5M, Cell signaling technology, Danvers, MA) or mouse anti-human β-actin (AC-15; 
Abcam, Cambridge, UK) and horseradish peroxidase (HRP)-conjugated swine-anti-rabbit 
Ig or goat-anti-mouse Ig (Dako, Glostrup, Denmark). Protein bands were visualized using 
Western Lightning Plus-ECL (Perkin Elmer Inc., Waltham, MA). 
Statistical analyses
Statistical analyses were performed using Graphpad Prism 7 (GraphPad Software Inc., 
San Diego, CA). Data are expressed as mean ± SEM. Data sets were tested for normal distri-
bution. Two-tailed t tests or analysis of variance were used to compare groups. Correlations 
between two parameters were tested by using Pearson’s or Spearman correlation coeffi-
cients. P-values <0.05 were considered as statistically different.
RESULTS
The expression ratio of MIF receptors CXCR4 and CD74 on B cells is 
increased during rapid MS onset
To determine whether the B cell-intrinsic MIF pathway is differentially regulated in early 
MS, we assessed the expression levels of MIF receptors CXCR4 and CD74 on blood B cells 
of relapsing-remitting MS (RRMS) patients and healthy controls (HC). CXCR4 was 1.4-fold 
increased on B cells from 15 RRMS patients compared to 15 age- and gender-matched HC 
(p=0.002, Fig. 1A, 1B and 1D), which was reproduced and validated in additional cohorts 
(Supplementary Fig. 1A and 1B). In contrast, CD74 expression was 1.4-fold reduced on 
B cells in RRMS versus HC (p=0.038, Fig. 1A, 1C and 1E). The ratio of CXCR4 and CD74 
expression levels on B cells was even further enhanced in RRMS (2.1-fold, p=0.004; Fig. 1F; 
Supplementary Fig. 1C and 1D), suggesting that both MIF receptors are dysregulated on a 
per-patient basis. 
Next to RRMS patients, patients with clinically isolated syndrome (CIS), a first manifes-
tation of suspected MS [14], were analyzed. Similar to RRMS, B cells from CIS patients with 
a very rapid onset of clinically definite MS (CDMS) (‘high-risk CIS’, n=16) showed 1.5-fold 
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increased CXCR4 (p=0.014, Fig. 2A) and 1.3-fold reduced CD74 surface levels (p=0.004, Fig. 
2B) compared to CIS patients with slow or no onset of CDMS (‘low-risk CIS’, n=17). This 
resulted in strongly elevated CXCR4/CD74 expression ratios per patient in the high-risk CIS 
group (2.5-fold; Fig. 2C). In CIS, a negative correlation was found between CXCR4 and CD74 
levels on B cells (r=-0.44, p=0.01; Fig. 2D), and CXCR4/CD74 expression ratios positively 








































Figure 1. CXCR4 upregulation and CD74 downregulation on B cells of clinically definite MS patients.
(A) Gating strategy for CD19+ B cells. (B-C) representative histograms of CXCR4 (B) and CD74 (C) expression levels 
in HC and RRMS. (D-F) Expression of MIF receptors CXCR4 (D) and CD74 (E) and their ratios (F) on blood B cells 
from 15 RRMS patients and 15 age- and gender-matched healthy controls (HC) as determined by FACS. Data was 
measured in 3 individual experiments, with 5 HC and 5 RRMS patients per experiment. Data are shown as mean ± 
SEM. Unpaired t-tests were used to compare groups. * p<0.05, ** p<0.01.
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In RRMS and high-risk CIS blood, transitional (IgM+CD27-CD38hiCD24hi) as well as naive 
mature (IgM+CD27-CD38-/dim) B-cell subsets displayed the highest CXCR4/CD74 expres-
sion ratios as compared to class-switched (CD27+/CD27- IgG+ and IgA+) and non–class-
switched (IgM+CD27+) memory subsets (Fig. 3; Supplementary Fig. 2), implying that the 
CXCR4hiCD74lo phenotype of B cells in early MS reflects a more immature state. These data 
demonstrate that MIF receptors CXCR4 and CD74 are inversely expressed on B cells, which 
is dysregulated during early disease onset in MS.
A B C
D E
Figure 2. High CXCR4/CD74 expression ratios on B cells of CIS patients associate with rapid MS diagnosis.
Expression of MIF receptors CXCR4 and CD74 and their ratios on blood B cells 17 low-risk CIS and 16 high-risk CIS 
patients (A-C), as determined by FACS. Gating on CD19+ B cells is depicted in Fig. 1. Data was measured in 9 indi-
vidual experiments, with 1-2 low-risk CIS and 1-2 high-risk CIS patients were measured per experiment. Data are 
shown as mean ± SEM. Unpaired t-tests were used to compare groups. (D) Correlation between CXCR4 and CD74 
expression on B cells in CIS patients (n=33). (E) Correlation between CXCR4/CD74 surface expression ratios on B 
cells and fatigue severity scores (FSS) for CIS patients (n=30). r = Pearson’s correlation coefficient (D) or Spearman 
correlation (E). * p<0.05, ** p<0.01, *** p<0.001. 
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MIF is predominantly expressed by B cells in healthy blood and 
downregulated in early MS patients
MIF levels in both serum and plasma were not different between CIS patients and 
healthy controls (Fig. 4A and Supplementary Fig. 3A) or high-risk and low-risk CIS sub-
groups (Fig. 4B and Supplementary Fig. 3B), and did not correlate with CXCR4 and CD74 
expression levels on B cells from the same individuals (Supplementary Fig. 3C and 3D).
However, among blood immune subsets, MIF mRNA was predominantly expressed by 
B cells compared to paired T cells, monocytes and dendritic cells (Fig. 4C), but downreg-
ulated in B cells from RRMS patients versus HC (p<0.01) and even further in B cells of CIS 
patients (CIS vs HC, p<0.0001; CIS vs RRMS, p<0.01; Fig. 4D). We found no differences in 
MIF mRNA levels between B cells from low-risk and high-risk CIS subgroups (Fig. 4E). Low 
MIF mRNA levels corresponded to high CXCR4/CD74 surface expression ratios in B cells of 
patients and controls (p=0.005; Fig. 4F). This points to the existence of a disturbed regula-
tion loop between MIF and MIF receptors in B cells of early MS patients.
MIF, CD74 and CXCR4 are part of a reciprocal negative regulation loop in 
human B cells
In vitro, B cells showed enhanced MIF expression and secretion after activation with 
anti-IgM, which was comparable between patients and controls (Fig. 5A and 5B). To deter-
mine potential crosstalk between MIF, CXCR4 and CD74, we used the specific MIF inhibitor 
ISO-1 [21] to block MIF-mediated signaling in in vitro-activated B cells. ISO-1 treatment of 
these B cells resulted in a CXCR4 upregulation and CD74 downregulation (Fig. 5C), reflect-
ing the inverse correlation between MIF and CXCR4/CD74 expression levels in B cells ex vivo 
(Fig. 4F). In parallel to this, in the human B-cell line Raji, which abundantly expresses CD74 
[22], the percentage of CD74hi cells decreased after MIF knockdown using three distinct 
shRNA constructs (Fig. 5D and 5E). This indicates that CXCR4 and CD74 surface expression 
is inversely regulated by endogenous MIF in B cells. After treatment with anti-CD74 anti-
body (LN2), CXCR4 surface expression was increased, whereas MIF expression was reduced 
in in vitro-activated B cells (Fig. 5F and 5H). Vice versa, activated B cells treated with CXCR4 
antagonist AMD3100 [23] showed increased CD74 and MIF levels (Fig. 5G and 5H). These 
data demonstrate that MIF, CD74 and CXCR4 expression in human B cells is tightly and 
mutually controlled.
CXCR4/CD74 controls the inflammatory, proliferative and Fas-mediated 
apoptotic potential of B cells
To determine how the reciprocal negative regulation of CD74 and CXCR4 is associated 
with the function of B cells, we compared the pro-inflammatory, proliferative and survival 
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Treatment of these B cells with anti-CD74 antibody LN2 (24h) suppressed the induction 
of pro-inflammatory genes NFKB1, IL6 and TNF (Fig. 6A). This was not found in in vitro-ac-
tivated B cells treated with CXCR4 antagonist AMD3100 (Fig. 6A). These differences were 
verified on protein level (Supplementary Fig. 4). Also B-cell proliferation was inhibited 
after treatment for 3 days with LN2 antibody and not with AMD3100, as determined by 
CFSE labeling (Fig. 6B and 6C). Finally, surface expression of the death receptor Fas (CD95) 
was triggered in AMD3100- and not in LN2-treated B cells after 3 days of activation (Fig. 
6D). These results imply that in humans, CD74 primarily boosts the pro-inflammatory and 
proliferative capacity of B cells, while CXCR4 makes B cells less sensitive for Fas-mediated 
apoptosis [24].
DISCUSSION
The aim of this study was to elucidate the impact of the B cell-intrinsic MIF pathway on 
early disease onset in MS patients. We demonstrate that decreased CD74 and increased 
CXCR4 expression on B cells in blood are associated with early MS diagnosis. This was 
shown for CIS patients who will rapidly develop MS as well as for clinically definite MS 
patients. In vitro experiments supported the inverse regulation of MIF/CD74 and CXCR4 
expression in B cells ex vivo, which differentially controlled their pro-inflammatory capac-
ity, proliferation and sensitivity to Fas-mediated apoptosis (Supplementary Fig. 5). The 
observed CXCR4hiCD74lo B-cell phenotype in early MS blood points to the presence of 
more immature B cell populations with senescent features that survived peripheral toler-
ance checkpoints in MS [3]. 
There are several lines of evidence implying that CD74 downregulation and CXCR4 
upregulation disrupt the selection of immature B cells. During B-cell development, ‘new 
emigrant’ transitional subsets in blood are negatively selected in secondary lymphoid 
Figure 3 (see left page). The CXCR4hiCD74lo phenotype of B cells in early MS blood is linked to transitional 
and naive mature populations.
(A) Used gating strategy for the different blood B-cell subsets analyzed in B-E: transitional (IgM+CD27–
CD38hiCD24hi), naive mature (IgM+CD27–CD38–/dim), IgM+CD27+ (non–class-switched memory), IgG+CD27+, 
IgG+CD27–, IgA+CD27+ and IgA+CD27– B cells. Blood from RRMS (B, C; n=15) and high-risk CIS (D, E; n=16) patients 
was used to assess CXCR4 (B, D) and CD74 (C, E) expression on these subsets. For RRMS patients, the data was 
measured in 3 individual experiments with 5 RRMS patients per experiment. For high-risk CIS patients, data was 
measured in 9 individual experiments with 1-2 patients per experiment. The expression level on each subset was 
compared to that of IgG+CD27+ memory B cells. Data are shown as mean ± SEM. Kruskal-Wallis test with Dunn’s 





Figure 4. Serum MIF levels are not different, while the predominant MIF expression in B cells is reduced in 
CIS and RRMS patients.
MIF serum levels (ng/μl) were compared between CIS patients (n=61) and HC (n=29; A), as well as between low-
risk CIS (n=33) and high-risk CIS (n=28) subgroups (B) using ELISA. Data is measured in one single experiment. 
Each dot represents the mean value of one individual, measured in duplicates. (C) Monocytes (n=10), dendritic 
cells (n=8), T cells (n=11) and B cells (n=10) were sorted from healthy blood and assessed for MIF mRNA expres-
sion relative to those of 18S mRNA using qPCR. Data was collected in 4 independent experiments with 2-4 donors 
per experiment. Similar analyses were performed for blood B cells from CIS patients (n=18), RRMS patients (n=19) 
and HC (D; n=22), as well as low-risk CIS (n=13) and high-risk CIS (n=5) groups (E). B cells of CIS patients were 
sorted in 9 independent experiments with 2-4 patients per experiment. B cells of HC and RRMS patients were 
sorted in 17 independent experiments, with 1-2 HC and 1-2 RRMS patients per experiment. MIF and 18S mRNA 
expression was measured in 6 individual experiments, with 2 independent experiments per patient group. Data 
are shown as mean ± SEM. Each dot represents the mean value of one individual, measured in duplicates. Stu-
dent’s t-tests were used to compare groups. (F) Correlation between MIF mRNA levels and CXCR4/CD74 surface 
expression ratios in B cells from patients and healthy controls (n=30). B cells were sorted, mRNA was measured 
in duplicates, and surface expression was analyzed in 6 independent experiments with 2 HC and 2-4 patients per 
experiment. r = Spearman’s correlation; * p<0.05, ** p<0.01, **** p<0.0001.
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Figure 5. Interference with MIF signaling pathways reveals mutual regulation of CD74, CXCR4 and MIF 
expression in in vitro-activated B cells.
B cells sorted from CIS, RRMS and HC blood (n=9-12 per group) were activated in vitro for 24h using anti-IgM and 
analyzed for MIF expression (A; qPCR) and secretion into culture media (B; ELISA). Stimulations have been done 
in 3 individual experiments with 3-4 patients per group per experiment. Each dot represents the mean value of 
one individual, measured in duplicates. (C) In vitro-activated B cells from healthy blood were treated with and 
without MIF inhibitor ISO-1 for 24h and assessed for CXCR4 and CD74 surface expression using FACS (n=6). Stim-
ulations have been done in 3 individual experiments with 2 controls per group per experiment. (D, E) The human 
B-cell line Raji (CD74hi) was transfected with three distinct MIF shRNA constructs and compared with scrambled 
controls for MIF mRNA levels (D) and the percentage of CD74hi cells (E) at day 3 (n=5). Data was measured in 5 
individual experiments with one set of scrambled and 3 different shRNA’s per experiment. In vitro-activated B cells 
were also evaluated for CXCR4 (F, n=7), CD74 (G, n=7) and MIF mRNA (H, n=5-6, measured in duplicates) expres-
sion after 24h treatment with anti-CD74 (LN2) or isotype antibody (F, H) and CXCR4 antagonist AMD3100 (G, H). 
Stimulations have been done in 3 individual experiments with 2-3 controls per group per experiment. All used 
controls were set at 1 (dotted line). Data are shown as mean ± SEM. Paired t-tests were performed to compare 
groups. * p<0.05, ** p<0.01, *** p<0.001.
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organs for autoreactive clones before developing into naive mature subsets. B cells in 
CD74-deficient mice revealed an arrest at the transitional stage [25] and a reduced lifespan 
[26]. Consistently, decreased CD74 expression impaired B-cell maturation in patients with 
X-linked lymphoproliferative disease [27]. Both cell autonomous and non-autonomous 
roles of CD74 could explain these defects in B-cell development. As a cell surface recep-
tor, CD74 triggers B-cell proliferation in mice [8] and humans (current study), supporting 
the lowered proliferative capacity of naive (CD74lo) versus memory (CD74hi) populations 
[28]. The reduced expression of CD74 on B cells in early MS blood thus might reflect a 
functional state of anergy, contributing to the persistence of pathogenic immature B cells 
in the periphery [29]. This is underlined by the down-modulation of pro-inflammatory 
B
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Figure 6. CD74 and CXCR4 on human B cells differentially control pro-inflammatory gene expression, pro-
liferation and sensitivity to Fas-mediated apoptosis.
B cells from healthy blood were in vitro-activated with a-IgM and subsequently treated with anti-CD74 antibody 
(LN2) or AMD3100. Data was compared to their respective controls for relative NF-κB, IL-6 and TNF-α mRNA ex-
pression after 24h using qPCR (A, n=4-6, measured in duplicates), as well as CFSE-based proliferation (B and C, 
n=5) and Fas (CD95) surface levels (D, n=5) after 3 days using FACS. Stimulations have been done in 3 individual 
experiments with 2 controls per group per experiment. All used controls were set at 1 (dotted line). Data are 
shown as mean ± SEM. Paired t-tests were performed to compare groups. * p<0.05, ** p<0.01.
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cytokines TNF-α and IL-6, as well as MIF after blockade of CD74 on B cells. Alternatively, 
defective processing of CD74 results in the accumulation of an N-terminal fragment, which 
interferes with B-cell receptor signaling to suppress B-cell maturation in an MHC class 
II-independent manner [9, 30, 31]. In addition to these cell-intrinsic effects, a loss of CD74 
can also influence T helper cell-mediated selection of naive mature B cells via altered MHC 
class II antigen presentation [32].
In contrast to CD74, CXCR4 was found to be the most abundant on naive B cells, 
which controls their development in germinal centers. CXCR4hi B cells are localized in the 
dark zone to undergo somatic hypermutation, whereas antigen- and T helper cell-based 
selection of CXCR4lo B cells occurs in the light zone [33, 34]. Our data show that blocking 
of CXCR4 signaling in B cells increases CD95 (Fas) expression, which is essential for the 
elimination of autoreactive clones by T helper cells [35]. Hence, it may be speculated that 
overexpression of CXCR4 on B cells as observed in early MS results in the escape of naive 
populations from T helper cell-based selection in the light zone, via reduced Fas expression 
and enhanced migration to the dark zone. Central tolerance checkpoints were not defec-
tive in MS patients [3], making it unlikely that the abundance of CXCR4 affects precursor 
B-cell selection in the bone marrow [36]. In vivo studies need to be performed in the future 
to confirm these roles of CD74 and CXCR4 in peripheral B-cell tolerance in MS.
To our knowledge, the co-regulation of MIF, CD74 and CXCR4 in human B cells and MS 
patients has never been studied before. Although abundantly expressed by B cells com-
pared to other immune populations, MIF is downregulated in blood B cells from early MS 
patients. This downregulation links to the survival of autoreactive naive B cells, as seen in 
atherosclerotic mice [13] and MS [3], and coincides with decreased CD74 and increased 
CXCR4 surface expression, as part of a tightly controlled regulation loop in B cells. The 
reciprocal expression of CD74 and CXCR4 was supported by the increased migration 
capacity of B cells towards CXCL12 after inhibition of CD74 [12, 37]. Since MIF has a higher 
affinity for CD74 than for CXCR4 [7, 10], a possible underlying mechanism of this recipro-
cal expression is that MIF-mediated endocytosis of CD74 results in interaction with the 
adaptor molecule β-arrestin, thereby preventing binding to and internalization of CXCR4 
[38-40] (Supplementary Fig. 5). 
Extracellular MIF levels were not different in the blood of early MS patients. However, 
previous studies showed increased levels of MIF in MS CSF [41] as well as in MS lesions 
and not normal-appearing white matter [42]. This suggests that local MIF production pre-
dominantly attracts CXCR4hi B cells from the blood [10, 12] to mediate early MS disease 
activity. Another CXCR4 ligand, CXCL12, was also found to be abundant in MS CSF, but did 
not correlate to local B-cell infiltration and activation [43]. After recruitment to the central 
nervous system, CXCR4hiCD74lo B cells will probably be activated, resulting in increased 
CD74 expression and MIF production. CD74 triggering by autocrine MIF may then enhance 
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their ability to proliferate, as shown for tumor cells [44], and produce pro-inflammatory 
cytokines to mediate central nervous system pathology in MS.
This study shows that MIF and MIF receptors CD74 and CXCR4 are coordinately 
expressed in B cells to control their inflammatory, proliferative and apoptotic potential in 
humans. The dysregulation of this B cell-intrinsic loop in early MS pleads for future studies 
on the processing and cooperation of CD74 and CXCR4 during autoreactive B-cell devel-
opment. Also more insights into the effects of autocrine and T helper cell-derived MIF on 
their development will lead to better understanding of the role of B cells as central players 
in MS and other autoimmune diseases.
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Supplementary Figure 1. Reproducibility and validation of the CXCR4hiCD74lo B-cell phenotype in early 
MS patients. 
(A) Blood B cells of RRMS patients (n=20) and HC (n=20) from the screening cohort (see Supplementary Table 
1) were reassessed for CXCR4 expression levels using the 12G5 antibody labeled with APC instead of PE-CF594. 
The latter antibody was used for the FACS analysis in Fig. 1B and 1D. Similar experiments were performed for B 
cells from an additional cohort of RRMS patients (n=20) and matched HC (n=20, see Supplementary Table 1; B). 
Data were obtained from 10 individual experiments, with B cells from 2 HC and 2 RRMS patients analyzed per 
experiment. (C-D) Representative dotplot and quantification of CXCR4hiCD74lo frequencies of B cells from RRMS 
patients and HC (screening cohort, see Supplementary Table 1). Data are shown as mean ± SEM. Student’s t-tests 
were used to compare the groups. * p<0.05, ** p<0.01. 
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Supplementary Figure 2. CXCR4/CD74 expression ratios on distinct B-cell subsets in RRMS versus HC 
blood.
Gating of the subsets is shown in Fig. 3. Data were obtained from 3 individual FACS experiments, with B cells from 
5 HC and 5 RRMS patients analyzed per experiment. Data are shown as mean ± SEM. Mann-Whitney U tests were 
used to compare subsets between the RRMS and HC groups. * p<0.05.
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Supplementary Figure 3. Circulating MIF levels and their association with CXCR4/CD74 expression ratios 
on blood B cells in CIS. 
MIF plasma levels (ng/μl) were compared between CIS patients (n=60) and HC (n=29; A), as well as low-risk CIS 
(n=32) and high-risk CIS (n=28; B) subgroups using ELISA. Data is measured in one single experiment. Each dot 
represents the mean value of one individual, measured in duplicates. Data are shown as mean ± SEM. The pres-
ence of MIF in serum (C) and plasma (D) was correlated to CXCR4/CD74 expression ratios on B cells in CIS blood 




















































































Supplementary Figure 4. Effects of CD74 and CXCR4 blocking on NF-κB1, IL-6 and TNF-α protein expres-
sion in primary B cells.
(A-B) Representative image (A) and quantification (B) of NF-κB1 protein p105 expression in untreated as well an-
ti-CD74 (LN2) or isotype control treated B cells from healthy blood after 24h of a-IgM stimulation (n=3, measured 
in one experiment). NF-κB1 p105 protein levels were normalized based on β-actin expression using the same 
blot. (C-E) IL-6 And TNF-α protein expression in anti-CD74 antibody (LN2) or AMD3100 treated healthy blood 
after in vitro-activation with a-IgM for 72h. Data was compared to their respective controls (n=3, measured in one 
experiment). (C) Gating of viable CD19+ B cells. (D-E) Gating and quantification of IL-6+ (D) and TNF-α+ fractions 
of treated B cells (E). All used controls were set at 1 (dotted line). Data are shown as mean ± SEM. Paired t-tests 
















Supplementary Figure 5. Potential counter-regulatory mechanism and downstream effects of CD74 and 
CXCR4 signaling in peripheral B cells of early MS patients.
Our data demonstrate that CXCR4 is upregulated and CD74 is downregulated on peripheral B cells from early MS 
patients. Mechanistically, this counter-regulation of CXCR4 and CD74 could be explained by the higher affinity 
of MIF for CD74 than for CXCR4. After MIF-mediated internalization, CD74 potentially interacts with the adaptor 
molecule β-arrestin, preventing binding to and endocytosis of surface CXCR4. Functionally, peripheral B cells are 
less able to proliferate and express pro-inflammatory cytokines (MIF, IL-6, TNF-α) via NF-κB (mediated by CD74), 
but more capable of surviving peripheral tolerance checkpoints and infiltrating the central nervous system via 
local MIF production (mediated by CXCR4) in early MS. We postulate that within the central nervous system, 
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Age in years, 
median (IQR)*
Follow-up time in 
years, median (IQR)*
Disease duration in 
months, median 
(IQR) †
FACS (B cells, ex vivo)
HC Screening 15 12 (80%) 46 (32-60) NA NA 
 Replication 20 16 (80%) 45 (32-60) NA NA 
 Validation 20 13 (65%) 46 (24-60) NA NA 
CIS Total 33 24 (73%) 34 (22-48) 6.04 (2.17 - 9.81) 2.0 (0.1 - 4.0) 
 Low-risk 17 12 (71%) 36 (22-48) 7.08 (5.21 - 9.81) 2.25 (1.0 - 4.0) 
 High-risk 16 12 (81%) 32 (24-39) 4.08 (2.17 - 8.69) 2.0 (0.1 - 3.75) 
RRMS Screening 15 12 (80%) 46 (31-61) NA NA 
 Replication 20 16 (80%) 46 (31-61) NA NA 
 Validation 20 13 (65%) 46.5 (24-61) NA NA 
RT-PCR (B cells, ex vivo)
HC  22 14 (64%) 43.5 (24-66) NA NA 
CIS Total 18 13 (72%) 35.5 (24-48) 6.65 (2.17-9.81) 2.25 (1.0-4.0) 
 Low-risk 13 10 (77%) 36 (25-48) 7.07 (5.21-9.81) 2.25 (1.0-4.0) 
 High-risk 5 3 (60%) 32 (24-39) 3.36 (2.17-8.69) 3.0 (2.0-3.75) 
RRMS  19 14 (74%) 42 (32-65) NA NA 
RT-PCR (B cells, in vitro)
HC  10 7 (70%) 30 (25-58) NA NA 
CIS 9 7 (78%) 33 (23-39) 4.31 (1.34-10.99) 3 (1.5-5.25) 
RRMS  9 8 (89%) 39 (21-54) NA NA 
ELISA (serum and plasma)
HC  29 19 (66%) 46 (24-60) NA NA 
CIS Total 61 43 (70%) 34,5 (19-51) 6.07 (2.17-9.81) 2.0 (0.0-4.0) 
 Low-risk 33 24 (73%) 36 (22-51) 6.45 (3.78-9.81) 2.25 (0.5-4.0) 
 High-risk 28 19 (68%) 33,5 (19-46) 5.51 (2.17-9.49) 2.0 (0.0-3.75) 
RRMS  NA NA NA NA NA 
ELISA (culture medium)
HC  12 9 (75%) 40.8 (25-58) NA NA 
CIS  12 8 (67%) 36 (23-47) 4.6 (0.55-8.53) 4.0 (0.0-6.0) 
RRMS  12 9 (75%) 40.5 (21-66) NA NA 
 
*, at time of sampling; †, time CIS to sampling; RRMS according to the McDonald 2010 criteria. Abbreviations: HC, 




Supplementary Table 2. Monoclonal antibodies used for FACS.
   
 
Marker Fluorochrome Clone Company 
CD3 AF700 SK7 Biolegend 
CD14 APC MOP9 BD Biosciences 
CD19 BV785 HIB19 Biolegend 
CD24 BV605 ML5 BD Biosciences 
CD27 BV421 M-T271 BD Biosciences 
CD38 PE-Cy7 HIT2 Biolegend 
CD56 PE-CF594 B159 BD Biosciences 
CD69 BV421 FN50 Biolegend 
CD74 APC LN2 Biolegend 
CD95 BV605 DX2 Biolegend 
CXCR4 PE-CF594 12G5 BD Biosciences 
CXCR4 APC 12G5 BD Biosciences 
HLA-DR PerCP-Cy5.5 L243 Biolegend 
IgA FITC IS11-8E10 Miltenyi-Biotec GmbH 
IgD PE-CF594 IA6-2 BD Biosciences 
IgG APC-H7 G18-145 BD Biosciences 
IgM BV510 MHM-88 Biolegend 
IL-6 PE MQ2-6A3 BD Biosciences 
TNF BV650 Mab11 BD Biosciences 
Supplementary Table 3. Primer sequences used for real-time PCR.    
Gene Forward primer Reverse primer 
MIF ACCGCTCCTACAGCAAGC CGCGTTCATGTCGTAATAGTTG 
IL6 ATGAGTACAAAAGTCCTGATCCA CTGCAGCCACTGGTTCTGT 
TNF GCCCAGGCAGTCAGATCATC GGGTTTGCTACAACATGGGCT 
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ABSTRACT 
Historically, multiple sclerosis (MS) has been viewed as being primarily driven by T 
cells. However, the effective use of anti-CD20 treatment now also reveals an important 
role for B cells in MS patients. The results from this treatment put forward T-cell activa-
tion rather than antibody production by B cells as a driving force behind MS. The main 
question of how their interaction provokes both B and T cells to infiltrate the CNS and 
cause local pathology remains to be answered. In this review, we highlight key patho-
genic events involving B and T cells that most likely contribute to the pathogenesis 
of MS. These include 1) peripheral escape of B cells from T cell-mediated control, 2) 
interaction of pathogenic B and T cells in secondary lymph nodes, and 3) reactivation 
of B and T cells accumulating in the CNS. We will focus on the functional programs of 
CNS-infiltrating lymphocyte subsets in MS patients and discuss how these are defined 
by mechanisms such as antigen presentation, co-stimulation and cytokine production 
in the periphery. Furthermore, the potential impact of genetic variants and viral trig-
gers on candidate subsets will be debated in the context of MS. 
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INTRODUCTION 
In multiple sclerosis (MS) patients, pathogenic lymphocytes are triggered in the 
periphery to infiltrate the central nervous system (CNS) and cause local inflammation 
and demyelination. Anti-CD20 therapy has recently been approved as a novel treatment 
modality for MS [1-3]. Although this underscores the fact that B cells play a key role in MS, 
the exact triggers, subsets and effector mechanisms contributing to the disease course 
are incompletely understood. The impact of this therapy on the antigen-presenting rather 
than the antibody-producing function of B cells in MS indicates that their interaction with 
T cells is an important driver of the pathogenesis [1, 4]. Alterations in cytokine production, 
co-stimulation and antigen presentation most likely contribute to the development of 
pathogenic B and T cells that are prone to enter the CNS [4, 6]. Such mechanisms might 
be influenced by the interplay between genetic and environmental risk factors [7]. The 
major HLA-DRB1*1501 locus accounts for 30% of the overall risk [7] and has been shown 
to promote B cell-mediated induction of brain-infiltrating T helper (Th) cells in MS patients 
[4]. Besides for HLA-DRB1*1501, other genetic risk variants that have been identified in the 
past decades also appear to potentiate B and Th cell activation, a feature that is shared 
amongst several autoimmune disorders [5]. Furthermore, infectious triggers such as the 
Epstein-Barr virus (EBV) alter their function and reactivity in MS [6-9]. The current view is 
that transmigration of lymphocyte subsets into the CNS signifies relapsing disease, while 
compartmentalized CNS inflammation, as seen during disease progression, seems to be 
driven by tissue-resident populations [10, 11]. Since there is a clear association of relapse 
occurrence and radiological disease activity early in MS with the severity of disability pro-
gression later in MS [12], it is crucial to understand what motivates these cells to invade the 
CNS and why these cells instigate local pathology in MS patients.
In this review, we will discuss which and how brain-infiltrating lymphocyte subsets 
can contribute to MS pathogenesis. These pathogenic events are characterized by: 1) 
peripheral escape of pathogenic B cells from T cell-mediated control, 2) mutual activation 
of pathogenic B and T cells within peripheral germinal centers, and 3) re-activation of infil-
trating B and T cells within the CNS. We will use current knowledge to consider the extent 
to which genetic and viral triggers may drive these pathogenic events in MS.
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IMPAIRED T CELL-MEDIATED CONTROL OF PATHOGENIC B 
CELLS IN MS
B and T cells closely interact in secondary lymphoid organs to generate an optimal 
immune response against invading pathogens. Within follicles, B cells recognize antigens 
via the highly specific B-cell receptor (BCR), resulting in internalization, processing and 
presentation to T cells. This mechanism is unique and tightly coordinated involving five 
consecutive and interdependent steps: 1) B-cell receptor signaling, 2) actin remodeling, 
3) endosomal formation and transport, 4) HLA class II synthesis and trafficking to special-
ized late endosomes (i.e. MIICs), and 5) antigen processing and loading onto HLA class II 
molecules for presentation to CD4+ Th cells [13, 14]. Through their interaction with Th cells, 
germinal center (GC)-dependent and -independent memory B cells are formed, a process 
that is governed by the strength of the HLA/peptide signal [15]. GC B cells respond to 
interleukin (IL)-21-producing follicular Th (Tfh) cells to develop into class-switched (IgG+) 
subsets or antibody-producing plasmablasts/plasma cells [15, 16]. Memory B cells, in 
return, specifically trigger Th effector subsets that help CD8+ cytotoxic T cells (CTLs) to kill 
the infected cell [17]. In MS, this crosstalk between B and T cells is likely disturbed, even-
tually causing pathogenic instead of protective immunity. This may already start during 
selection of naive autoreactive B cells in the periphery.
Normally, after removal of the majority of B-cell clones expressing polyreactive anti-
bodies in the bone marrow (central tolerance), surviving autoreactive B cells are kept in 
check by peripheral tolerance checkpoints [18]. In contrast to most other autoimmune 
diseases, only peripheral and not central B-cell tolerance checkpoints are defective in MS, 
which coincides with increased frequencies of naive polyreactive populations in the blood 
[18-21]. Although the exact cause is currently unknown, the escape of pathogenic B cells 
from peripheral control may be related to 1) chronic T-cell stimulation and 2) T cell-intrinsic 
defects (see Figure 1). 
EBV is one of the most thoroughly investigated pathogens regarding T-cell responses 
in MS. Many theories have been proposed how EBV can influence MS pathogenesis [9]. 
One hypothesis is that, due to the chronic nature of this infection, continuous antigen pre-
sentation by B cells leads to functionally impaired, so-called ‘exhausted’ T cells [8, 22]. This, 
together with the impact of HLA and other risk alleles [23], may result in inappropriate T 
cell-mediated control of EBV-infected (pathogenic) B cells. Consistent with this, peripheral 
CD8+ CTLs show decreased responses to EBV and not to cytomegalovirus antigens during 
the MS course [8]. EBV antigens can also induce IL-10-producing CD4+ T regulatory cells 
(Tregs) capable of suppressing effector T-cell responses to recall antigens [24], as seen 
for other persistent viral infections such as lymphocytic choriomeningitis virus [25, 26]. 
However, forkhead box P3 (FOXP3+) Tregs have also been described to control infections 
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Figure 1. Model of the key pathogenic events involving human B- and T-cell subsets driving MS disease activity. 
In MS patients, B- and T-cells interact in the periphery and central nervous system (CNS) to contribute to disease pathogenesis. 
In this model, we put forward three important meeting points of pathogenic B and T cells that drive the disease course of MS. In 
secondary lymphoid organs, B-cell tolerance defects in MS patients allow EBV-infected B cells to escape from suppression by CD8+ 
and T regulatory (Treg) cells (1). Subsequently, these activated B cells enter germinal centers (GCs) and interact with follicular Th 
cells to further differentiate into pathogenic memory B cells. Under the influence of IFN-γ and IL-21, B cells develop into T-bet-ex-
pressing memory cells, which in turn activate Th effector cells such as Th17.1 (2). These subsets are prone for infiltrating the CNS 
of MS patients by distinct expression of chemokine receptors (CXCR3, CCR6), adhesion molecules (VLA-4) as well as pro-inflamma-
tory cytokines. (3) Within the CNS, IFN-γ- and GM-CSF-producing T cells and T-bet+ memory B cells probably come into contact in 
follicle-like structures, resulting in clonal expansion inflammation and demyelination. T-bet+ memory B cells further differentiate 
into plasmablasts/plasma cells to secrete high numbers of potentially harmful antibodies (oligoclonal bands).
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[27] T-Lymphocyte, suggesting that additional T cell-intrinsic defects are involved. For 
example, Treg populations that are enriched in MS patients produce increased levels of 
interferon gamma (IFN-γ), express reduced levels of FOXP3 and have defective suppressive 
activity in vitro [28]. This is not only accompanied with less suppression of effector T cells 
[29, 30], but possibly also with impaired removal of pathogenic B cells, as described for 
other autoimmune diseases [18, 31, 32]. The direct impact of Tregs on B cells in MS patients 
is still unknown. Treg function may be altered by variation in IL2RA and IL7RA, two known 
MS risk loci [33, 34]. FOXP3 correlates with IL-2 receptor (IL-2R) as well as IL-7 receptor (IL-
7R) expression in Tregs [35]. It can thus be expected that IL2RA and IL7RA [33, 34], but also 
BACH2 [36] variants impair Treg development in MS. This may even influence FOXP3- and 
IL-2R-expressing CD8+ T cells, which can suppress pro-inflammatory CD4+ Th cells [37] and 
are reduced in the blood during MS relapses [38-40].
THE GERMINAL CENTER AS A POWERHOUSE OF PATHO-
GENIC B- AND TH-CELL INTERACTION IN MS 
Th cells as inducers of pathogenic memory B cells 
After their escape from peripheral tolerance checkpoints, naive B cells likely interact 
with Th cells in GCs to eventually develop into memory populations potentially capable of 
infiltrating the MS brain (Figure 1). Little is known about how peripheral effector Th cells 
mediate the development of such pathogenic B cells in MS patients. In GCs of autoimmune 
mice, autoreactive B cells are triggered by Tfh cells producing high levels of IFN-γ [16]. 
IFN-γ induces the expression of the T-box transcription factor T-bet, which upregulates 
CXC chemokine receptor 3 (CXCR3), elicits IgG class switching and enhanced antiviral 
responsiveness of murine B cells [41-43] . Recently, we found that B cells from MS patients 
preferentially develop into CXCR3+ populations that transmigrate into the CNS [44]. The 
IFN-γ receptor (IFNGR) and downstream molecule signal transducer and activator of tran-
scription (STAT)1 in B cells are major determinants of autoimmune GC formation in mice 
[45, 46]. After ligation of the IFNGR, STAT1 is phosphorylated, dimerizes and translocates 
into the nucleus to induce genes involved in GC responses, such as T-bet and B-cell lym-
phoma 6 (BCL-6) [16, 47]. Although IFN-γ-stimulated B cells of MS patients show enhanced 
pro-inflammatory capacity [44, 48], it is unclear whether alterations in the IFN-γ signaling 
pathway contribute to the development of T-bet+ B cells infiltrating the CNS. Interestingly, 
a missense SNP in IFNGR2 has been found in MS, which may alter their development 
[49, 50]. Another target gene of the IFN-γ pathway is IFI30, which encodes for the IFN-γ-
inducible lysosomal thiol reductase (GILT) and is considered one of the causal risk variants 
in MS [5]. GILT is a critical regulator of antigen processing for presentation by HLA class 
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II molecules [51-53]. Together, these findings point to T-bet-expressing B cells as potent 
antigen-presenting cells that are highly susceptible to triggering by IFN-γ-producing Th 
effector subsets in MS [44, 54] (Figure 2).
EBV may be an additional player in the formation of T-bet-expressing B cells. In mice, 
persistent viral infections sustain the development of these types of B cells, in which T-bet 
enhances their ability to recognize viral and self-antigens [41, 55]. EBV is hypothesized to 
persist latently in pathogenic B cells and mimic T-cell help for further differentiation in GCs 
[6, 22, 56, 57]. During acute infection, EBV uses a series of latency programs that drive B 
cells towards a GC response in an antigen-independent manner. Latent membrane protein 
(LMP)2A and LMP1 resemble signals coming from the BCR and CD40 receptor [56, 57]. 
In addition to their regulation of GC responses independently of T-cell help [58], recent 
evidence implicates that LMP2A and LMP1 can synergize with BCR and CD40 signaling 
as well [59]. Interestingly, downstream molecules of the BCR (e.g. Syk, CBL-B) and CD40 
receptor (e.g. TRAF3) are genetic risk factors for MS [23, 60], therefore potentially coop-
erating with these latent proteins to enhance pathogenic B-cell development (Figure 2). 
This is supported by the binding of LMP2A to Syk in B cells and their escape from deletion 
in GCs of transgenic mice [61]. Alternatively, pathogenic B cells can be induced via patho-
gen-associated TLR9, which binds to unmethylated CpG DNA and further integrate with 
BCR, CD40 and cytokine signals [62-65]. Moreover, pathogenic B-cell responses in systemic 
autoimmune diseases such as systemic lupus erythematosus are enhanced after IFN-γ and 
virus-mediated induction of the T-bet [45, 55, 64, 65]. In MS patients, TLR9 ligation is also 
a major trigger of pro-inflammatory B cells [48] and crucial for the differentiation of T-bet-
expressing IgG1+ B cells during IFN-γ- and CD40-dependent GC-like cultures in vitro. Thus, 
under influence of specific genetic factors, EBV might join forces with IFN-γ-producing Th 
cells to stimulate pathogenic (T-bet+) GC B cells both in a direct (via infection and per-
sistence in pathogenic subsets) and indirect (via TLR7/9) fashion in MS (Figure 2).
B cells as inducers of pathogenic memory Th cells
Synchronously, within peripheral GCs, T-bet-expressing memory B cells are ideal candi-
dates to trigger IFN-γ-producing, CNS-infiltrating Th cells in MS (Figure 1). In both mice and 
humans, T-bet promotes the antigen-presenting cell function of B cells. This may be related 
to the impact of EBV infection on B cell-intrinsic processing and presentation of antigens 
such as myelin oligodendrocyte glycoprotein (MOG)[6]. The potent antigen-presenting 
cell function of B cells in MS patients is further reflected by the effective use of anti-CD20 
therapy. This therapy does not affect antibody serum levels, but significantly reduces 
pro-inflammatory Th-cell responses in MS, both ex vivo and in vivo [1]. CD20 was found to 
be enriched on IFN-g-inducible T-bet-expressing IgG+ B cells in MS blood [44], pointing to 
this pathogenic subset as an important therapeutic target. Furthermore, genetic changes 
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in HLA class II molecules, as well as costimulatory molecules (e.g. CD80 [66, 67] and CD86 
[68]), may additionally enhance Th cell activation by such memory B cells (Figure 2). HLA 
class II expression on murine B cells was reported to be indispensable for EAE disease onset 
[69, 70]. The in silico evidence that autoimmunity-associated HLA class II molecules have an 
altered peptide-binding groove [71, 72], together with the potential role of several minor 
risk variants in the HLA class II pathway (e.g. CIITA, CLEC16A, IFI30 [Figure 2]), insinuates that 
antigens are differently processed and presented by B cells [4, 6]. This is supported by the 
increased ability of memory B cells to trigger CNS-infiltrating Th cells in MS patients car-
rying HLA-DRB1*1501 [4]. These CNS-infiltrating T cells induced by B cells showed features 
of both Th1 and Th17, therefore representing highly pathogenic subsets. Such subsets are 































Figure 2. Potential contribution of EBV and genetic risk factors to pathogenic B- and Th-cell development in MS patients. 
IFN-γ is a key player in autoreactive B- and Th-cell interaction and autoimmune germinal center (GC) formation in mice. In MS, 
we propose that EBV infection together with specific genetic risk variants promote the IFN-γ-mediated interplay between B and 
T cells within GCs. EBV directly infects naive B cells and mimic GC responses. EBV DNA can also bind to TLR7/9, and together with 
IFN-γ, induces T-bet+ memory B cells. Their interplay may be additionally stimulated by both B cell-intrinsic (IFN-γ sensitivity: IFN-
GR2; B cell receptor-antigen uptake: CBLB, SYK, CLEC16A; HLA class II pathway: CLEC16A, CIITA, IFI30; co-stimulation: CD80, CD86) 
and Th cell-intrinsic (surface receptors: IL2RA, IL7RA, IL12RB1; downstream molecules: TYK2, STAT3, STAT4) genetic risk variants. 
IL12R/IL-23R complexes trigger JAK2/STAT3-dependent RORγt and TYK2/STAT4-dependent T-bet expression in Th effector cells. 
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is involved in the co-expression of IL-17 and GM-CSF in mice but not in humans [75, 76]. 
GM-CSF is an emerging pro-inflammatory cytokine produced by Th cells in MS [33, 75, 77]. 
Our group recently revealed that a Th subset producing high levels of IFN-γ and GM-CSF, 
but low levels of IL-17, termed Th17.1, plays a key role in driving early disease activity in MS 
patients [78]. Proportions of Th17.1 cells were reduced in the blood and highly enriched 
in the CSF of rapid-onset MS patients. In addition, Th17.1 cells and not classical Th1 and 
Th17 cells accumulated in the blood of MS patients who clinically responded to natali-
zumab (anti-VLA-4 mAb). The increased pathogenicity of Th17.1 is further exemplified by 
their high levels of multidrug resistance, anti-apoptotic and cytotoxicity-associated genes 
ABCB1 (MDR1), FCMR (TOSO) and GZMB (granzyme B), respectively [78-81]. Th17.1 cells 
also show pronounced expression of the IL-23 receptor (IL-23R) [78], which is essential for 
maintaining the pathogenicity of Th17 cells during CNS autoimmunity [82]. IL-23 signals 
through the IL-23R and IL-12 receptor beta chain (IL-12Rβ1), resulting in JAK2-mediated 
STAT3 and TYK2-mediated STAT4 phosphorylation, and thereby inducing RORγt and T-bet, 
respectively [83]. IL-12RB1, TYK2, STAT3 and STAT4 are known genetic risk variants and thus 
may directly induce Th effector cells in MS (Figure 2). In addition to its potential effect 
on Tregs (see above), MS-associated risk variant IL-2RA enhances GM-CSF production by 
human Th effector cells [33]. To confirm the influence of these and other risk loci [84] on 
the induction of pathogenic Th cells such as Th17.1 in MS, functional studies need to be 
performed in the near future. 
The increased pathogenicity of Th effector cells may additionally be skewed by IL-6-
producing B cells [85, 86], which have been shown to trigger autoimmune GC formation 
and EAE in mice [87, 88]. Blocking of IL-6 prevents the development of myelin-specific 
Th1 and Th17 cells in EAE [89]. The IL-6-mediated resistance of pathogenic Th cells to Treg 
mediated suppression in MS [90, 91] further links to the abundant expression of anti-apop-
totic gene FCMR in Th17.1 [78, 92]. Intriguingly, B cell-derived GM-CSF can be an additional 
cytokine driving pathogenic Th cells in MS patients by inducing pro-inflammatory myeloid 
cells [93]. Although the causal MS autoantigen is still unknown, previous work implies that 
B cell-mediated presentation of EBV antigens at least contributes to pathogenic Th-cell 
induction [6, 94]. As mentioned above, antiviral CD8+ CTLs can become exhausted during 
persistent viral infections. Normally, this mechanism is compensated by the presence of 
cytotoxic CD4+ Th cells, which keep these types of infections under control [95]. Such Th 
populations have been associated with MS progression [96] and are also formed after EBV 
infection, producing high levels of IFN-γ, IL-2, granzyme B and perforin [97, 98]. Similarly, 
EBV- and myelin-reactive Th cells from MS patients produce high levels of IFN-γ and IL-2 
[7] and strongly respond to memory B cells presenting myelin peptides [99]. These studies 
indicate that the involvement of EBV-infected B cells, especially those expressing T-bet (see 
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3.1), in activating Th effector cells with cytotoxic potential [78, 100, 101] deserves further 
attention in MS. 
REACTIVATION OF CNS-INFILTRATING B AND T CELLS IN MS
Mechanisms of infiltration
Under normal physiological conditions, the CNS has been considered an immune 
privileged environment and consists of a limited number of lymphocytes that cross the 
blood brain barrier (BBB) [102]. However, the revelation of meningeal lymphatic structures 
emphasized the cross-talk between CNS and peripheral lymphocytes in secondary lym-
phoid organs [103]. The choroid plexus has been identified as the main entry of memory 
cells into the CNS, which is in the case of T cells mostly mediated by CCR6 [104, 105]. The 
normal human CSF, as is acquired from the arachnoid space by lumbar spinal taps, con-
tains more CD4+ Th cells compared to CD8+ T cells with central memory characteristics 
[106-108]. The arachnoid space is a continuum with the perivascular space surrounding 
penetrating arterial and venous structures into the parenchyma [109]. Within the brain 
parenchyma, more CD8+ T cells than CD4+ Th cells are found, however their numbers 
remain low and can be found virtually restricted to the perivascular space [11, 110]. These 
T cells display a phenotype mostly associated with non-circulating tissue resident memory 
T cells. The perivenular perivascular space has been argued to be the common drainage 
site of antigens mobilized with the glymphatics flow [111]. The exact relationship between 
memory T cells in the subarachnoid and perivascular space has been poorly identified in 
terms of replenishment and clonal association.
The BBB is dysfunctional during the early phase of MS, resulting in or is due to local 
recruitment of pathogenic T and B cells [112]. Differential expression of pro-inflamma-
tory cytokines, chemokine receptors and integrins by infiltrating lymphocytes have been 
argued to mediate disruption of the BBB in MS [104, 113]. Myelin-reactive CCR6+ and 
not CCR6- memory Th cells from MS patients not only produce high levels of IL-17, but 
also IFN-γ and GM-CSF [80]. Previous studies mainly focused on the migration of IL-17-
producing CCR6+ Th cells through the choroid plexus in EAE and in vitro human brain 
endothelial cell layers in MS brain tissues [104, 114]. In our recent study, we subdivided 
these CCR6+ memory Th cells into distinct Th17 subsets and found that especially IFN-γ 
producing Th17.1 (CCR6+CXCR3+CCR4-) cells were capable of infiltrating the CNS, both in ex 
vivo autopsied brain tissues and in in vitro transmigration assays [78]. The fact that Th17.1 
cells have cytotoxic potential and strongly co-express IFN-γ with GM-CSF [78] suggests 
that these cells are involved in disrupting the permeability of the BBB in MS [115, 116]. 
The impact of CXCR3 on their transmigration capacity is likely the result of binding to the 
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chemokine ligand CXCL10, which is produced by brain endothelial cells and is abundant in 
the CSF of MS patients [117, 118]. Similar observations were made for CXCR3(T-bet)+ B cells 
[44]. CCR6 is also highly expressed on memory B-cell precursors within the Th cell-contain-
ing light zone of GCs [119], and on IFN-γ-producing CD8+ T cells infiltrating the MS brain 
[120]. This implies that both populations are susceptible to enter the CNS of MS patients. 
In addition to chemokine receptors and pro-inflammatory cytokines, adhesion molecules 
such as activated leukocyte cell adhesion molecule (ALCAM) enhance transmigration of 
pathogenic B and T cell subsets [115, 121, 122]. Furthermore, CXCR3 is co-expressed with 
integrin α4β1 (VLA-4), which allows both B- and T-cell populations to bind to vascular 
cell adhesion protein 1 (VCAM-1) on brain endothelial cells [123]. This is supported by 
the reducing effects of VLA-4 inhibition on B- and Th17-cell infiltration into the CNS and 
disease susceptibility in EAE [124]. Natalizumab, a monoclonal antibody against VLA-4, is 
used as an effective second-line treatment for MS [125]. Discontinuation of this treatment 
often results in severe MS rebound effects [126]. Hence, the peripheral entrapment of 
populations like Th17.1 and T-bet+ B cells in natalizumab-treated patients [44, 78] prob-
ably underlies the massive influx of blood cells causing these effects. The same is true for 
EBV-reactivated B cells, which are enriched in lesions from MS patients after natalizumab 
withdrawal [127]. A previous gene network approach using several GWAS datasets further 
highlights the relevance of adhesion molecules on the BBB endothelium for the crossing 
of T and B cells [128], especially those affected by IFN-γ [115]. 
Local organization and impact
Both B and T cells accumulate in active white matter lesions of the MS brain [10, 129]. 
In diagnostic biopsy studies, T cell-dominated inflammation is a characteristic of all lesion-
types observed [130]. Also in post-mortem MS lesions, white matter MS lesions with active 
demyelination associate with an increase in T cell numbers [10, 129]. Although CD4+ Th 
cells are in general outnumbered by CD8+ CTLs in brain lesions as investigated in autopsy 
studies [10], their role as triggers of local pathology should not be overlooked in MS. This is 
consistent with the enrichment of CD4+ Th cells in white matter lesions with active demy-
elination [10]. An abundant number of CD4+ Th cells were also visible in pre-active lesion 
sites, suggesting an involvement of these cells in the early stages of lesion formation [131]. 
Additionally, it was demonstrated that in contrast to CD8+ CTLs, brain-associated CD4+ 
Th-cell clonotypes are reduced in MS blood, indicating specific recruitment (as described 
above) or, alternatively, clonal expansion in the CNS [132]. Furthermore, dominant Th-cell 
clones were undetectable following reconstitution after autologous hematopoietic stem 
cell transplantation in MS patients, which was not seen for CD8+ T cells [133]. Interestingly, 
T-cell clones are shared between CNS compartments within a patient, including CSF and 
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anatomically separated brain lesions [134-137]. This suggests that brain-infiltrating T cells 
bear similar reactivity against local (auto)antigens. 
In subsets of MS autopsy cases with acute and relapsing remitting MS, B cells can also 
be found predominantly in the perivascular space in association with active white matter 
lesions [10]. The role of these perivascular B cells, including T-bet+ B cells [44], could be 
to re-activate (infiltrating) pro-inflammatory CD4+ and CD8+ T cells to cause MS pathol-
ogy (Figure 1). Identical B-cell clones have been found in different CNS compartments of 
MS patients, including the meninges [138, 139]. Within the meninges, B- and T cell-rich 
follicle-like structures have been found that localize next to cortical lesions, presumably 
mediating progressive loss of neurological function in MS [140, 141]. Interestingly, MS 
brain-infiltrating lymphocytes express and respond to IL-21 [142], the cytokine that drives 
follicular T- and B-cell responses. Additionally, IFN-γ triggering of B cells promotes ectopic 
follicle formation in autoimmune mice [16, 45], suggesting that the structures observed in 
the MS CNS are induced by B cells interacting with IFN-γ-producing T cells. However, the 
role of IL-17 in this process should not be ruled out, as shown in EAE [143]. 
Besides mediating migration and organization of pathogenic lymphocytes in the MS 
brain, cytokines are likely relevant effector molecules. IFN-γ production by Th cells also 
associates with the presence of demyelinating lesions in the CNS [144-146]. IFN-γ, and 
possibly also GM-CSF, can activate microglia or infiltrated macrophages to cause damage 
to oligodendrocytes [93, 147, 148]. As for B cells, increased production of TNF-α, IL-6 and 
GM-CSF has been found [48, 87] and we have recently shown that during Tfh-like cultures, 
IFN-γ drives IgG-producing plasmablasts in MS [44]. One could speculate that after their 
re-activation by IFN-γ-producing Th cells within the meningeal follicles, T-bet+ memory B 
cells rapidly develop into antibody-producing plasmablasts/plasma cells (Figure 1). IFN-γ-
induced GC formation promotes the generation of autoantibodies in lupus mice [16, 45]. 
The targeting of B cells and not plasmablasts/plasma cells by clinically effective anti-CD20 
therapies in MS, as well as the abundance of oligoclonal bands in MS CSF, at least support 
the local differentiation of B cells into antibody-secreting cells [48, 149]. We argue that 
IgG secreted by local T-bet-expressing plasmablasts/plasma cells are highly reactive in 
the MS brain [43, 44, 55], although the (auto)antigen specificity and pathogenicity of such 
antibodies remain unclear in MS, as well as their contribution as effector molecules to MS 
pathology.
Several antigenic targets have been proposed to contribute to MS pathology. Next to 
myelin, which is one of the most intensively studied antigens [150], also EBV antigens are 
considered as major candidates. EBNA-1 specific IgG antibodies are predictive for early dis-
ease activity [151] and are present in CSF from MS patients [152, 153]. Some studies imply 
that reactivated B cells in ectopic meningeal follicles [154, 155] cross-present EBV peptides 
to activate myelin- and EBNA-1 specific Th cells [7, 156, 157]. Whether EBV is detected in 
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the brain or solely recognized in the periphery and how this contributes to local pathology 
is still a matter of intense debate in the field [127, 158-162]. In addition to myelin [150] and 
EBV [7], other antigenic targets of locally produced IgG and infiltrating T cells have been 
suggested, such as sperm-associated antigen 16 (SPAG16 [163]), neurofilament light, RAS 
guanyl-releasing protein 2 (RASGRP2 [4]), αB-crystallin and GDP-l-fucose synthase [135]. 
CONCLUDING REMARKS
In this review, we have discussed potential triggers and mechanisms through which 
interacting B and T cells drive the pathogenesis of MS. In our presented model, peripheral 
B cells escape from tolerance checkpoints as the result of impaired control by chronically 
exhausted or genetically altered regulatory T cells. Subsequently, B cells interact with 
IFN-γ-producing effector Th cells in germinal centers of lymphoid organs to create a feed-
forward loop, after which highly pathogenic subsets break through blood-CNS barriers 
and, together with infiltrating CD8+ CTLs are locally reactivated to cause MS pathology. 
Although definite proof is still lacking, these pathogenic events are likely mediated by an 
interplay between persistent infections such as EBV and genetic risk variants. Together, 
these factors may alter the selection, differentiation and pathogenic features of B- and 
T-cell subsets. In our view, more in-depth insights into how infections and genetic burden 
define the CNS-infiltrating potential and antigen specificity of such subsets should be 
the next step to take in the near future. The development of small molecule therapeutics 
against subsets driving the disease course would be an effective way of generating clini-
cally relevant benefits without harmful effects in MS patients.
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The contribution of B cells to the pathogenesis of multiple sclerosis (MS) is indisput-
able. However, the exact B-cell subset and mechanisms that mediate the disease are still 
unclear. Previously, MS was mainly considered a T cell-driven chronic inflammatory disor-
der of the central nervous system (CNS), although the presence of oligoclonal bands in the 
cerebrospinal fluid (CSF) already indicated a pathophysiological role of B cells. This was 
largely strengthened by the strong clinical benefits of anti-CD20 mediated B-cell depletion 
in MS. Since long-lived antibody-producing plasma cells do not express CD20 and thus are 
not removed with this therapy, B cells also promote MS pathogenesis in an antibody-inde-
pendent manner. It has become evident that B cells can drive autoimmune diseases such 
as MS through the presentation of autoantigens to T cells, secretion of cytokines and the 
formation of ectopic lymphoid structures in chronically inflamed tissue (chapter 1). In this 
thesis, we aimed to uncover genes and pathways that are functionally altered in human B 
cells and could explain their contribution to MS pathogenesis. To study this, we made use 
of gene silencing and functional assays related to B- and TH-cell interaction and took advan-
tage of recent genome-wide association study (GWAS) data, different patient cohorts and 
the effects of immunosuppressive conditions and treatment on disease activity.
In chapter 6, we discuss our hypothesis that multiple events involving B-T cell inter-
action play a key role in MS. During B cell development, naive B cells likely escape from 
peripheral selection to enter secondary lymphoid organs and encounter T-follicular helper 
(TFH) cells. After mutual activation, B cells further develop into pathogenic memory subsets 
within germinal centers (GCs), which migrate into the CNS and meet again with T cells 
to cause local pathology. Within this general discussion, we elaborate on alterations in 
functional B-cell pathways that possibly drive these events in MS. This involves altered 
B-cell antigen processing and presentation via HLA-II molecules, T cell-derived interferon 
gamma (IFN-γ) as inducer of pathogenic memory B cells, local organization within GCs to 
facilitate pathogenic B-cell differentiation as well as their capacity to infiltrate the CNS.
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PART I. DYSREGULATION OF THE B-CELL ANTIGEN PRO-
CESSING AND PRESENTATION PATHWAY IN MS
Expression and impact of class II–associated invariant chain peptides 
(CLIP) on B cells
Naive B cells circulate within the bloodstream and recruit to secondary lymphoid fol-
licles. When a naive B cell recognizes and processes an antigen, it will migrate towards 
the follicular border. Here, the B cell presents the processed antigen to a TFH cell, which 
together with cytokine and costimulatory signals results in TFH-cell activation. During this 
interaction, the B cell also receives survival and proliferating signals from the T cell. In 
chapter 3, we analyzed both CLIP and HLA-DR surface expression as indirect measure of 
B-cell antigen presentation efficiency [1] in both relapsing-remitting MS (RRMS) patients 
and clinically isolated syndrome (CIS) patients. The used cerCLIP.1 antibody specifically 
recognizes CLIP-loaded HLA-II, while L243 antibody detects peptide-loaded HLA-II (HLA-
DR; [1]). CLIP was upregulated on B cells of RRMS as well as high-risk CIS patients, while 
surface HLA-DR expression was not increased, resulting in an increased CLIP/HLA-DR 
ratio. This increased CLIP/HLA-DR ratio was seen for all subsets, including transitional 
(IgM+CD27-CD38high), naive mature (IgM+CD27-CD38-/dim), non-switched (IgM+CD27+) as 
well as switched (IgG+CD27+ and IgA+CD27+) B-cell subsets.
There could be several reasons for the increased expression of CLIP on B cells of early 
MS patients. In naive B cells, CLIP remains bound to the peptide-binding groove of HLA-II 
molecules until the B-cell receptor (BCR) is engaged with an antigen. It has been proposed 
that before receiving an antigen-specific signal, polyclonal activation of B cells results in 
increased CLIP expression and improper control of T cell-induced cell death, thereby con-
tributing to chronic inflammation in mice [2]. This polyclonal activation is mediated via 
toll-like receptor (TLR) activation during infections. TLR-mediated activation of B cells not 
only results in ectopic CLIP expression, but also increased expression of HLA-II itself. After 
polyclonal activation, recognition of an antigen triggers an adaptive immune response by 
supporting survival of antigen-specific and promoting MHC-dependent death of non-spe-
cific B cells. The increased CLIP expression on naïve B cells in the blood of MS patients may 
thus be the result of improper control of such polyclonal, potentially autoreactive B cells 
[3].
Another possible reason for the abundance of CLIP on B cells in MS might be that 
chronic exposure to antigens in the absence of TH cell stimulation can eventually result in 
anergy [4]. This makes B cells less able to recognize and internalize antigens for exchange 
with CLIP on HLA-II within HLA-II peptide-loading compartments (MIICs). Furthermore, 




autoreactive naive B cells [5, 6]. In chapter 3, we demonstrate that CLIP upregulation on B 
cells from healthy subjects is mainly induced by CD40-CD40L interaction. The fact that CLIP 
was already highly expressed on naive B cells of MS patients, and not further enhanced by 
CD40 triggering, provides further insights into how CLIPhigh B cells may be able to circum-
vent T cell-mediated selection in MS [3]. Defective TREG responses are often considered as 
the main cause of autoreactive B-cell survival in the periphery [7-9]. Notably, in mice, CLIP 
upregulation impedes TREG activation [10, 11], which may represent a second mechanism 
by which CLIPhigh naive B cells escape from peripheral tolerance in MS.
Dual role for the invariant chain in B cells
CLIP remains in the HLA-II peptide-binding groove after cleavage of the invariant chain 
(CD74). In chapter 4, we show that surface expression of CD74 on B cells from RRMS and 
high-risk CIS patients is decreased compared to healthy controls and low-risk CIS patients, 
respectively. The downregulation of CD74 and upregulation of CLIP especially on naive B 
cells supports our hypothesis that invariant chain processing into CLIP is enhanced during 
polyclonal activation (see above). Furthermore, we demonstrate that a CD74 blocking 
antibody suppressed the proliferation, and induction of pro-inflammatory genes NFKB1, 
IL6 and TNF, after α-IgM stimulation of B cells in vitro. The reduced expression of CD74 on 
B cells in early MS blood might therefore reflect a functional state of anergy, contributing 
to the persistence of pathogenic immature B cells in the periphery [12]. Next to its role 
as a chaperone of the HLA-II molecule (chapter 1), 2-5% of the invariant chain or CD74 is 
expressed at the surface independently of HLA-II [13, 14]. When present on the cell surface, 
CD74 can serve as a high-affinity receptor for the macrophage migration inhibitory factor 
(MIF) [15]. MIF is a pro-inflammatory and immune-regulatory cytokine, which is ubiqui-
tously expressed in mammalians. Extracellular MIF binds to CD74 and triggers B-cell pro-
liferation, migration and inhibition of apoptosis [15, 16]. Although binding of MIF to CD74 
is essential for the signaling, it was not sufficient to trigger downstream transduction. It 
depends on the presence of co-receptors CD44, CXCR2 or CXCR4, which recruit signaling 
components with their cytoplasmic domains [17-19]. 
Very little is known about how the expression of the invariant chain is distributed 
between functioning as a MHC-II chaperone or as a MIF signaling receptor. There are sev-
eral isoforms of CD74; p33, p35, p41 and p43 [20]. The latter two have an additional exon 
in the luminal domain, while p35 and p43 have an extra N-terminal extension which is an 
endoplasmic reticulum (ER) retention motif. The p35 and p43 therefore cannot leave the 
ER without assembling MHC-II, since this will mask the ER retention motif, which allows 
the exit of the complex to the cell surface [21]. However, p33 and p41 do not have this ER 
retention motif and therefore can exit the ER without MHC-II [22], potentially function as 
MIF receptor. However, these isoforms can also still assemble MHC-II molecules and be a 
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chaperone. More research is needed to separate these functions of the invariant chain and 
to understand the full potential and biology.
Minor risk alleles and the HLA-II pathway
After their escape from selection and BCR-mediated uptake of an antigen, B cells pro-
cess and present (auto)antigens to receive signals from cognate TFH cells [23] and differen-
tiate into memory subsets or plasmablasts/plasma cells. Within GC, memory B cells serve 
as potent antigen-presenting cells to trigger pathogenic TH subsets, as recently described 
for MS [24]. These subsets express high levels of IFN-γ and have a similar phenotype as the 
MS brain-homing TH cells found by our team [25, 26]. In chapter 2, we found that blocking 
of IFN-γ suppressed human TH cell activation, proliferation and effector memory skewing 
during autologous co-cultures. Although the exact antigen in MS is still unknown, the dis-
ease pathology likely involves interaction of B cells with IFN-γ-producing TH cells within 
lymphoid organs, which creates a feedforward loop resulting in the development of highly 
pathogenic B- and T cell subsets.
Several lines of evidence indicate that the exchange of CLIP for antigenic peptides on 
HLA-II is at least partially controlled by genetic autoimmune traits. Firstly, the strong effects 
of certain HLA-II loci in autoimmune diseases such as type I diabetes, rheumatoid arthritis 
and MS are associated with specific amino acid changes in the peptide-binding groove [27-
29]. However, in CIS, we did not find an association between B cell-intrinsic CLIP expression 
and the presence of HLA-DRB*1501. In addition, HLA-DM polymorphisms, which may affect 
HLA-II peptide binding [30], did not link to disease susceptibility or myelin-specific T-cell 
responses in MS [31]. Secondly, non-HLA risk loci are being identified that regulate the 
BCR-mediated HLA-II pathway [1, 23, 32]. 
Multiple GWAS have demonstrated that C-type lectin gene CLEC16A genetically links 
to several autoimmune diseases including MS [33]. Our group previously found that it has 
a non-classical C-type lectin function in myeloid cells by participating in dynein-mediated 
transport of MIICs [34]. In chapter 3, we show that CLEC16A is co-expressed and -regulated 
with surface CLIP in human B cells. Based on the expression patterns amongst distinct 
ex vivo B-cell subsets and gene silencing experiments, CLEC16A seems to be especially 
involved in the HLA-II pathway of IgM+ B cells residing outside the GC (i.e. naive and natural 
effector memory subsets) [35, 36]. This is supported by an earlier study in mice [37]. The 
more dispersed localization of MIICs in CLIPhigh Raji B cells after CLEC16A silencing agrees 
with our previous findings in other antigen presenting cells (APCs) [34]. Additionally, 
HLA-DR and CD74 as well as IgM/antigen complexes were trapped at the plasma mem-
brane of CLEC16A-silenced Raji cells. This not only confirms the role of CLEC16A in retro-
grade transport of MIICs [34, 38], but also points to a function in BCR-mediated internaliza-




acidification in perinuclear regions that is required for optimal antigen processing and 
loading onto HLA-II molecules in DCs. In the absence of CLEC16A, both HLA-II/invariant 
chain and BCR/antigen complexes probably do not reach these MIICs for proper cleav-
age into CLIP and exchange with antigenic peptides. Like CLEC16A, non-classical HLA-II 
chaperone HLA-DO is highly expressed in naive B cell populations [39], which inhibits 
this exchange via HLA-DM [40]. Considering the proposed HLA-DM-independent nature 
of CLIP release from autoimmunity-related HLA-II molecules [27], it will be interesting to 
further analyze patient B cells for CLEC16A and CLIP co-regulation in the context of both 
classical and non-classical HLA-II proteins.
Next to CLEC16A, GWAS studies have identified multiple other single nucleotide poly-
morphisms (SNPs) that can be linked to the regulation of the HLA-II pathway. Two of those 
SNPs are located in CBLB and MARCH1 [41-43]. CBL-B is an E3 ubiquitin ligase that tags 
proteins with ubiquitin for degradation. CBL-B acts as a scaffolding molecule to coordi-
nate the delivery of BCR-captured antigens to TLR9 in subcellular compartments [44]. 
Furthermore, CBL-B negatively regulates CD40-mediated B-cell responses [45]. MARCH1 
is another E3 ubiquitin ligase that serves as the master regulator of MHC-II expression at 
the post-transcriptional level [46]. Ubiquitination of MHC-II in both murine and human 
cells represents a critical molecular switch that regulates its transport to and from the cell 
surface [47-50]. HLA-DM and costimulatory molecule CD86 are regulated by MARCH1 
ubiquitination as well [51, 52] [53]. Intriguingly, one of the very few SNPs in a protein-cod-
ing region is located in IFI30 (rs11554159) [41]. IFI30 is a gene that encodes for GILT and 
mainly resides in late endosomes. Here, it reduces protein disulfide bonds and cleaves the 
invariant chain into CLIP, thus facilitating efficient peptide loading and presentation by 
HLA-II molecules [54-56]. This missense SNP is located next to the active site of GILT and is 
predicted to be the causal MS risk variant in IFI30 [32]. IFI30 as well as the master regulator 
of HLA-II pathway termed CIITA are under tight control of IFN-γ (unpublished data and 
[57]). Another missense risk SNP is found in IFNGR2 (rs9808753; [43, 58]), which encodes 
for the IFN-γ receptor β chain and has been linked to disease progression in MS [58, 59]. 
The exact mechanisms by which this risk SNP in IFNGR2 contributes to MS is still unknown. 
Since these two, out of the very few, exonic SNPs are located in IFN-γ-associated genes, it 
is highly tempting to speculate that the IFN-γ signaling pathway in B cells is alternatively 
regulated and contributes to the development of pathogenic subsets in MS.
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PART II. INCREASED IFN-γ SENSITIVITY AND DEVELOP-
MENT OF BRAIN-INFILTRATING B CELLS IN MS
Function of coding MS risk variant IFNGR2
The IFN-γ receptor (IFNGR) consist of a ligand binding chain (IFNGR1) and a non-ligand 
binding chain (IFNGR2) [60, 61]. Once IFN-γ binds to the IFNGR, Janus kinase (Jak)1 and 
Jak2 are activated and signal transducer and activator of transcription 1 (STAT1) gets phos-
phorylated [62]. Phosphorylated STAT1 (pSTAT1) dimerizes and translocates to the nucleus 
where it initiates transcription of genes such as T-bet, IRF1 and BCL-6 [23, 62] (Figure 1A).
Preliminary work by our group suggests that STAT1 is highly phosphorylated and stim-
ulates T-bet under IFN-γ-stimulating conditions in human B-cell lines carrying MS risk allele 
IFNGR2. For this, we first genotyped the IFNGR2 risk SNP (rs9808753; [43, 58]) in 19 human 
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Figure 1. Model showing the potential impact of a missense risk SNP (rs9808753) in IFNGR2 on the IFN-γ 
signaling pathway .
A: The IFNGR is expressed at the surface of B cells and consists of an α (IFNGR1) and β (IFNGR2) chain. Once IFN-γ 
binds to the receptor, signaling is initiated and results in the expression of IFN-γ target genes. B: After the IFN-γ 
binding and IFNGR signaling, IFNGR2 is removed from the surface to prevent further stimulation of the B cell. C: 
In IFNGR2 SNP carriers, the IFNGR2 is possibly not removed from the surface, resulting in a prolonged signaling of 




carried both risk alleles (MC116). After stimulation with IFN-γ for 10 min, we analyzed 
STAT1 and pSTAT1 protein expression by western blotting (Figure 2A). We found that the 
B-LCL carrying both risk alleles had an enhanced phosphorylation of STAT1 compared to 
the B-LCL carrying no risk alleles (Figure 2B). This association between STAT1 phosphor-
ylation and the presence of the IFNGR2 risk allele was confirmed using two other B-LCLs 
(data not shown). Next, we screened 90 healthy controls and 130 CIS patients for the pres-
ence of the IFNGR2 risk SNP (Figure 2C). We were able to select and purify B cells from the 
blood of 4 CIS patients who were homozygous risk carriers. After stimulation with IFN-γ for 
various time points between 0 and 30 min, observed differences in pSTAT1 expression in 
B cells between these patients and 4 heterozygous risk and 4 non-risk carriers could not 
be reproduced using FACS. Alternatively, we stimulated B cells from these same patients 
for 24h with IFN-γ and analyzed the expression of IFN-γ-associated genes using qPCR. 
Interestingly, T-bet, IRF1 and IFNGR2 levels turned out to be higher in the homozygous risk 



































































































































  # (%) *   
  A/A A/G G/G total # 
HC 75 (83.3) 15 (16.7) 0 (0.0) 90 
CIS 102 (78.5) 24 (18.5) 4 (3.0) 130 
C
Figure 2. The impact of coding MS risk variant IFNGR2 on the IFN-γ pathway in human B cells.
A: A human EBV-negative B-LCL carrying no IFNGR2 risk alleles (Karpas422; A/A) and a human EBV-negative B-LCL 
carrying both IFNGR2 risk alleles (MC116; G/G) were analyzed for pSTAT1 and STAT1 protein expression before and 
after 10 min stimulation with IFN-γ using western blotting. This was repeated 6 times in two independent exper-
iments, corrected for β-actin expression and depicted as pSTAT1/STAT1 ratios (B). (C) T-bet (TBX21), IRF-1 (IRF1) 
and IFNGR2 gene expression in 24h-stimulated B cells was compared between CIS patients who were non-risk 
(A/A), heterozygous (A/G) and homozygous risk (G/G) carriers (n=4 per subgroup) using qPCR. In D, IFNGR2 gene 
expression was compared to the unstimulated condition per patient (dotted line). For statistical analysis, paired 
t-tests (B) and Mann-Whitney U tests (C) were carried out. *p<0.05, ** p<0.01, ****p<0.0001
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group (Figure 2D), suggesting that the IFN-γ signaling pathway is affected by the IFNGR2 
risk allele in human primary B cells as well. These results need to be confirmed in larger 
numbers of individuals. 
It also remains to be determined whether and how this SNP affects the expression of 
IFNGR. In T cells, IFNGR2 trafficking tunes IFN-γ signaling, by altering its surface expression 
[63]. Under normal conditions, IFNGR2 is removed from the cell surface after ligation to 
prevent further stimulation by IFN-γ (Figure 1B). Although IFNGR1 expression is ubiquitous, 
IFNGR2 expression is fine-tuned by many factors, including ligand-dependent engulfment 
of IFNGR2 and downregulation of IFNGR2 transcription [63-66]. In our analyses, we found 
that for the homozygous risk group, IFNGR2 expression is less decreased in B cells after 
IFN-γ triggering (Figure 2E). This implies that the risk SNP interferes with the removal of 
surface IFNGR2, resulting in prolonged IFN-γ signaling (Figure 1C). This should to be vali-
dated and further investigated in the near future. 
Synergy between IFN-γ and TLR9 ligand 
It has been shown previously that B cells of MS patients are more sensitive to IFN-γ 
signaling [67]. More general, in an autoimmune setting, it has been shown that additional 
production of IFN-γ by TFH cells elicits autoimmune GC formation. This first became evi-
dent from studies in SLE [68], where it has been shown that deletion of the IFN-γ receptor 
in B-cells inhibits the formation of autoimmune GCs and production of class-switched 
autoantibodies. In B cells, IFN-γ has been shown to induce the expression of T-bet, which 
triggers class switching under inflammatory conditions in both mice and humans [69-71]. 
T-bet induces CXCR3 expression, which is involved in the localization of B cells and differ-
entiation into plasma cells within GCs [72, 73]. Furthermore, class-switching and autoan-
tibody production can also be mediated by TLR9 signaling [74]. In chapter 2, we show 
that naive B cells from MS patients are differentially influenced by IFN-γ and TLR9 ligand 
CpG-ODN during TFH-like cultures. IFN-γ stimulated the development of plasmablasts, 
whereas IFN-γ together with CpG-ODN triggered the differentiation of IgG1+ memory B 
cells. Furthermore, we demonstrate that TLR9 triggering enhanced T-bet and CXCR3 sur-
face expression during IFN-γ-mediated GC-like cultures with naive B cells. Interestingly, 
these synergistic effects on T-bet/CXCR3 induction and B-cell differentiation were not seen 
when culturing purified memory B cells, indicating that IFN-γ and TLR9 ligand are import-
ant for the fate of naive B cells in autoimmune diseases such as MS [68, 70, 75]. 
GC organization versus CNS recruitment 
Increased levels of CXCL10, CXCL12 and CXCL13 in the CNS of MS patients probably 
facilitate the recruitment and organization of memory B cells [76-78]. In chapter 2, we 




after treatment with natalizumab, an effective MS drug that blocks the entry of pro-in-
flammatory lymphocytes into the CNS. Additionally, CXCR3+ B cells were enriched in fresh 
single-cell suspensions from CSF and brain tissue versus blood of progressive MS patients. 
Further analysis of these cells in the blood of natalizumab-treated MS patients revealed 
that particularly IgG(1)+ memory B cells express high levels of CXCR3 and accumulate 
within 1 year after treatment. CXCR3+IgG1+ memory B cells also preferentially migrated 
towards CXCL10 in human brain endothelial in vitro transmigration assays. It is therefore 
highly likely that CXCR3highCD27+IgG1+ B-cell populations in the blood preferentially recruit 
to the CNS during MS pathogenesis, as discussed in more detail in chapter 6. 
Once in the CNS, B cells are possibly re-activated within ectopic lymphoid follicle-like 
structures found in the meninges, which could mimic a GC response (chapter 1). Here, the 
aberrant CXCR4 and CXCR5 expression might play an important role in the local organiza-
tion and differentiation of memory B cells and antibody-producing plasma cells. Within the 
periphery, the local organization within a GC is crucial for efficient selection and develop-
ment of B cells, which is mediated through various chemokines and their receptors. After 
interaction with pre-TFH cells at the follicular border, B cells are attracted to CXCL12 within 
the GC dark zone through the expression of CXCR4 [79, 80] and undergo extensive prolif-
eration and SHM (chapter 1). Subsequently, CXCR4 is downregulated and both CXCR5 and 
CCR6 direct the B cell towards the light zone [79, 81]. Here, B cells interact with follicular DCs 
and TFH cells to undergo selection and eventually differentiate into class-switched memory 
or long-lived plasma cells [82]. The number of peptide-MHC complexes presented on the 
cell surface dictates the quantity of T cell help and thereby drives the selection of light zone 
B cells [83]. If required, GC B cells can be directed back into the dark zone for further rounds 
of somatic hypermutation and maturation before they exit the GC as memory B cells or 
plasma cells. In chapter 4, we demonstrate that CXCR4 expression is increased on B cells of 
CIS patients who rapidly developed MS as well as in clinically definite MS patients. CXCR4 
was found to be the highest on naive B cells, which probably controls their development 
within GCs, as shown in SLE [84]. Our data shows that blocking of CXCR4 signaling in B cells 
increases CD95 (Fas) expression. Fas is essential for the elimination of autoreactive B-cell 
clones by TH cells [85]. Hence, the overexpression of CXCR4 on naïve B cells, as observed in 
early MS patients, may promote their escape from TH cell-based selection in the light zone 
via reduced Fas expression and enhanced migration into the dark zone. Next to the initial 
GC-response, memory B cell can re-enter the GC for a secondary immune response after 
antigen re-challenge [86]. Here, memory B cells can differentiate into long-lived plasma 
cells or undergo additional rounds of expansion, SHM and affinity maturation. Especially 
this reactivation of memory B cells and formation of long-lived (potentially tissue-resident) 
plasma cells is speculated to happen within ectopic lymphoid follicles [87]. 
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Whether the local organization and subsequent reactivation within the CNS corre-
spond to MS relapse risk has not been elucidated. Pregnancy results in a natural and tran-
sient period of immune suppression [88], enabling the analysis of different B-cell subsets 
during periods with low relapse risk (3rd trimester) and high relapse risk (early postpartum) 
[89, 90]. In chapter 5, we show that CXCR4 expression is decreased while CXCR5, CCR6 and 
CXCR3 expression are increased on B cells in the early postpartum period as compared 
to 3rd trimester. These differences were most pronounced in MS patients and reflected a 
GC light zone phenotype. Not only surface expression of IgM and IgG, but also in vitro 
differentiation of IgM- and IgG-secreting plasma cells was increased for memory B cells 
from postpartum blood samples. This indicates that the increased postpartum relapse risk 
may be partially explained by the increased potential of B cells to migrate into the GC light 
zone, interact with IFN-γ-producing TFH cells and differentiate into CXCR3
+ memory B cells 
that are prone to enter the CNS and locally develop in potentially tissue-resident plasma 
cells in MS [91, 92].
FUTURE PERSPECTIVES
Functional B-cell genetics
GWAS identified now more than 200 SNPs that are associated with MS, however only 
limited research has been done on the function of such a SNP. In this thesis, we took a first 
step by linking MS risk variant CLEC16A to the HLA-II pathway and IFNGR2 to the IFN-γ 
signaling pathway in B cells. However, to do real functional studies on the effect of one 
single nucleotide change in human lymphocytes, different techniques should be used. 
CRISPR/Cas9 is one of those techniques that is potentially very useful to introduce a SNP in 
a specific cell type. However, doing CRISPR/Cas9 SNP editing in human B cells in vitro is a 
challenge and needs further development before we can implicate this for future research.
While HLA-DRB1*15:01 is associated with an increased risk of MS development, it is still 
unknown why. Many studies have been performed on the functional consideration on the 
effect of this HLA-II allele and suggest that it has probably to do with the peptide binding 
motif which is unique for this allele [93]. However, the exact peptide that is presented by 
HLA-II molecules to T cells in MS is currently still unknown. Some studies suggest that it is a 
specific peptide from the MBP protein, but this has not been validated in vivo [94]. 
Another interesting strategy is to study genetic risk scores by selecting the risk genes 
within these GWAS analysis that are important for the function of B cells. Based on those 
risk SNPs calculate a genetic risk score and compare this to the actual function or pheno-
type of the cells. This could give more relevant insight and could possibly predict disease 




of the SNPs are located intergenic or intragenic, which makes it difficult to determine on 
which gene the SNP would have an effect. Hopefully, more insight is gained in the function 
of these SNPs in the future.
Selective B-cell therapeutics
Targeting B cells with a-CD20 B-cell depletion therapies such as rituximab and ocreli-
zumab is highly efficient, and is now even the first therapy to be approved for progressive 
MS patients [95]. However, deleting all B-cell can have severe side effects. Moreover, the 
sooner we could identify the pathogenic B cell subtype, the better we can target these 
cells more specific. Therefore, more specific targeted therapy needs to be developed that 
targets only selected B cell subsets, or specific B cell functions. Within this thesis we have 
shown that the CXCR3+ (T-bet+) IgG1+ memory B cells is of high interest to be targeted by 
therapy, since this subset is most prone to migrate to the CNS to mediate the disease locally 
(chapter 2). This subset is generated after stimulation of both IFN-γ and TLR-9 pathways. 
Small molecule inhibitors of the IFN-γ signaling (jakinibs) [96, 97] and TLR pathway [98] are 
currently being used for treating other inflammatory diseases. Such targeted treatments 
may be applied for suppression of IFN-γ and/or TLR signals in B cells, specifically targeting 
the potential disease causing B cell subsets (Figure 3).
Another potential therapeutic target in B cells is Bruton’s tyrosine kinase (BTK). BTK is a 
member of the Tec family of kinases and transmit signals through multiple receptors on the 
B cell, including the BCR and TLR. Furthermore, BTK also controls CXCR4 signaling as well 
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Figure 3. The different B-cell pathways addressed in this thesis and possible targets to interfere with the 
development of pathogenic B cells in MS. 
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in several autoimmune diseases, including SLE, RA and MS. A recently published place-
bo-controlled phase II trial of an oral BTK inhibitor (evobrutinib) showed promising results 
and underlines further investigation for the use as therapy in MS [99].
Currently within our group, we are studying the effect of evobrutinib on human B cell 
differentiation and migration in vitro. Furthermore, we are investigating the effect of BTK 
inhibition after IFN-γ and TLR9 stimulation and subsequent development of CXCR3+(T-bet+) 
B cells. Although still preliminary, these result show that evobrutinib inhibits the differenti-
ation of naive B cells towards CXCR3+(T-bet+) memory B cells, as well as the differentiation 
of memory B cells towards antibody-producing plasma cells. In addition, specific migration 
of IFN-γ- and TLR9-induced CXCR3+ B cells towards CXCL10 across the blood-brain barrier 
seems to be partially inhibited by evobrutinib (data not shown). These results suggest that 
inhibiting BTK could be a good strategy to inhibit the differentiation and CNS-homing 
capacity of potentially pathogenic CXCR3+(T-bet+) B cells.
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Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous 
system (CNS). Various pro-inflammatory immune cells mediate local pathology. CD20 
depletion therapies and genome-wide association studies (GWAS) have shown that the 
contribution of B cells to the pathogenesis of MS is indisputable. The strong and rapid ben-
eficial clinical effects of anti-CD20 treatment in MS patients has revealed that B cells serve 
as antigen-presenting rather than antibody-producing cells in the periphery. Although 
pro-inflammatory TH-cell responses are significantly reduced in these patients, the exact 
underlying antibody-independent functions of B cells in MS are poorly understood. B cells 
activate TH cells through the presentation of antigens, expression of costimulatory mole-
cules and secretion of cytokines. In this thesis, we aimed to uncover genes and pathways 
that are functionally altered in human B cells and potentially contribute to MS. To study 
this, we made use of gene silencing and functional assays related to B- and TH-cell inter-
action and took advantage of recent GWAS data, different MS cohorts and the effects of 
immunosuppressive conditions and treatment on disease activity.
The identification of functional B-cell subsets that can preferentially migrate into the 
CNS and contribute to local inflammation is of considerable interest. In chapter 2, we 
studied the triggers, development and CNS infiltration capacity of human B cells in the 
context of MS. We found that CXCR3-expressing B cells are selectively enriched in the CNS 
of MS patients, while being decreased in the periphery. Treatment of MS patients with 
natalizumab, a drug that blocks lymphocyte recruitment to the CNS, resulted in selective 
accumulation of CXCR3+IgG1+ B cells in the periphery. Furthermore, we demonstrated that 
these CXCR3+IgG1+ B cells have an enhanced capacity to transmigrate across the blood-
brain barrier in vitro. Finally, we showed that integrating interferon gamma (IFN-γ) and 
pathogen-associated Toll-like receptor 9 (TLR9) signals are critically involved in the devel-
opment of these brain-homing B cells in MS. 
HLA class II (HLA-II) is the major genetic risk factor for MS development, however little 
is known about how B cell-intrinsic HLA-II expression is regulated during MS disease onset. 
In chapter 3, we studied the impact of a minor MS- and autoimmunity-associated risk 
allele, CLEC16A, on HLA-II antigen presentation pathway in B cells. We demonstrated that 
CLEC16A contributes to this tightly coordinated pathway in B cells by influencing both 
B-cell receptor-mediated antigen uptake and the biogenesis of HLA-II peptide-loading 
compartments. In primary B cells, CLEC16A was only induced under class-II associated 
chain peptides (CLIP)-stimulating conditions in vitro and was predominantly expressed in 
CLIPhigh naive populations. Consistently, CLEC16A levels associated with the presentation 
of CLIP-loaded HLA-II molecules by human B-cell lines and primary B cells. This association 
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was not found in B cells from the blood of early MS patients, showing abundant expression 
of surface CLIP and impaired co-regulation with CLEC16A.
In chapter 4, we assessed a pro-inflammatory cytokine that is functionally associated 
with the precursor of CLIP (CD74) termed the macrophage migration inhibitory factor or 
MIF. We demonstrated that MIF and MIF receptor CD74 were downregulated, while MIF 
receptor CXCR4 was upregulated on B cells from early onset MS patients. This was shown 
for CIS patients who will rapidly develop MS as well as for clinically definite MS patients. 
In vitro experiments supported the inverse regulation of MIF/CD74 and CXCR4 expression 
in B cells ex vivo. Functionally, MIF signalling via CD74 controlled their pro-inflammatory 
capacity and proliferation, while signalling via CXCR4 regulated their sensitivity to Fas-
mediated apoptosis. The observed CXCR4highCD74low B-cell phenotype in early MS blood 
points to the presence of more immature B cell populations with senescent features. This 
may contribute to the increased ability of naive B cells to survive peripheral tolerance 
checkpoints in MS.
Pregnancy is a natural modifier of disease activity in MS patients, but the underlying 
mechanisms remain elusive. In chapter 5, we studied how peripheral B-cell differentiation 
is regulated during pregnancy-associated low and high relapse risk periods in patients 
with MS. Reduced proportions of transitional B cells were seen from the first to the third 
trimester, which significantly increased again in the early postpartum period. Although 
frequencies were modestly reduced, memory B cells showed increased immunoglobulin 
(Ig) expression and a more germinal center (GC) light zone-related chemokine receptor 
expression profile (CXCR4lowCXCR5highCCR6highCXCR3high) in postpartum versus paired third 
trimester samples. This profile implied an increased potential of these B cells to interact 
with TFH cells that are located within GC light zones. Because such memory B cells are prone 
to infiltrate the CNS, we assessed whether this phenotype may also be related to their 
capacity to further differentiate into antibody-secreting cells. Indeed, under TFH-like in vitro 
conditions, especially postpartum memory B cells of MS patients were highly capable of 
differentiating into Ig-secreting (CD138+) plasma cells.
In chapter 6, we discussed where and how the interaction between B and T cells are 
expected to play a role in MS. During B-cell development, peripheral B cells escape from 
tolerance checkpoints, possibly as the result of impaired control by chronically exhausted 
or genetically altered regulatory T cells. Subsequently, B cells interact with IFN-γ-producing 
effector TH cells in germinal centers of lymphoid organs to create a feedforward loop, after 
which highly pathogenic subsets break through blood-CNS barriers and are locally reac-
tivated to cause MS pathology. Although definite proof is still lacking, these pathogenic 
events are likely mediated by an interplay between persistent infections such as EBV and 
genetic risk variants. Together, these factors may alter the selection, differentiation and 




We conclude this thesis with chapter 7, in which we further elaborated on specific 
alterations in functional B-cell pathways in MS. This involves altered B-cell antigen process-
ing and presentation via HLA-II molecules, T cell-derived IFN-γ and organization within 
GCs to trigger pathogenic B cells as well as their capacity to infiltrate and further mature 
in the CNS. We also proposed future studies such as the use of CRISPR/Cas9 technology 
to edit and study the effect of one single nucleotide change as well as weighted genetic 
risk scores to assess the overall impact on B cells. Moreover, we discussed the design of 
more targeted therapy that inhibit the development or function of pathogenic B cells, 
while leaving other subsets unharmed. In this thesis, we have shown that CXCR3+ (T-bet+) 
memory B cells are ideal candidates for such targeting, being potent antigen-presenting 




Multipele sclerose (MS) is een chronische immuun-gemedieerde ziekte van het cen-
traal zenuwstelsel (CZS). Verschillende pro-inflammatoire immuun cellen mediëren lokale 
pathologie. CD20 depletie therapieën en genoom-brede associatiestudies (GWAS) hebben 
aangetoond dat de bijdrage van B cellen aan de pathogenese van MS onbetwistbaar zijn. 
De sterke en snelle effecten van anti-CD20 behandeling in MS patiënten heeft laten zien 
dat B cellen fungeren als antigeen-presenterende in plaats van antilichaam-producerende 
cellen in de periferie. Hoewel de pro-inflammatoire TH-cel reacties significant verminderd 
zijn in deze patiënten, zijn de exacte onderliggende antilichaam-onafhankelijke functies 
van B cellen in MS niet goed begrepen. B cellen kunnen TH cellen activeren door middel 
van antigeen presentatie, expressie van co-stimulerende moleculen en uitscheiding van 
cytokines. Onze doelstelling van dit proefschrift was om genen en signaalroutes die functi-
oneel veranderd zijn in humane B cellen en die mogelijk bijdrage aan MS te ontdekken. Om 
dit te onderzoeken hebben de expressie van genen uitgeschakeld en andere functionele 
proeven gerelateerd aan de functie van B- en TH cel interacties uitgevoerd. Hierbij hebben 
we gebruik gemaakt van recente GWAS data, verschillende MS cohorten, de effecten van 
immunosuppressieve condities en behandelingen van ziekteactiviteit.
De identificatie van de functionele B-cel subgroep die preferentieel migreert naar het 
CSZ en bijdraagt aan de lokale ontsteking is van aanzienlijk belang. In hoofdstuk 2 hebben 
we de impulsen, ontwikkeling en CZS infiltratie capaciteit van humane B cellen in de con-
text van MS onderzocht. Hier hebben we gevonden dat B cellen die CXCR3 tot expressie 
brengen selectief verrijkt zijn in het CZS van MS patiënten, terwijl deze verminderd zijn in 
de periferie. Behandeling van MS patiënten met natalizumab, een medicijn dat de migratie 
van lymfocyten naar het CZS remt, resulteerde in selectieve ophoping van CXCR3+IgG1+ B 
cellen in de periferie. Bovendien hebben we aangetoond dat deze CXCR3+IgG1+ B cellen 
een verhoogde capaciteit hebben om te migreren over de bloed-brein barrière in vitro. Tot 
slot laten we zien dat de integratie van de interferon gamma (IFN-γ) en pathogeen-geas-
socieerde Toll-like receptor 9 (TLR9) signalen een cruciale rol spelen in de ontwikkeling van 
deze brein-geassocieerde B cellen in MS.
HLA klasse II (HLA-II) is de grootse genetische risicofactor voor MS ontwikkeling, echter 
is er maar weinig bekend over hoe B-cel intrinsieke HLA-II expressie gereguleerd wordt tij-
dens MS ziekte ontwikkeling. In hoofdstuk 3 hebben we onderzoek gedaan naar de impact 
van een minor MS- en auto-immuun-geassocieerde risico allel, CLEC16A, op de HLA-II anti-
geen presentatie route in B cellen. We hebben aangetoond dat CLEC16A bijdraagt aan deze 
strikt gecoördineerde route in B cellen door zowel B-cel receptor-gemedieerde antigeen 
opname en de biogenese van HLA-II peptide-beladingscompartimenten te beïnvloeden. 




peptiden (CLIP)-stimulerende condities in vitro en kwam voornamelijk tot expressie in 
CLIPhoge naïeve populaties. Daarnaast associeerden de CLEC16A expressie niveaus met 
de presentatie van CLIP-geladen HLA-II moleculen door humane B cellijnen en primaire 
B cellen. Deze associatie werd niet gevonden met B cellen in het bloed van vroege MS 
patiënten, waarin CLIP hoog tot expressie komt en er dus een verstoorde co-regulatie is 
met CLEC16A.
In hoofdstuk 4 hebben we een pro-inflammatoire cytokine onderzocht die functioneel 
geassocieerd is met de voorloper van CLIP (CD74) genaamd de macrofaag migratie inhibi-
tie factor of in het kort MIF. We hebben aangetoond dat MIF en zijn receptor CD74 vermin-
derd tot expressie kwam, terwijl een andere MIF receptor CXCR4 verhoogd tot expressie 
kwam op B cellen van patiënten met een vroege ontwikkeling naar MS. We hebben dit 
laten zien voor zowel klinisch geïsoleerd syndroom (CIS) patiënten die in de toekomst snel 
MS ontwikkelde, als voor klinisch definitief MS (CDMS) patiënten. In vitro experimenten 
ondersteunde de omgekeerde regulatie van MIF/CD74 en CXCR4 expressie in B cellen ex 
vivo. Functioneel hebben we laten zien dat MIF signalering via CD74 de pro-inflammatoire 
capaciteit en proliferatie van B cellen reguleerde, terwijl de signalering via CXCR4 de sensi-
tiviteit voor Fas-gemedieerde apoptose reguleerde. De geobserveerde CXCR4hoogCD74laag 
B cel fenotype in het bloed van vroege MS patiënten wijst naar de aanwezigheid van een 
meer immature B cel populatie met senescente kenmerken. Dit draagt mogelijk bij aan 
het verhoogde vermogen van naïeve B cellen om perifere tolerantie controlepunten te 
overleven in MS.
Zwangerschap veranderd ziekteactiviteit in MS patiënten op een natuurlijke manier, 
maar het onderliggende mechanisme hiervan blijft ongrijpbaar. In hoofdstuk 5 hebben 
we onderzocht hoe perifere B-cel differentiatie gereguleerd wordt gedurende zwanger-
schap-geassocieerde lage en hoge relapse risicoperiodes in patiënten met MS. We vonden 
verlaagde frequenties van transitionele B cellen in de derde trimester versus de eerste 
trimester van de zwangerschap, welke weer significant verhoogde in de vroege postpar-
tum fase. Hoewel de proporties van geheugen B cellen gematigd verlaagd waren, was 
de immunoglobuline expressie significant verhoogd. Verder vertoonde deze geheugen 
B cellen een meer kiemcenter (‘germinal center’; GC) lichte zone-gerelateerd chemokine 
receptor expressie profiel (CXCR4laagCXCR5hoogCCR6hoogCXCR3hoog) in postpartum versus 
derde trimester samples. Dit profiel impliceerde een verhoogde potentie van deze B cellen 
om in aanraking te komen met TFH cellen welke gevestigd zijn binnen de lichte zones van 
een GC. Omdat dergelijke geheugen B cellen geneigd zijn om het CZS te infiltreren, onder-
zochten we of dit fenotype wellicht ook gerelateerd was aan de capaciteit om verder te 
differentiëren in antilichaam-afscheidende (plasma) cellen. Hier vonden we inderdaad dat 
onder TFH-lijkende in vitro condities, voornamelijk postpartum geheugen B cellen van MS 
patiënten zeer capabel waren om te differentiëren naar (CD138+) plasmacellen. 
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In hoofdstuk 6 hebben we besproken waar en hoe de interactie tussen B en T cellen 
mogelijk een rol speelt in MS. Tijdens de ontwikkeling van een B-cel ontsnappen perifere 
B cellen aan tolerantie controlepunten, wat mogelijk een gevolg is van verminderde con-
trole door chronisch vermoeide of genetisch veranderde regulatoire T cellen. Vervolgens 
kunnen deze B cellen een interactie aangaan met IFN-γ-producerende TH cellen in GCs van 
lymfatische organen om een voorwaartskoppeling te maken, waarbij zeer pathogene sub-
groepen door de bloed-CZS barrière kunnen breken en lokaal gereactiveerd worden om 
MS pathologie te veroorzaken. Hoewel dit voor een deel nog hypothetisch is, denken wij 
dat deze pathogene gebeurtenissen mogelijk gemedieerd worden door een wisselwer-
king van aanhoudende infecties zoals EBV en genetische risico variaties. Samen verande-
ren deze factoren mogelijk de selectie, differentiatie en pathogene kenmerken van B- en 
T-cel subgroepen in MS patiënten. 
We eindigen dit proefschrift met hoofdstuk 7, waarin we verder ingaan op specifieke 
veranderingen in functionele B-cel signaleringsroutes in MS. Dit betreft gewijzigde B-cel 
antigeen verwerking en presentatie via HLA-II moleculen, de rol van T-cel-afkomstige IFN-γ, 
de organisatie binnen GCs welke pathogene B cellen activeren en hun capaciteit om het 
CZS te infiltreren en daar lokaal verder te differentiëren. Ook bespreken we mogelijke toe-
komstige studies zoals het gebruiken van CRISPR/Cas9 technologie om een enkele nucleo-
tide te veranderen en te onderzoeken evenals het gebruiken van ‘afgewogen’ (weighted) 
genetische risico scores om de totale impact op B cellen te onderzoeken. Daarnaast 
bespreken we de ontwikkeling van meer doelgerichte therapieën welke de ontwikkeling 
of functie van pathogene B cellen kan remmen, terwijl andere subgroepen onaangetast 
blijven. In dit proefschrift hebben we aangetoond dat CXCR3+ (T-bet+) geheugen B cellen 
ideale kandidaten zijn voor desbetreffende doelgerichte therapieën, aangezien dit effec-
tieve antigeen-presenterende cellen zijn welke een verhoogde capaciteit hebben om te 





Als laatste jaar VWO scholier moest ik een keuze maken, wat ga ik met mijn toekomst 
doen? Ik vond dat destijds heel erg lastig. Omdat ik altijd interesse had in het laboratorium 
onderwijs en de werking van het menselijk lichaam heb ik uiteindelijk besloten dat ik de 
HLO wilde gaan doen. Mijn mentor destijds, Con van Zundert, kon mij wel onder m’n 
kont schoppen dat ik ‘maar’ een HBO opleiding ging doen, ik had volgens hem veel meer 
in mijn mars (ik hoop dat ik het hiermee nu wel goed gemaakt heb :)). Maar eigenwijs 
en vastbesloten dat ik was ging ik de laboratoriumopleiding doen. Hoewel dit een hele 
leuke en leerzame opleiding was, werd mij mede dankzij mijn stagebegeleider, Dr. Mark 
Begieneman, tijdens het afstuderen wel duidelijk dat ik veel meer interesse had in het 
wetenschappelijk onderzoek. Daarom besloot ik ook om een research master te gaan 
doen aan het Erasmus MC. Tijdens mijn afstudeerstage op de afdeling Immunologie kwam 
ik binnen de groep van Dr. Menno van Zelm, en onder supervisie van Dr. Jorn Heeringa, 
in aanraking met het onderzoek naar B lymfocyten. Mede dankzij hun enthousiasme 
ben ik toen na het behalen van mijn master begonnen als PhD student op de afdeling 
Immunologie, binnen de MS groep. Onderzoek doen naar de rol van antigeen-presentatie 
door B lymfocyten in MS. Hiervoor wil ik Prof. Dr. Jon Laman en ook Prof. Dr. Rogier 
Hintzen bedanken. Het vertrouwen dat zij mij destijds hebben gegeven om aan dit traject 
te beginnen heeft mij gebracht tot waar ik nu ben. 
Dit proefschrift is tot stand gekomen door middel van veel bloed (vooral van patiënten), 
zweet (van mij en iedereen die geholpen heeft) en ook wel wat tranen (voornamelijk van 
mij...). Dit had ik niet kunnen doen zonder de vele mensen die direct of indirect geholpen 
hebben en daarvoor wil ik mijn dank graag uitspreken.
Beste Marvin, allereerst wil ik jou bedanken voor al je tijd die je hebt gestoken als 
copromotor in het opleiden van mij tot onafhankelijke onderzoekster. Ik denk dat het 
uiteindelijk aardig gelukt is :). De vele uren die je hebt gespendeerd aan het nakijken van 
mijn manuscripten, vaak met als resultaat een rode in plaats van zwarte tekst, maar het 
werd er altijd beter van! We hebben samen, met de hele NIB groep, onwijs veel onderzoek 
kunnen doen en een aantal mooie papers kunnen publiceren. Ik hoop dat dit onderzoek 
bijdraagt aan het vervolgonderzoek binnen de NIB groep, en dat jij, als super gemo-
tiveerde en creatieve onderzoeker, nog vele jaren aan de oorzaak en behandeling van MS 
kan werken. Nu je de VIDI hebt binnen gehaald zal dit alleen nog maar beter gaan! Succes 
met al het vervolgonderzoek en met de toekomst! 
Dear Prof. Dr. Peter Katsikis, I would like to thank you for your time that you spent as 
my promoter after Rogier passed away. Immediately you were willing to help, so I did not 
need to worry about having a promoter, and could finish my thesis successfully. 
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Beste Prof. Dr. Peter Sillevis Smitt, ik wil ook jou bedanken voor de tijd die je gesto-
ken hebt in het afronden van mijn proefschrift. Na het overlijden van Rogier was ook jij 
meteen bereid om een deel van het promotorschap over te nemen, waarvoor dank. Dit 
heeft ervoor gezorgd dat ik mij daar niet druk over hoefde te maken en het onderzoek tot 
een succesvol einde kon brengen.
Kleine commissieleden Prof. Dr. Ton Langerak, Prof. Dr. Bert t’ Hart en Prof. Dr. 
Veerle Somers hartelijk dank voor jullie waardevolle beoordeling. Dankzij jullie is het een 
compleet boekje. Grote commissieleden, bedankt dat jullie als opponenten wilden deel-
nemen aan mijn verdediging.
Beste Rogier, hoewel het misschien raar is om iets te schijven aan iemand die overleden 
is, zou ik het ook heel gek vinden om je niet te noemen in mijn dankwoord. In een van 
mijn persoonlijk lastigste jaren kwam ook nog het nieuws dat jij ongeneeslijk ziek was en 
kort daarop ben je ook overleden. Dit kwam hard aan bij mij. Ik heb je altijd bewonderd 
voor de persoon, arts en wetenschapper die je was. Tikkeltje chaotisch soms, maar altijd 
gemotiveerd om MS de wereld uit te helpen. Het onderzoek waar ik aan heb gewerkt was 
niet tot stand gekomen zonder jou, waarvoor dank! Ik vind het onwijs jammer dat je het 
eindresultaat niet meer hebt kunnen zien. 
Dit proefschrift had nooit tot stand kunnen komen zonder de hulp van iedereen 
binnen de MS groep! Lieve MS groupies, bedankt voor de gezelligheid en al het lief en leed 
dat we hebben gedeeld de afgelopen 6 jaar. Allereerst Marie-José, zonder jou had ik dit 
proefschrift nooit kunnen voltooien. Naast mijn paranimf was je al die tijd mijn rechterhand 
in het lab (en soms ook mijn linkerhand, toen die in het gips zat bv ;)). We hebben samen 
vele uren in het lab doorgebracht, hard gewerkt maar ook veel gekletst en gelachen! 100e 
kloontjes doorzetten, ingewikkelde experimenten met levende krioelende beestjes, en nog 
vele andere experimenten welke ik niet zonder je had kunnen doen! Je bent een beetje als 
een 2e moeder voor mij geweest. Ik hoop dan ook dat we in de toekomst nog regelmatig 
kunnen kletsen onder het genot van een drankje. Succes met al het vervolgonderzoek 
binnen de MS groep en veel geluk in de toekomst! Ik ga je missen! Jamie, ik schrijf dit in 
het Nederlands omdat je nu officieel ingeburgerd bent en dus gewoon Nederlands moet 
praten ;). Ik vind het onwijs leuk dat jij mijn paranimf bent en andersom ik die van jou. 
We hebben zeker de laatste 2-3 jaar hard gewerkt samen aan het onderzoek en zaten in 
dezelfde fase van ons proefschrift. Naast mijn paranimf was je mijn kamergenoot de laat-
ste paar jaar, wat super gezellig was altijd! Zo konden we even onze frustraties uitten, maar 
ook overleggen over het volgende experiment of resultaten waar niets van te begrijpen 
was. Ik ga de gezelligheid en de samenwerking met jou missen! Succes met jouw toekom-
stige carrière, je bent een top onderzoekster! Steven, als mijn ex-student en inmiddels 
OIO binnen de MS groep ben je toch altijd een beetje mijn ‘kindje’ geweest. Maar ik denk 




wel weer flauwe speedvac of CRISPR grapjes maken hier, maar dat is inmiddels wel beetje 
afgezaagd ;). Je bent een creatieve onderzoeker met altijd veel ideeën. Onthoud dat pro-
moveren niet het enige belangrijke is, dus neem af en toe ook een beetje tijd voor jezelf. 
Die reviewers gaan echt niet sneller nakijken omdat jij 3x per dag checkt of er al reactie is! 
Succes met de laatste loodjes van je PhD en met het maken van je toekomstplannen. En 
een beetje lief zijn voor Jamie ;). Annet, ook jouw hulp was onmisbaar voor het afronden 
van dit proefschrift! Hoewel we iets minder direct hebben samengewerkt, hebben we het 
toch altijd gezellig gehad op het lab. Je bent een super gemotiveerde analist en een fijn 
persoon om als collega te hebben! Succes nog met al het onderzoek binnen de MS groep 
en hopelijk tot ziens! Malou, ook jij zit nu in de laatste fase van je proefschrift en mag deze 
binnenkort verdedigen. En beiden zijn we nu begonnen aan het volgende avontuur als 
AIOS. Ik wens je veel succes hiermee en geluk in de toekomst. Ook wil ik alle studenten die 
bijgedragen hebben aan dit onderzoek, Maeva, Steven en Alp, bedanken. 
Verder wil ik de collega’s van de ErasMS groep binnen de afdeling Neurologie bedanken. 
Joost, als vervanger van Rogier had je een lastige taak, maar ik denk dat iedereen heel blij 
is met jou! Een jonge en enthousiaste arts en wetenschapper die het MS onderzoek de 
komende jaren enorm gaat helpen! Verder de ‘dames van de neuro’ Roos, Yuyi, Arlette 
en Kathelijn. Zonder jullie inspanningen om patiënten voor het onderzoek te verzamelen 
hadden we geen bloed om het onderzoek mee te doen. Het was altijd prettig samenwerken! 
Ook Karim bedankt voor je hulp met het genetische deel van het onderzoek. Jon, bedankt 
voor het destijds aannemen van mij als OIO en het daarmee gestelde vertrouwen in mij! 
Helaas vertrok je al heel snel naar Groningen, maar jouw jarenlange bijdrage aan het MS 
onderzoek heeft onze groep mede gevormd tot wat het nu is.
Buiten de MS groep zijn er nog verschillende mensen die ik kort wil bedanken. 
Allereerst wil ik de voormalige BCD groep bedanken, waar ik ooit begonnen ben als 
stagiaire op de afdeling Immunologie. Jorn bedankt voor al je tijd en geduld als mijn 
supervisor, en Menno bedankt voor je vertrouwen in mij destijds als student, en dat je mij 
vervolgens aanbevolen hebt aan de MS groep als OIO. Zonder jou was ik waarschijnlijk 
nooit aan dit project begonnen! Ook alle andere OIO’s en studenten binnen de BCD groep 
wil ik bedanken voor de leuke tijd! 
Willem-Jan, als mijn kamergenoot de eerste paar jaar heb ik heel veel aan je gehad en 
heb ik je ook echt gemist toen jij weg ging. Tot ik een kamer ging delen met Jamie, hebben 
de buren nooit meer geklaagd over geluidsoverlast ;). Succes met jouw laatste loodjes 
en veel geluk voor jou en je gezin! Fabian, ik bewonder jouw doorzettingsvermogen en 
onderzoek skills. Die PhD komt er echt ooit wel! Jorn, dank voor alle gezellige praatjes en 
ik hoop je in de toekomst binnen de wereld van de klinische chemie nog regelmatig te 
zien! Marieke, Martine, Manzhi, Marjolein, Christina, Britt, Christiaan, Javad, Erika, 
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Astrid, Sander en alle andere (oud) OIOs van de afdeling Immunologie, dank voor de 
gezelligheid tijdens de borrels en retraites en voor alle hulp.
Verder dank aan alle andere collega’s van de afdeling Immunologie die hebben bijge-
dragen aan een leuke tijd. Anne, Wouter, Ruth en Jane, voor de oprechte gesprekken en 
steun die ik van jullie heb mogen ontvangen. Harm en Peter, bedankt voor de vele uren 
achter de sorteermachine voor mijn onderzoek! Gellof, Monique, Marie-Joan, Sascha, 
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Christina, Sascha, Kim en Marjolein, bedanken. In mijn allereerste jaar als OIO hebben 
we samen als feestcommissie heel veel leuke dingen mogen en kunnen organiseren, waar 
ik nog altijd met veel plezier op terug kijk!
Ook wil ik Prof. Dr. Marieke van Ham, Dr. Peter-Paul Unger en Tineke Jorritsma 
van de afdeling Immunopathologie van Sanquin bedanken voor het brainstormen en jullie 
hulp bij het opzetten van de Salmonella en B-T cell co-culture experimenten! Zonder jullie 
hadden we nooit deze proeven kunnen doen.
Zonder de vele gezellige feestjes, borrels, etentjes, drankjes en polonaises met 
vriendinnen was het mij ook niet gelukt om deze promotie te doorstaan. Kyra, vanaf de 
1e dag van onze masteropleiding waren we al vriendinnen, en dit is altijd zo gebleven. 
Samen als stagiair op de afdeling Immunologie, wat super leuk was! En nu we beiden bezig 
zijn als AIOS klinische chemie denk ik en hoop ik dat dit nog lang zo mag blijven! Jacolien 
en Mariëlle, als lab-vriendinnen weten jullie maar al te goed hoe het er aan toe gaat op 
het lab. Hopelijk blijven we elkaar ook nog spreken in de toekomst. Iris, Sezen en Tanika, 
vriendinnen vanaf de basis- en/of middelbare school die mij altijd gesteund hebben! Niets 
is teveel, we kunnen altijd op elkaar rekenen en dat is onwijs fijn! Hopelijk kunnen we 
snel weer vele drankjes en etentjes doen! In het bijzonder extra dank aan Tanika voor 
het ontwerpen van mijn kaft en de rest van de lay-out! Ik ben jaloers op jouw creativi-
teit, het is echt super mooi geworden! Samanthi, Astrid en Iris de hoeveelheid biertjes 
die we samen gedaan hebben zijn niet meer te tellen. Ook jullie stonden altijd klaar voor 
mij wanneer ik het even lastig had! Ik waardeer jullie vriendschap en hopelijk kunnen we 
die biertjes nog lang blijven doen! En ook dank aan alle paarden-vriendinnen, Roxanne, 
Jenny, Michelle, Nanda, Ilse, Chantal, Denise, Kirsten en Shirley voor de ontspanning 
en gezelligheid! 
Als laatste wil ik ook mijn familie bedanken. Ook al hadden jullie meestal geen idee 
van wat ik aan het doen was de afgelopen 6 jaar, hebben jullie wel bijgedragen aan mijn 
ontwikkeling tot de persoon die ik nu ben! Papa en Mama, dankjewel voor jullie onvoor-
waardelijke liefde. Ik kan altijd bij jullie terecht, in goede en slechte tijden. Jullie hebben 




een geluk heb ik met zulke leuke, lieve en jonge grootouders! Hoewel ik niet altijd evenveel 
tijd heb om op de koffie te komen, denk ik vaak aan jullie! Mijn ‘kleine’ zusje Mandy, trots 
ben ik op jou hoe je het maar allemaal doet, samen met Kevin, als moeder van lieve Lewis 
en met je eigen kapsalon. Ook jij bent er altijd voor mij! Als laatste wil ik Mark bedanken. 
Ook jij had vaak geen idee waar ik het allemaal over had en snapte mijn frustraties niet 
altijd, toch heb je mij op jouw manier altijd gesteund door er gewoon te zijn. Je hebt mij 
gemotiveerd om het beste uit mijzelf te halen en bent nu zelfs met mij mee verhuisd naar 
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